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Abstract: 
Purpose: Repeated failures in melanoma therapy made clear that the molecular mechanisms 
leading to melanoma are still poorly understood. Here, we aim to provide a more 
comprehensive understanding of the transcriptional profiles and signaling pathways 
associated with melanoma. 
Methods: Gene expression was analyzed using the Affymetrix Human Genome U133A 2.0 
GeneChip arrays. To avoid culture artifacts, we used microdissected fresh frozen material of 
18 melanocytic nevi (MN), 20 primary melanomas (PM) and 20 metastatic melanomas (MM). 
Statistical analysis was performed with Genomatix Chipinspector, Ingenuity™ Software, 
SPSS Software and Partek Genomic Suite 6.4. Expression levels of selected transcripts were 
verified by quantitative real-time RT-PCR and immunostaining of a tissue microarray 
sampling more than 280 cases of MN, PM, and MM with known clinical outcome. 
Results: A total of 284 differentially expressed genes was detected in PM compared to MN 
and 189 genes in MM compared to PM affecting common cancer pathways such as MAPK-, 
Wnt-, and Notch-signaling. Using principal component analysis, the samples could be 
grouped according to their histological entity. We identified a panel of novel melanoma-
associated markers: FRZB, an antagonist of Wnt; TLE1, a transcription factor partner of 
TCF/LEF-1; CNTN1, an activator of Notch signaling; two Serpin peptidase inhibitors, Serpin 
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Melanoma is increasing in incidence with 68,130 cases expected for 2010 in the United States 
and an annual death rate of 4.07 per 100,000, corresponding to a total of 8700 estimated 
deaths [1]. Melanoma patients with a tumor thickness of < 1mm have a favorable cure rate but 
once melanoma has progressed into systemic disease, median survival drops below 7-8 
months and the 5 year survival is less than 5% [2]. Since cellular homeostasis in melanoma is 
deregulated by a concert of genes [3], it is important to develop new diagnostic and 
therapeutic strategies taking into account the entire tumor signature rather than one single 
marker. To gain insights into genome-wide gene expression patterns in cancer, microarray 
technology became a powerful instrument and the recent progress in computational analysis 
allows investigating whole networks of signaling pathways in individual patient samples at 
the same time. Since single pathways, e.g. MAPK signaling, have been targeted so far only 
with limited success [4], a better understanding of the entire spectrum of signaling networks 
and there interconnection is highly needed for the design of future therapies [5]. 
 
Although applied for years now, the benefit of microarrays for melanoma research is still 
limited, because the majority of studies has been based on cultured cell lines. Certainly, 
experimental conditions can be stably controlled in cell culture, but on the downside, gene 
expression is affected by the selected culture media leading to artifacts in the results. Among 
the few studies that have analyzed in vivo patient samples, e.g. Jaeger et al. [6] compared 
gene expression patterns of 19 primary melanomas (PM) and 22 melanoma metastases (MM). 
Their results showed that PM and MM were characterized by distinct gene expression patterns 
and represent different biological stages of tumor progression. However, since benign nevi 
(MN) were not included, an interpretation with regard to initial malignant processes was not 
possible. A former study of our group on a limited number of laser-microdissected patient 
samples, indicated that particularly the comparison to MN could reveal significant changes in 
the transcriptional profiles of PM [7]. 
 
Here, we aim to detect new gene expression alterations in PM and MM compared to MN, 
which may contribute to tumor initiation and progression of this deadly disease. We applied 
high throughput transcriptional profiling followed by network analysis to a large number of 
fresh frozen patient specimens of MN, PM and MM and subsequently performed validation 





For microarray analysis, tissue samples from 18 MN, 20 PM (2 acral lentiginous melanomas, 
3 lentigo maligna melanomas, 4 nodular melanomas, 5 secondary nodular melanomas, and 6 
superficial spreading melanomas) and 20 MM (cutaneous and lymph node metastases) were 
collected at the Department of Dermatology, University of Regensburg, Germany (Table 1). 
Patients’ written consent was obtained prior to surgery. The tissue specimens were 
immediately frozen in liquid nitrogen and stored at –80°C. Histological diagnoses were 
routinely assessed by two expert dermatopathologists (M.L. and T.V.) prior to RNA 
extraction. 
 
RNA Isolation and microarray hybridization 
RNA was extracted using QIAshredder columns (Quiagen, Hilden, Germany) and the RNeasy 
Mini Kit (Quiagen) as previously described [8]. RNA quality control was done with an 
Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, USA). 1 to 5 micrograms of total 
RNA from each tissue specimen were used to generate double-stranded cDNA and biotin-
labeled cRNA (One Cycle Target Labeling Kit, Affymetrix). The length of the cRNA 
products was assessed using the Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, 
USA). Following fragmentation, cRNA products (10 µg) were hybridized to Affymetrix 
Human Genome U133A 2.0 GeneChip (Affymetrix, Santa Clara, USA) arrays for 16 h at 
45° C in a rotating chamber. The array contained about 22,000 probe sets representing 14,500 
human genes. Hybridized arrays were washed and stained in Affymetrix Washing Station 
FS400 using Streptavidin Phycoerythrin conjugate (Molecular Probes, Eugene, USA) together 
with biotinylated anti-streptavidin antibody (Vector Laboratories, Burlingame, USA), and the 
fluorescent signals were measured with the Affymetrix GeneChip® Scanner 3000. Quality 
control of the isolated RNA samples and sample processing were performed at a regional 
German Affymetrix Service Provider and Core Facility, “KFB - Center of Excellence for 
Fluorescent Bioanalytics” (www.kfb-regensburg.de). 
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Tissue microarrays and Immunohistochemistry 
Tissue microarrays were constructed as described previously [9] and contained formalin-
fixed, paraffin-embedded (FFPE) human tissue samples of 127 MN, 73 PM, and 89 MM. The 
University of Regensburg institutional review board granted approval for the project. In brief, 
tissues were deparaffinized and rehydrated, according to standard protocols and subsequently 
incubated with a 1:600 dilution of anti-GDF15 polyclonal antibody (Abcam, Cambridge, UK) 
and a 1:2000 dilution of mouse anti-MMP1 monoclonal antibody (Millipore Corporation, 
Billerica, USA) overnight at 4°C. The secondary antibody [biotinylated polyvalent antibody, 
Zytochem Plus (HRP) Broad Spectrum Kit, Zytomed Systems, Berlin, Germany] was 
incubated for 30 minutes at room temperature, followed by incubation with horseradish 
peroxidase [Zytochem Plus (HRP) Broad Spectrum Kit] for 15 minutes at room temperature. 
Antibody binding was visualized using AEC solution (Zytochem Plus HRP Broad Spectrum 
Kit). Tissues were counterstained with hematoxylin. Immunostaining was confirmed in a 
series of ‘whole tumor sections’ to exclude spatial restriction of marker expression in TMAs 
(not shown). To avoid experimental bias within the set of tumor samples, 
immunohistochemistry of all examined tissue samples was performed under identical 
experimental conditions. Immunostaining was assessed by two independent investigators 
(A.M., T.V.). Cytoplasmic GDF15 and MMP1 staining intensity was estimated using a 5-step 
scoring system (range 0-4) with regard to staining intensity: 0, negative; 1(+) weakly positive 
(<50% positive cells and weak intensity); 2 + positive (<50% and moderate); 3 ++ strongly 
positive (<50% and strong intensity or >50% and weak intensity); 4 +++ very strongly 
positive (>50% moderate and strong intensity). The Pearson Chi square test was used for 
statistical analyses, p<0.05 was considered significant. 
 
Quantitative real-time RT-PCR 
For microarray validation, quantitative real-time RT-PCR (QPCR) was performed as 
described previously [8]. RNA was isolated from 5 representative MN, 5 PM, and 5 MM that 
were included before in the microarray analysis. One microgram of RNA was reversely 
transcribed using the SuperScript II reverse transcription system (Invitrogen, Carlsbad, USA) 
in combination with random hexa primers. The resulting cDNA was used as template for RT-
PCR on an ABI 7000 Sequence Detection System (Applied Biosystem, Foster City, USA). 
The ddCT method was applied for quantitation of gene expression. Expression signals were 
normalized to 18S rRNA. The analyses were done in triplicates using commercial TaqManTM 
assays (Applied Biosystems) and custom-designed primer pairs (Apara Bioscience, 
 12
Denzlingen, Germany): Serpin B3: Hs00199468_m1; Serpin B4: Hs01691258_g1; 18S 
rRNA: Hs99999901_s1; FRZB proximal forward: 5’-AAACTGTAGAGGGGCAAGCA-3’, 
reverse: 5’-GGCAGCCAGAGCTGGTATAG-3’, TLE1 proximal forward: 5’-
CACGACTTCACCTCCCAGAT-3’, reverse: 5’-CTGGAATATGCTGGCTCCAT-3’, 




Chipinspector version 1.3 (Genomatix Software GmbH, Munich, Germany) was used for 
single probe based analysis of gained CEL files as described earlier [10]. For testing statistical 
significance false discovery rate (FDR) was set to 0, minimal probe coverage was set to 3, 
minimal probe change <-2 and >2. To reveal functional connections between the regulated 
transcripts, a network and pathway analysis of the pre-filtered genes was performed as 
described [11] using the IngenuityTM Pathways Analysis online application 
(www.ingenuity.com, IngenuityTM Systems, Mountain View, USA). The significance of 
networks was calculated by integrated IngenuityTM algorithms [11]. Principal component 
analysis (PCA) was performed with Partek Genomic Suite 6.4 (Partek Inc., St. Louis, USA). 
Comparison of the survival curve with low and high expressing melanoma was performed 
with SPSS V.18.0 (SPSS Inc., Chicago, USA). Values of p<0.05 were considered to be 
significant. All specimens on the TMAs were considered independently. Progression free 
survival (PFS) curves comparing patients with GDF15 and MMP1 staining patterns were 
calculated by the Kaplan–Meier method, with significance evaluated by two-sided log rank 





Comparative gene expression profiling 
To investigate the transcriptional profiles that are associated with malignant progression in 
melanoma, we compared 18 MN to 20 PM and 20 MM using a single probe based microarray 
analysis. CEL files were analyzed by Chipinspector version 1.3 (Genomatix Software GmbH, 
Munich, Germany), which is based on single probe analysis and de novo gene annotation that 
bypasses probe set definitions. After elimination of probes that could cross-hybridize to other 
transcripts, Chipinspector (CI) identified significantly regulated individual probes using 
default settings. At least 3 probes had to match per annotated transcript and minimal probe 
coverage was set to 3 with a fold change of <-2 and >2. In the comparison of PM with MN, 
Chipinspector identified 52055 probes significantly up- and 48713 probes significantly down-
regulated after elimination of probes that could cross-hybridize to other transcripts. We 
received 691 transcripts matching 284 significantly regulated genes; 167 up- and 117 down-
regulated in PM compared to MN. Comparing MM to PM we found 39016 and 35455 probes 
significantly up- and down-regulated (586 transcripts matching 189 genes, 26 up-, 163 down-
regulated in MM compared to PM) (Supplemental Table 1). 
 
Among the 167 genes that were up-regulated in PM compared to MN, we found a high 
overlap with previously reported genes, e.g. PRAME, SSP1 [13, 14], CXCL9, PHACTR1, 
CITED-1, BCL2A1 [13, 15] S100A9, MMP1, FN1 [16], NNMT, SERPIN A3 [13], MCAM 
[17], ISG15 [18], CDK-2, and CDK-4 [19], GDF15 [13, 15, 20] and Hey1 [15, 16]. 
Comparing genes that were down-regulated from PM to MN with previous studies, we found 
consensus for CIRBP, FEZ1, PPP1R3C, LDOC1, TRPM1 [16], Desmoglein [17], KRT-15 
[13], FABP7 [20], p57KIP2, and CDKN1 [21]. In MM, only a few genes have been described 
so far to be up-regulated compared to PM. Interestingly, we also found only 26 up-regulated 
genes. Of these, significant regulation has been described before for VEGFA [22, 23], FN1 [6, 
24], IGFBP2 [25], SPP1, MAGEA12, c-MET [6, 15, 26], STC1, and PLOD2 [6]. Down-
regulation in MM included the previously published genes Serpin B5 [27], SPRR1A, KRT 
16/17/6B, CD 24, LOR, DSC1 [26], KRT 1/14/6A/5, CXCL14 and SPINT2 [6]. For the full 
list of regulated transcripts, see Supplemental Table 1.  
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Expression profile-based sample classification 
To classify the tumor specimens based on their transcriptional profiles, we used principal 
component analysis (PCA) anticipating that the specimens would group according to their 
histological origin, i.e. MN, PM, and MM. Indeed, PCA displayed a clear spatial separation 
between the three histological entities reflecting considerable differences in respective gene 
expression signatures. The most significant difference was seen between PM and MN 
(Supplemental Figure 1) confirming previous data of our group [7] which pointed out that 
gene expression patterns differ dramatically between MN and PM and not so much between 
PM and MM. 
 
Identification of signaling pathways and networks 
To further unravel functions and networks of the regulated transcripts, we mapped the 
microarray ‘hits’ according to biological functions in Ingenuity’sTM Knowledge Base. 
Comparing PM to MN, particularly such genes were differentially regulated that play a role in 
cancer, dermatological diseases and conditions, cellular growth and proliferation, cellular 
movement, inflammatory response (Supplemental Table 2). Applying Ingenuity’s Network 
AlgorithmTM, 15 functional gene networks could be constituted in total. Each of them 
contained more than 10 regulated focus genes with significant Ingenuity scores [11] of 11 and 
more (for example, maximum score of network 1 was 42, see Supplemental Figure 2A). 
Within these networks several genes were comprised with known relevance for melanoma 
biology, e.g. SPP1, STAT1, MMP1, or CDK2. Consequently, we found an affection of 
canonical pathways that are known to play a role in melanoma development, such as MAPK-
signaling, apoptosis, Notch-, WNT/beta catenin- and integrin-signaling, as well as G1/S and 
G2/M checkpoint control [28, 29] (Table 2). When we grouped the 189 genes that were 
differentially regulated between MM and PM according to biological functions in 
Ingenuity’sTM Knowledge Base, we found an association to hair and skin development and 
function, dermatological diseases and conditions, cancer, cellular development, cellular 
movement, cellular growth and proliferation and inflammatory response (Supplemental Table 
3). Also in MM, these functions were linked to melanoma-typical signaling pathways such as 
WNT/beta catenin-, integrin-, VEGF-, PI3/AKT- and cell-to-cell signaling (Table 2, 
Supplemental Figure 2B).  
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Novel melanoma-associated genes 
To filter out novel genes with relevance for melanoma, we performed a separate IngenuityTM 
pathway analysis that only comprised the most significant transcripts, i.e. showing an up- and 
down-regulation with a minimum log ratio of 1.5 (Supplemental Figure 2C). Based on our 
comprehensive GO analysis (Table 2), we primarily expected to find genes with relationship 
to major melanoma pathways like MAPK-, Notch- or Wnt-signaling. Indeed, we found a 
relatively new player of the Notch pathway, the cell adhesion molecule contactin 1 (CNTN1), 
to be significantly down-regulated in PM compared to MN. In the Wnt/beta catenin pathway, 
we found frizzled-related protein (FRZB) and the tranducin-like enhancer of split 1 (TLE1) to 
be differentially expressed (both down in PM). Also included in the strongest up-regulated 
genes in PM, we found the Serpin peptidase inhibitors Serpin B3 and B4, both linked to 
MAPK signaling [30]. At last, we could confirm the recently described up-regulation of the 
TGF-β family member growth differentiation factor 15 (GDF15) in PM [13, 15, 16].  
 
To verify the expression levels of FRZB, TLE1, CNTN1, Serpin B3 and Serpin B4 we 
performed quantitative real-time RT-PCR (QPCR) using the same mRNA templates as for the 
microarrays. The down-regulation of FRZB, TLE1, and CNTN1 from benign MN to 
malignant PM and MM was largely confirmed with high statistical significance 
(Supplemental Figure 3). Also in case of Serpin B4, the up-regulation in PM compared to MN 
and MM could be reproduced by QPCR (p=0.028 and p=0.001, respectively). The Serpin B3-
QPCR confirmed the significant down-regulation in MM compared to PM (p=0.001) and 
showed a trend towards up-regulation in PM (p=0.422). 
 
For proof-of-principle that the observed transcriptional changes also translate into different 
protein levels, we picked one candidate marker with particularly interesting biology, GDF15 
(up-regulated in melanoma), for further tissue microarray analysis (Figure 1). As control gene 
with known regulation, MMP1 was selected. Two independent investigators (A.M., T.V.) 
evaluated immunostaining of >280 human tissue specimens based on a 5-step scoring system 
(for details, see Methods, Supplemental Table 4). Inter- and intra-examiner reproducibility 
was 86.2 % (GDF15) and 79.5 % (MMP1), respectively. In accordance with the microarray 
data, PM and MM revealed a high expression of GDF15 protein (average scores 2.52 and 
2.21, respectively), whereas GDF15 expression in MN was almost negligible (average score 
0.91). The differences in expression were highly significant with p=1.8 E-20 for MN vs. PM 
and p<0.05 for PM vs. MM, respectively (Chi square test). To our knowledge this is the first 
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time that GDF15 protein expression was analyzed in a large panel of melanocytic tumors. 
Interestingly, progression free survival (PFS) in melanoma patients with low GDF15 staining 
(0 to 2+) was significantly higher compared to patients with high GDF15 expression (3+ to 
4+) (p=0.037; Figure 2A). Confirming previous reports on matrix metalloproteinases [31, 32], 
we observed a high immunoreactivity for MMP1 in PM (average score 3.02) with a 
significant decrease in MM (2.46, p=1.26 E-5, Chi square test) and MN (mean 2.29, p=2 E-
12, Chi square test). Here, no significant difference in PFS was observed between melanoma 





In this study, we performed gene expression profiling and computational network analysis of 
a large series of patient samples derived from MN, PM and MM to gain new insights into 
melanoma biology. Our experiments discovered a panel of new candidate markers that are 
associated with melanoma-relevant signaling pathways such as MAPK-, Notch-, and Wnt-
signaling. 
 
Since the discovery of activating BRAF mutations in high percentage of melanoma [33-35], 
the MAPK signal transduction (with its various cascades of MAPKKKs, MAPKKs, and 
MAPKs) has been put into focus of melanoma research, not least, because of its highly drug-
targetable potential. However, recent failures in BRAF-targeting therapy [4] disclosed our 
considerable lack in understanding this pathway and its interaction with other signaling 
networks [5]. As expected, also in our set of samples, we found differential expression of 
genes with known association to MAPK signaling. For example, STAT1 and SPP1 were up-
regulated in PM compared to MN whereas PPP1R3C was down-regulated. In response to 
cytokines and growth factors, STAT family members are phosphorylated by the receptor 
associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus, 
where they act as transcription activators. In former studies, SPP1 was found to be strongly 
up-regulated in PM and MM [6, 13, 36], which is in accordance with our data. Little is known 
about the function and role of PPP1R3C in human cancer. It is supposed to have tumor 
suppressor function since promoter hypermethylation and reduced mRNA expression were 
shown in melanoma compared to melanocytes [37].   
 
As novel progression-related markers with association to MAPK signaling, we identified two 
Serpin peptidase inhibitors, Serpin B3 (squamous cell carcinoma antigen 1, SCCA1) and 
Serpin B4 (SCCA2, leupin). Both were strongly up-regulated in PM compared to MN and 
down-regulated in MM. Recently, it has been shown that Serpin B3 is a specific endogenous 
inhibitor of c-Jun-NH²-terminal kinase-1 (JNK1/MAPK8) and protects UV-exposed 
keratinocytes from apoptotic cell death after sun exposure [38]. Little is known about the role 
of Serpin B3 and Serpin B4 in melanoma. In squamous cell carcinomas of the cervix, lung, 
head and neck, however, Serpin B3 is already used as a tumor marker [39, 40]. Serpin B4 
could be a general marker for tumor invasion and metastasis because its suppression by 
antisense cDNA, e.g. in uterine cancer cells, is followed by a decrease of E-cadherin 
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expression, which determines a common step in loss of cell-cell adhesion [41]. Since also 
melanoma cells can escape from keratinocyte control through down-regulation of E-cadherin 
[17], we assume that Serpins play an important role also during melanoma progression. This 
conclusion is further supported by our observation that another family member, Serpin B5 
(maspin), was additionally decreased in MMs. Loss of Serpin B5 is another marker for 
invasion and migration in a variety of other tumors such as breast, prostate, and pancreatic 
cancer [42]. 
 
Next to the MAPK pathway, TGF-β signaling is critical for tumor cell invasion and metastasis 
[43]. We found GDF15, a member of the TGF-β superfamily, to be dramatically up-regulated 
in PM and MM compared to MN. In addition, we found that low GDF15 expression in 
melanoma patients is associated with higher progression free survival compared to high 
GDF15 expression. This matches previous reports on GDF15 suggesting a role in 
invasiveness of gastric cancer cells through up-regulation of the urokinase-type plasminogen 
activator system in an ERK1/2- dependent pathway [44]. Just recently, Boyle and co-workers 
started to mechanistically unravel the role of GDF15 in melanoma. They showed that shRNA 
knockdown in three different melanoma cell lines resulted in significantly decreased 
tumorigenicity in a mouse xenograft model [45]. This is also in accordance with a former 
finding by Talantov et al. who proposed that GDF15 is a better marker for differentiation 
between melanomas from benign nevi than the conventional markers tyrosinase, me20m and 
MART1 [15]. Because of its additional connection to other cancer pathways such as p53 [46], 
MITF [47], and PI3K/AKT signaling [45, 48, 49], it may represent a new key player in the 
development of metastatic melanoma associated with poor prognosis and survival [50]. 
 
With FRZB and TLE1 we also detected two players of the Wnt signaling pathway to be 
down-regulated in PM compared to MN. FRZB (sFRP3) belongs to the secreted Frizzled-
related protein family, whose members prevent ligand-receptor interaction by binding to 
extracellular Wnt ligands [51, 52]. It has been suggested that FRZB exhibits tumor suppressor 
activity since down-regulation of FRZB has been shown to be involved in pleural 
mesothelioma [53] and prostate cancer [54]. TLE1 is a member of the Groucho/TLE/Grg 
family of corepressors that operate in many signaling pathways [55, 56]. It has important 
transcription factor partners, e.g. TCF/LEF-1 in the case of the Wnt signaling pathway [57]. 
TLE1 inactivation was suggested to contribute to the development of hematologic 
 19
malignancies by disrupting critical differentiation and growth suppressing pathways [58]. In 
Notch signaling, TLE1 functions as a co-repressor for HES1, which is activated in some 
human malignancies and allows tumor cells to evade differentiation and irreversible cell cycle 
arrest [52, 59]. Although there is increasing evidence for the critical role of Wnt signaling in 
tumor development, there are only a few studies available on Wnt in melanoma [60-63]. 
According to our data, particularly FRZB and TLE1 would represent promising future study 
targets in this context. 
 
CNTN1, a member of the immunoglobulin superfamily, is a GPI- anchored neuronal 
membrane protein that functions as a cell adhesion molecule and acts as a functional ligand 
for Notch, e.g. during oligodendrocyte maturation [64]. Depending on the tissue context, 
Notch signaling can exhibit tumor initiating or tumor suppressive properties through complex 
modulation of tumor cell differentiation, proliferation, and apoptosis [65, 66]. In melanoma, 
activation of Notch signaling seems to be important throughout tumor progression. For 
example, stable overexpression of Nic, the active form of Notch, in benign melanocytes leads 
to transformation into a malignant phenotype whereas activation of Notch1 in primary 
melanoma cells resulted in a more metastatic phenotype [67, 68]. Hence, CNTN1 could be a 
so far overlooked critical progression factor in melanoma and should be investigated in follow 
up studies. 
 
In confirmation with previous profiling studies by others and us, the present data support the 
concept that primary and metastatic melanomas are characterized by distinct gene expression 
patterns, in particular when compared to benign melanocytic nevi. These expression patterns 
reflect the activation/deactivation of cancer signaling pathways that are well-known for 
melanoma, such as MAPK-, Wnt-, or Notch-signaling. However, novel molecular players are 
still emerging and need to be further evaluated to get a better and more comprehensive 
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Characteristics PM (%) MM (%) MN (%) 
Tissue samples 20 20 18 
Mean age 68.5 +-13.4 55 +- 15.63 23.33 +- 13.6 
Gender    
 Female 10 (50) 4 (29) 8 (50) 
 Male 10 (50) 10 (71) 8 (50) 
PM subtypes    
 ALM 2 (10)   
 LMM 3 (15)   
 NMM 4 (20)   
 SNM 5 (25)   
 SSM 6 (30)   
Tumor thickness according 
to Breslow 
   
 ≤1mm 4 (20)   
 1-2mm 4 (20)   
 ≥2mm 12 (60)   
Clark Level    
 I    
 II    
 III 3 (15)   
 IV 13 (65)   
 V 4 (20)   
T stage    
  T1 4 (20)   
 T2 6 (30)   
 T3 4 (20)   
 T4 6 (30)   
 
Table 1: Patient information with PM subtypes (ALM= acral lentiginous melanoma; LMM=  lentigo maligna 







Table 2: Melanoma-typic pathways are found regulated within the set of differentially expressed genes. ↑↓ 
refers to up- or down-regulated genes in PM (column 2), MM (column 3)  
 
Pathway PM c/t MN 
MM c/t PM 
MAPK (e.g. STAT1 ↑, SPP1 ↑, PPP1R3C ↓, GDF15 ↑, 
MMP1 ↑, Serpin B3 ↑ , Serpin B4 ↑) 
(Serpin B3 ↓, Serpin B4 ↓) 
PI3/AKT  (e.g. SFN ↓) 
Cell cycle control (e.g. cyclin B1 ↑, cyclin B2 ↑, CDKN1C↓, CDK2 ↑) (e.g. SFN ↓) 
Apoptosis (e.g. SPP1 ↑, TNFRSF21 ↑, BCL2A1 ↑)  
Cell-cell adhesion  (e.g. E-cadherin ↓, P-cadherin ↓) 
Wnt (e.g. TLE1 ↓, FRZB ↓) (e.g. E-cadherin ↓, P-cadherin ↓) 
Notch (e.g. CNTN1↓, HEY1 ↑)  
Integrin (e.g. ACTN1 ↑,ITGB2↑, FN1 ↑, LAMB4 ↓, 
COL4A1 ↑, COL4A2 ↑) 
(e.g. FN1 ↑, LAMC2 ↓, LAMA3 ↓) 




Figure 1: Immunohistochemical staining of GDF15 (A, B, C) and MMP1 (D, E, F) based on a 5-step scoring 
system (range 0-4+). Negative staining of GDF15 in a MN (A), positive (4+) staining in a PM (B) and MM (C), 
positive (2+) staining of MMP1 in a MN (D), positive (4+) staining in a PM (E) and positive (2+) staining in a 











Figure 2: Distribution of time (months) to melanoma progression among patients with low (0, 1+, 2+) and high 
(3+, 4+) immunoreactivity as estimated by the Kaplan-Meier method. IHC, immunohistochemistry; PFS, 











Gene up regulated in PM compared to MN 
23532 23532 PRAME preferentially expressed antigen in melanoma 3.297 9.82869584 
6696 6696 SPP1 secreted phosphoprotein 1 (osteopontin, bone sialoprotein 
I, early T-lymphocyte activation 1) 
2.815 7.03719261 
4283 4283 CXCL9 chemokine (C-X-C motif) ligand 9 2.743 6.69460994 
221692 221692 PHACTR1 phosphatase and actin regulator 1 2.628 6.1816844 
6280 6280 S100A9 S100 calcium binding protein A9 2.628 6.1816844 
4312 4312 MMP1 matrix metallopeptidase 1 (interstitial collagenase) 2.624 6.16456887 
3854 3854 KRT6B keratin 6B 2.474 5.55582054 
10537 10537 UBD ubiquitin D 2.349 5.0947099 
7453 7453 WARS tryptophanyl-tRNA synthetase 2.263 4.79988553 
6318 6318 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 2.256 4.77665275 
3627 3627 CXCL10 chemokine (C-X-C motif) ligand 10 2.121 4.34995356 
5996 5996 RGS1 regulator of G-protein signalling 1 2.106 4.3049605 
2335 2335 FN1 fibronectin 1 2.102 4.29304115 
3868 3868 KRT16 keratin 16 (focal non-epidermolytic palmoplantar 
keratoderma) 
2.091 4.26043281 
3853 3853 KRT6A keratin 6A 2.087 4.24863675 
6698 6698 SPRR1A small proline-rich protein 1A 2.061 4.17275437 
9518 9518 GDF15 growth differentiation factor 15 2.037 4.10391258 
2 2 A2M alpha-2-macroglobulin 1.987 3.96411825 
713 713 C1QB complement component 1, q subcomponent, B chain 1.936 3.82643263 
5266 5266 PI3 peptidase inhibitor 3, skin-derived (SKALP) 1.841 3.58258268 
91316 91316 LOC91316 similar to bK246H3.1 (immunoglobulin lambda-like 
polypeptide 1, pre-B-cell specific) 
1.829 3.55290718 
3371 3371 TNC tenascin C (hexabrachion) 1.79 3.45814893 
3492 3492 IGH@ immunoglobulin heavy locus 1.785 3.44618464 
27299 27299 ADAMDEC1 ADAM-like, decysin 1 1.78 3.43426175 
6279 6279 S100A8 S100 calcium binding protein A8 1.724 3.30351066 
91353 91353 CTA-246H3.1 similar to omega protein 1.685 3.21540396 
10563 10563 CXCL13 chemokine (C-X-C motif) ligand 13 (B-cell 
chemoattractant) 
1.66 3.16016525 
712 712 C1QA complement component 1, q subcomponent, A chain 1.63 3.09512999 
9232 9232 PTTG1 pituitary tumor-transforming 1 1.615 3.06311599 
6241 6241 RRM2 ribonucleotide reductase M2 polypeptide 1.593 3.01676015 
3937 3937 LCP2 lymphocyte cytosolic protein 2 (SH2 domain containing 
leukocyte protein of 76kDa) 
1.557 2.94241349 
6699 6699 SPRR1B small proline-rich protein 1B (cornifin) 1.55 2.92817139 
6317 6317 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 1.54 2.90794503 
4837 4837 NNMT nicotinamide N-methyltransferase 1.52 2.8679105 
55872 55872 PBK PDZ binding kinase 1.506 2.84021472 
3838 3838 KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 1.487 2.8030549 
4435 4435 CITED1 Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 1 
1.481 2.79142153 
7037 7037 TFRC transferrin receptor (p90, CD71) 1.475 2.77983644 
3872 3872 KRT17 keratin 17 1.474 2.77791027 
3429 3429 IFI27 interferon, alpha-inducible protein 27 1.469 2.76829943 
597 597 BCL2A1 BCL2-related protein A1 1.466 2.7625489 
10437 10437 IFI30 interferon, gamma-inducible protein 30 1.462 2.75490009 
6772 6772 STAT1 signal transducer and activator of transcription 1, 91kDa 1.46 2.75108364 
3512 3512 IGJ immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides 
1.456 2.74346658 
11065 11065 UBE2C ubiquitin-conjugating enzyme E2C 1.449 2.73018744 
3595 3595 IL12RB2 interleukin 12 receptor, beta 2 1.448 2.72829567 
7378 7378 UPP1 uridine phosphorylase 1 1.448 2.72829567 
7262 7262 PHLDA2 pleckstrin homology-like domain, family A, member 2 1.436 2.70569646 
963 963 CD53 CD53 molecule 1.422 2.6795672 
23327 23327 NEDD4L neural precursor cell expressed, developmentally down-
regulated 4-like 
1.402 2.64267681 
2633 2633 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa 1.383 2.60810147 
2537 2537 IFI6 interferon, alpha-inducible protein 6 1.382 2.6062943 
7805 7805 LAPTM5 lysosomal associated multispanning membrane protein 5 1.378 2.59907812 
1508 1508 CTSB cathepsin B 1.377 2.59727721 
6362 6362 CCL18 chemokine (C-C motif) ligand 18 (pulmonary and 
activation-regulated) 
1.369 2.5829147 
813 813 CALU calumenin 1.369 2.5829147 
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4162 4162 MCAM melanoma cell adhesion molecule 1.362 2.57041267 
3108 3108 HLA-DMA major histocompatibility complex, class II, DM alpha 1.356 2.55974483 
9636 9636 ISG15 ISG15 ubiquitin-like modifier 1.355 2.55797116 
2207 2207 FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide 
1.351 2.55088878 
822 822 CAPG capping protein (actin filament), gelsolin-like 1.344 2.53854177 
6947 6947 TCN1 transcobalamin I (vitamin B12 binding protein, R binder 
family) 
1.343 2.5367828 
929 929 CD14 CD14 molecule 1.343 2.5367828 
1687 1687 DFNA5 deafness, autosomal dominant 5 1.339 2.52975908 
6363 6363 CCL19 chemokine (C-C motif) ligand 19 1.331 2.51576994 
1282 1282 COL4A1 collagen, type IV, alpha 1 1.32 2.4966611 
891 891 CCNB1 cyclin B1 1.314 2.48629934 
9332 9332 CD163 CD163 molecule 1.293 2.45037066 
1164 1164 CKS2 CDC28 protein kinase regulatory subunit 2 1.291 2.44697608 
11015 11015 KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 3 
1.288 2.44189303 
6574 6574 SLC20A1 solute carrier family 20 (phosphate transporter), member 1 1.287 2.44020102 
22996 22996 C1orf34 chromosome 1 open reading frame 34 1.284 2.43513204 
5653 5653 KLK6 kallikrein-related peptidase 6 1.282 2.43175857 
6035 6035 RNASE1 ribonuclease, RNase A family, 1 (pancreatic) 1.279 2.42670712 
684 684 BST2 bone marrow stromal cell antigen 2 1.273 2.41663569 
6352 6352 CCL5 chemokine (C-C motif) ligand 5 1.271 2.41328784 
914 914 CD2 CD2 molecule 1.26 2.39495741 
22974 22974 TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) 1.259 2.39329793 
6955 6955 TRA@ T cell receptor alpha locus 1.258 2.39163959 
51303 51303 FKBP11 FK506 binding protein 11, 19 kDa 1.254 2.38501774 
55379 55379 LRRC59 leucine rich repeat containing 59 1.249 2.37676621 
962 962 CD48 CD48 molecule 1.239 2.36034869 
3778 3778 KCNMA1 potassium large conductance calcium-activated channel, 
subfamily M, alpha member 1 
1.234 2.3521825 
9133 9133 CCNB2 cyclin B2 1.232 2.34892394 
55062 55062 WIPI1 WD repeat domain, phosphoinositide interacting 1 1.229 2.34404457 
5698 5698 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 
(large multifunctional peptidase 2) 
1.226 2.33917533 
5315 5315 PKM2 pyruvate kinase, muscle 1.225 2.3375545 
51514 51514 DTL denticleless homolog (Drosophila) 1.224 2.33593479 
57103 57103 C12orf5 chromosome 12 open reading frame 5 1.211 2.31498043 
7298 7298 TYMS thymidylate synthetase 1.209 2.31177341 
344 344 APOC2 apolipoprotein C-II 1.204 2.30377528 
9404 9404 LPXN leupaxin 1.204 2.30377528 
7305 7305 TYROBP TYRO protein tyrosine kinase binding protein 1.204 2.30377528 
3576 3576 IL8 interleukin 8 1.198 2.29421405 
9768 9768 KIAA0101 KIAA0101 1.198 2.29421405 
23406 23406 COTL1 coactosin-like 1 (Dictyostelium) 1.197 2.29262437 
3001 3001 GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte-
associated serine esterase 3) 
1.197 2.29262437 
9787 9787 DLG7 discs, large homolog 7 (Drosophila) 1.193 2.28627667 
5327 5327 PLAT plasminogen activator, tissue 1.183 2.2704842 
4318 4318 MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) 
1.174 2.25636427 
3059 3059 HCLS1 hematopoietic cell-specific Lyn substrate 1 1.172 2.25323846 
397 397 ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 1.159 2.23302592 
972 972 CD74 CD74 molecule, major histocompatibility complex, class II 
invariant chain 
1.157 2.22993244 
9833 9833 MELK maternal embryonic leucine zipper kinase 1.157 2.22993244 
1284 1284 COL4A2 collagen, type IV, alpha 2 1.156 2.2283873 
6790 6790 AURKA aurora kinase A 1.152 2.22221746 
4069 4069 LYZ lysozyme (renal amyloidosis) 1.15 2.21913894 
87 87 ACTN1 actinin, alpha 1 1.146 2.21299471 
23462 23462 HEY1 hairy/enhancer-of-split related with YRPW motif 1 1.143 2.20839769 
1017 1017 CDK2 cyclin-dependent kinase 2 1.141 2.20533833 
1033 1033 CDKN3 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual 
specificity phosphatase) 
1.141 2.20533833 
4939 4939 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa 1.134 2.19466388 
6890 6890 TAP1 transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
1.133 2.19314318 
3669 3669 ISG20 interferon stimulated exonuclease gene 20kDa 1.13 2.1885874 
27242 27242 TNFRSF21 tumor necrosis factor receptor superfamily, member 21 1.128 2.18555548 
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4111 4111 MAGEA12 melanoma antigen family A, 12 1.127 2.18404109 
6490 6490 SILV silver homolog (mouse) 1.121 2.17497678 
11332 11332 ACOT7 acyl-CoA thioesterase 7 1.121 2.17497678 
3003 3003 GZMK granzyme K (granzyme 3; tryptase II) 1.121 2.17497678 
51338 51338 MS4A4A membrane-spanning 4-domains, subfamily A, member 4 1.119 2.17196371 
6271 6271 S100A1 S100 calcium binding protein A1 1.119 2.17196371 
6347 6347 CCL2 chemokine (C-C motif) ligand 2 1.114 2.16444929 
3959 3959 LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein 1.114 2.16444929 
57016 57016 AKR1B10 aldo-keto reductase family 1, member B10 (aldose 
reductase) 
1.104 2.14949835 
12 12 SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 
1.099 2.14206165 
3002 3002 GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-
associated serine esterase 1) 
1.087 2.12431837 
7852 7852 CXCR4 chemokine (C-X-C motif) receptor 4 1.084 2.11990557 
3394 3394 IRF8 interferon regulatory factor 8 1.08 2.11403608 
6373 6373 CXCL11 chemokine (C-X-C motif) ligand 11 1.075 2.10672207 
10095 10095 ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa 1.071 2.10088909 
5265 5265 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
1.071 2.10088909 
5214 5214 PFKP phosphofructokinase, platelet 1.069 2.09797866 
3123 3123 HLA-DRB1 major histocompatibility complex, class II, DR beta 1 1.067 2.09507225 
51056 51056 LAP3 leucine aminopeptidase 3 1.065 2.09216988 
6402 6402 SELL selectin L (lymphocyte adhesion molecule 1) 1.064 2.0907202 
533 533 ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 1.064 2.0907202 
58986 58986 TMEM8 transmembrane protein 8 (five membrane-spanning 
domains) 
1.062 2.08782385 
717 717 C2 complement component 2 1.061 2.08637719 
8836 8836 GGH gamma-glutamyl hydrolase (conjugase, 
folylpolygammaglutamyl hydrolase) 
1.057 2.08060053 
11031 11031 RAB31 RAB31, member RAS oncogene family 1.056 2.07915887 
51330 51330 TNFRSF12A tumor necrosis factor receptor superfamily, member 12A 1.056 2.07915887 
9263 9263 STK17A serine/threonine kinase 17a 1.055 2.07771821 
3122 3122 HLA-DRA major histocompatibility complex, class II, DR alpha 1.044 2.06193664 
948 948 CD36 CD36 molecule (thrombospondin receptor) 1.041 2.05765342 
1893 1893 ECM1 extracellular matrix protein 1 1.04 2.05622765 
3689 3689 ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 
4 subunit) 
1.04 2.05622765 
11145 11145 HRASLS3 HRAS-like suppressor 3 1.034 2.0476938 
10962 10962 MLLT11 myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 11 
1.033 2.04627494 
4314 4314 MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) 1.032 2.04485706 
915 915 CD3D CD3d molecule, delta (CD3-TCR complex) 1.031 2.04344017 
3113 3113 HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 1.026 2.0363704 
6999 6999 TDO2 tryptophan 2,3-dioxygenase 1.025 2.03495938 
3109 3109 HLA-DMB major histocompatibility complex, class II, DM beta 1.019 2.0265138 
1123 1123 CHN1 chimerin (chimaerin) 1 1.019 2.0265138 
8870 8870 IER3 immediate early response 3 1.018 2.02510961 
2745 2745 GLRX glutaredoxin (thioltransferase) 1.018 2.02510961 
79139 79139 DERL1 Der1-like domain family, member 1 1.01 2.0139111 
3713 3713 IVL involucrin 1.01 2.0139111 
332 332 BIRC5 baculoviral IAP repeat-containing 5 (survivin) 1.009 2.01251565 
1503 1503 CTPS CTP synthase 1.007 2.00972764 
1601 1601 DAB2 disabled homolog 2, mitogen-responsive phosphoprotein 
(Drosophila) 
1.006 2.00833509 
9055 9055 PRC1 protein regulator of cytokinesis 1 1.006 2.00833509 
10112 10112 KIF20A kinesin family member 20A 1.006 2.00833509 
1476 1476 CSTB cystatin B (stefin B) 1.005 2.0069435 
29887 29887 SNX10 sorting nexin 10 1.003 2.00416321 
5641 5641 LGMN legumain 1.001 2.00138677 
5476 5476 CTSA cathepsin A 1 2 
Gene down regulated in PM compared to MN 
6137 6137 RPL13 ribosomal protein L13 -1.004 2.00555287 
80201 80201 HKDC1 hexokinase domain containing 1 -1.005 2.0069435 
4501 4501 MT1X metallothionein 1X -1.005 2.0069435 
29997 29997 GLTSCR2 glioma tumor suppressor candidate region gene 2 -1.005 2.0069435 
5803 5803 PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 
1 
-1.013 2.01810327 
91851 91851 CHRDL1 chordin-like 1 -1.014 2.0195026 
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23650 23650 TRIM29 tripartite motif-containing 29 -1.016 2.02230416 
10351 10351 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 -1.019 2.0265138 
2628 2628 GATM glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
-1.021 2.02932509 
3590 3590 IL11RA interleukin 11 receptor, alpha -1.024 2.03354935 
6304 6304 SATB1 SATB homeobox 1 -1.029 2.04060932 
23461 23461 ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5 -1.031 2.04344017 
120 120 ADD3 adducin 3 (gamma) -1.033 2.04627494 
3480 3480 IGF1R insulin-like growth factor 1 receptor -1.033 2.04627494 
55638 55638 FLJ20366 hypothetical protein FLJ20366 -1.034 2.0476938 
92211 92211 PCDH21 protocadherin 21 -1.037 2.05195629 
23705 23705 CADM1 cell adhesion molecule 1 -1.037 2.05195629 
1153 1153 CIRBP cold inducible RNA binding protein -1.039 2.05480288 
9638 9638 FEZ1 fasciculation and elongation protein zeta 1 (zygin I) -1.04 2.05622765 
3316 3316 HSPB2 heat shock 27kDa protein 2 -1.044 2.06193664 
7102 7102 TSPAN7 tetraspanin 7 -1.045 2.06336636 
10278 10278 EFS embryonal Fyn-associated substrate -1.047 2.06622878 
5325 5325 PLAGL1 pleiomorphic adenoma gene-like 1 -1.048 2.06766147 
2947 2947 GSTM3 glutathione S-transferase M3 (brain) -1.049 2.06909516 
7306 7306 TYRP1 tyrosinase-related protein 1 -1.049 2.06909516 
55366 55366 LGR4 leucine-rich repeat-containing G protein-coupled receptor 
4 
-1.054 2.07627854 
56967 56967 C14orf132 chromosome 14 open reading frame 132 -1.057 2.08060053 
81578 81578 COL21A1 collagen, type XXI, alpha 1 -1.057 2.08060053 
23075 23075 SWAP70 SWAP-70 protein -1.069 2.09797866 
3131 3131 HLF hepatic leukemia factor -1.071 2.10088909 
51309 51309 ARMCX1 armadillo repeat containing, X-linked 1 -1.074 2.10526231 
23037 23037 PDZD2 PDZ domain containing 2 -1.076 2.10818285 
1474 1474 CST6 cystatin E/M -1.083 2.11843667 
23641 23641 LDOC1 leucine zipper, down-regulated in cancer 1 -1.088 2.12579135 
224 224 ALDH3A2 aldehyde dehydrogenase 3 family, member A2 -1.092 2.13169347 
1028 1028 CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) -1.098 2.1405774 
84909 84909 C9orf3 chromosome 9 open reading frame 3 -1.11 2.15845647 
1828 1828 DSG1 desmoglein 1 -1.113 2.16294953 
7991 7991 TUSC3 tumor suppressor candidate 3 -1.115 2.16595009 
79652 79652 C16orf30 chromosome 16 open reading frame 30 -1.124 2.17950422 
7704 7704 ZBTB16 zinc finger and BTB domain containing 16 -1.126 2.18252775 
26053 26053 AUTS2 autism susceptibility candidate 2 -1.129 2.18707091 
7101 7101 NR2E1 nuclear receptor subfamily 2, group E, member 1 -1.129 2.18707091 
22798 22798 LAMB4 laminin, beta 4 -1.134 2.19466388 
23678 23678 SGK3 serum/glucocorticoid regulated kinase family, member 3 -1.136 2.19770844 
1832 1832 DSP desmoplakin -1.138 2.20075722 
25854 25854 DKFZP564J102 DKFZP564J102 protein -1.14 2.20381023 
1974 1974 EIF4A2 eukaryotic translation initiation factor 4A, isoform 2 -1.145 2.21146131 
8796 8796 SCEL sciellin -1.156 2.2283873 
6662 6662 SOX9 SRY (sex determining region Y)-box 9 (campomelic 
dysplasia, autosomal sex-reversal) 
-1.156 2.2283873 
7088 7088 TLE1 transducin-like enhancer of split 1 (E(sp1) homolog, 
Drosophila) 
-1.163 2.23922578 
738 738 C11orf2 chromosome 11 open reading frame2 -1.168 2.24699981 
2153 2153 F5 coagulation factor V (proaccelerin, labile factor) -1.169 2.24855785 
51302 51302 CYP39A1 cytochrome P450, family 39, subfamily A, polypeptide 1 -1.177 2.26106113 
9890 9890 LPPR4 plasticity related gene 1 -1.186 2.27521046 
563 563 AZGP1 alpha-2-glycoprotein 1, zinc-binding -1.187 2.27678806 
114088 114088 TRIM9 tripartite motif-containing 9 -1.194 2.28786195 
4897 4897 NRCAM neuronal cell adhesion molecule -1.195 2.28944832 
9413 9413 C9orf61 chromosome 9 open reading frame 61 -1.197 2.29262437 
23635 23635 SSBP2 single-stranded DNA binding protein 2 -1.207 2.30857084 
65982 65982 ZSCAN18 zinc finger and SCAN domain containing 18 -1.218 2.32624008 
1823 1823 DSC1 desmocollin 1 -1.245 2.37018554 
3400 3400 ID4 inhibitor of DNA binding 4, dominant negative helix-loop-
helix protein 
-1.269 2.40994463 
2261 2261 FGFR3 fibroblast growth factor receptor 3 (achondroplasia, 
thanatophoric dwarfism) 
-1.269 2.40994463 
55227 55227 LRRC1 leucine rich repeat containing 1 -1.271 2.41328784 
1825 1825 DSC3 desmocollin 3 -1.274 2.41831135 
3861 3861 KRT14 keratin 14 (epidermolysis bullosa simplex, Dowling-Meara, 
Koebner) 
-1.275 2.41998818 
25875 25875 LETMD1 LETM1 domain containing 1 -1.282 2.43175857 
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1308 1308 COL17A1 collagen, type XVII, alpha 1 -1.292 2.44867278 
8470 8470 SORBS2 sorbin and SH3 domain containing 2 -1.299 2.46058269 
4014 4014 LOR loricrin -1.3 2.46228883 
80310 80310 PDGFD platelet derived growth factor D -1.303 2.46741434 
259217 259217 HSPA12A heat shock 70kDa protein 12A -1.306 2.47255052 
51765 51765 RP6-213H19.1 serine/threonine protein kinase MST4 -1.32 2.4966611 
23382 23382 KIAA0828 adenosylhomocysteinase 3 -1.329 2.51228476 
4023 4023 LPL lipoprotein lipase -1.33 2.51402675 
2878 2878 GPX3 glutathione peroxidase 3 (plasma) -1.345 2.54030197 
3769 3769 KCNJ13 potassium inwardly-rectifying channel, subfamily J, 
member 13 
-1.347 2.54382601 
3852 3852 KRT5 keratin 5 (epidermolysis bullosa simplex, Dowling-
Meara/Kobner/Weber-Cockayne types) 
-1.349 2.54735495 
51673 51673 CGI-38 brain specific protein -1.355 2.55797116 
5836 5836 PYGL phosphorylase, glycogen; liver (Hers disease, glycogen 
storage disease type VI) 
-1.366 2.57754926 
2625 2625 GATA3 GATA binding protein 3 -1.377 2.59727721 
113146 113146 C14orf78 chromosome 14 open reading frame 78 -1.401 2.64084568 
8404 8404 SPARCL1 SPARC-like 1 (mast9, hevin) -1.403 2.64450921 
5348 5348 FXYD1 FXYD domain containing ion transport regulator 1 
(phospholemman) 
-1.41 2.65737163 
3080 3080 CFHR2 complement factor H-related 2 -1.435 2.70382167 
63928 63928 LOC63928 hepatocellular carcinoma antigen gene 520 -1.45 2.73208051 
688 688 KLF5 Kruppel-like factor 5 (intestinal) -1.456 2.74346658 
10218 10218 ANGPTL7 angiopoietin-like 7 -1.46 2.75108364 
9355 9355 LHX2 LIM homeobox 2 -1.499 2.82646729 
667 667 DST dystonin -1.506 2.84021472 
83604 83604 TMEM47 transmembrane protein 47 -1.533 2.89386977 
1272 1272 CNTN1 contactin 1 -1.542 2.9119791 
1428 1428 CRYM crystallin, mu -1.561 2.95058291 
3849 3849 KRT2 keratin 2 (epidermal ichthyosis bullosa of Siemens) -1.574 2.97729051 
23086 23086 EXPH5 exophilin 5 -1.608 3.04828966 
9547 9547 CXCL14 chemokine (C-X-C motif) ligand 14 -1.619 3.07162054 
2487 2487 FRZB frizzled-related protein -1.642 3.12098192 
4308 4308 TRPM1 transient receptor potential cation channel, subfamily M, 
member 1 
-1.646 3.12964713 
5507 5507 PPP1R3C protein phosphatase 1, regulatory (inhibitor) subunit 3C -1.66 3.16016525 
10391 10391 CORO2B coronin, actin binding protein, 2B -1.664 3.16893924 
2259 2259 FGF14 fibroblast growth factor 14 -1.673 3.18876991 
445 445 ASS1 argininosuccinate synthetase 1 -1.697 3.24226048 
4118 4118 MAL mal, T-cell differentiation protein -1.711 3.27387673 
10850 10850 CCL27 chemokine (C-C motif) ligand 27 -1.756 3.37760355 
3848 3848 KRT1 keratin 1 (epidermolytic hyperkeratosis) -1.77 3.41053957 
55118 55118 CRTAC1 cartilage acidic protein 1 -1.776 3.42475314 
11341 11341 SCRG1 scrapie responsive protein 1 -1.956 3.87984764 
2861 2861 GPR37 G protein-coupled receptor 37 (endothelin receptor type B-
like) 
-1.957 3.88253788 
25891 25891 DKFZP586H2123 regeneration associated muscle protease -1.976 3.9340083 
64131 64131 XYLT1 xylosyltransferase I -1.985 3.95862663 
2173 2173 FABP7 fatty acid binding protein 7, brain -2.009 4.02503129 
10752 10752 CHL1 cell adhesion molecule with homology to L1CAM (close 
homolog of L1) 
-2.124 4.35900845 
7021 7021 TFAP2B transcription factor AP-2 beta (activating enhancer binding 
protein 2 beta) 
-2.479 5.57510895 
3866 3866 KRT15 keratin 15 -2.662 6.32909841 
5764 5764 PTN pleiotrophin (heparin binding growth factor 8, neurite 
growth-promoting factor 1) 
-2.895 7.43843954 













Gene up regulated in MM compared to PM 
6696 6696 SPP1 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, 
early T-lymphocyte activation 1) 
1.797 3.47496874 
4745 4745 NELL1 NEL-like 1 (chicken) 1.697 3.24226048 
6192 6192 RPS4Y1 ribosomal protein S4, Y-linked 1 1.554 2.93630127 
91353 91353 CTA-
246H3.1 
similar to omega protein 1.515 2.85798828 
91316 91316 LOC91316 similar to bK246H3.1 (immunoglobulin lambda-like polypeptide 1, 
pre-B-cell specific) 
1.499 2.82646729 
4256 4256 MGP matrix Gla protein 1.392 2.62442251 
216 216 ALDH1A1 aldehyde dehydrogenase 1 family, member A1 1.367 2.5793365 
4111 4111 MAGEA12 melanoma antigen family A, 12 1.333 2.51925996 
3426 3426 CFI complement factor I 1.278 2.42502564 
2947 2947 GSTM3 glutathione S-transferase M3 (brain) 1.262 2.39827983 
23336 23336 DMN desmuslin 1.247 2.3734736 
12 12 SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 
1.211 2.31498043 
3485 3485 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 1.206 2.30697121 
3492 3492 IGH@ immunoglobulin heavy locus 1.191 2.28310941 
6781 6781 STC1 stanniocalcin 1 1.157 2.22993244 
730 730 C7 complement component 7 1.151 2.22067767 
7422 7422 VEGFA vascular endothelial growth factor A 1.14 2.20381023 
4233 4233 MET met proto-oncogene (hepatocyte growth factor receptor) 1.136 2.19770844 
2138 2138 EYA1 eyes absent homolog 1 (Drosophila) 1.087 2.12431837 
2335 2335 FN1 fibronectin 1 1.071 2.10088909 
7991 7991 TUSC3 tumor suppressor candidate 3 1.044 2.06193664 
5352 5352 PLOD2 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 1.038 2.05337909 
7078 7078 TIMP3 TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, 
pseudoinflammatory) 
1.026 2.0363704 
7018 7018 TF transferrin 1.024 2.03354935 
1E+05 114088 TRIM9 tripartite motif-containing 9 1.022 2.0307322 
5740 5740 PTGIS prostaglandin I2 (prostacyclin) synthase 1.002 2.00277451 
Gene down regulated in MM compared to PM 
27065 27065 D4S234E DNA segment on chromosome 4 (unique) 234 expressed 
sequence 
-1.011 2.01530752 
6283 6283 S100A12 S100 calcium binding protein A12 -1.013 2.01810327 
2878 2878 GPX3 glutathione peroxidase 3 (plasma) -1.017 2.0237064 
7286 7286 TUFT1 tuftelin 1 -1.019 2.0265138 
909 909 CD1A CD1a molecule -1.022 2.0307322 
4155 4155 MBP myelin basic protein -1.024 2.03354935 
445 445 ASS1 argininosuccinate synthetase 1 -1.027 2.03778239 
11254 11254 SLC6A14 solute carrier family 6 (amino acid transporter), member 14 -1.028 2.03919537 
23593 23593 HEBP2 heme binding protein 2 -1.033 2.04627494 
26085 26085 KLK13 kallikrein-related peptidase 13 -1.033 2.04627494 
3557 3557 IL1RN interleukin 1 receptor antagonist -1.036 2.05053448 
55040 55040 EPN3 epsin 3 -1.037 2.05195629 
306 306 ANXA3 annexin A3 -1.038 2.05337909 
1E+05 131578 LRRC15 leucine rich repeat containing 15 -1.038 2.05337909 
2707 2707 GJB3 gap junction protein, beta 3, 31kDa -1.044 2.06193664 
6401 6401 SELE selectin E (endothelial adhesion molecule 1) -1.048 2.06766147 
55612 55612 C20orf42 chromosome 20 open reading frame 42 -1.051 2.07196553 
3983 3983 ABLIM1 actin binding LIM protein 1 -1.062 2.08782385 
563 563 AZGP1 alpha-2-glycoprotein 1, zinc-binding -1.064 2.0907202 
646 646 BNC1 basonuclin 1 -1.065 2.09216988 
1646 1646 AKR1C2 aldo-keto reductase family 1, member C2 (dihydrodiol 
dehydrogenase 2; bile acid binding protein; 3-alpha 
hydroxysteroid dehydrogenase, type III) 
-1.065 2.09216988 
3918 3918 LAMC2 laminin, gamma 2 -1.067 2.09507225 
10276 10276 NET1 neuroepithelial cell transforming gene 1 -1.076 2.10818285 
288 288 ANK3 ankyrin 3, node of Ranvier (ankyrin G) -1.076 2.10818285 
10850 10850 CCL27 chemokine (C-C motif) ligand 27 -1.077 2.10964463 
4499 4499 MT1M metallothionein 1M -1.078 2.11110744 
51458 51458 RHCG Rh family, C glycoprotein -1.08 2.11403608 
1515 1515 CTSL2 cathepsin L2 -1.083 2.11843667 
3117 3117 HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 -1.085 2.12137548 
6362 6362 CCL18 chemokine (C-C motif) ligand 18 (pulmonary and activation- -1.094 2.13465068 
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regulated) 
80004 80004 RBM35B RNA binding motif protein 35B -1.097 2.13909418 
51228 51228 GLTP glycolipid transfer protein -1.106 2.15248025 
1040 1040 CDS1 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 
1 
-1.124 2.17950422 
3909 3909 LAMA3 laminin, alpha 3 -1.129 2.18707091 
202 202 AIM1 absent in melanoma 1 -1.132 2.19162353 
5655 5655 KLK10 kallikrein-related peptidase 10 -1.134 2.19466388 
9314 9314 KLF4 Kruppel-like factor 4 (gut) -1.14 2.20381023 
4856 4856 NOV nephroblastoma overexpressed gene -1.14 2.20381023 
1359 1359 CPA3 carboxypeptidase A3 (mast cell) -1.159 2.23302592 
1718 1718 DHCR24 24-dehydrocholesterol reductase -1.164 2.24077843 
51200 51200 CPA4 carboxypeptidase A4 -1.176 2.25949443 
1001 1001 CDH3 cadherin 3, type 1, P-cadherin (placental) -1.199 2.29580483 
11187 11187 PKP3 plakophilin 3 -1.201 2.2989897 
242 242 ALOX12B arachidonate 12-lipoxygenase, 12R type -1.209 2.31177341 
3934 3934 LCN2 lipocalin 2 (oncogene 24p3) -1.211 2.31498043 
222 222 ALDH3B2 aldehyde dehydrogenase 3 family, member B2 -1.238 2.35871318 
10974 10974 C10orf116 chromosome 10 open reading frame 116 -1.238 2.35871318 
3120 3120 HLA-DQB2 major histocompatibility complex, class II, DQ beta 2 -1.245 2.37018554 
53905 53905 DUOX1 dual oxidase 1 -1.256 2.38832637 
8673 8673 VAMP8 vesicle-associated membrane protein 8 (endobrevin) -1.258 2.39163959 
6785 6785 ELOVL4 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, 
yeast)-like 4 
-1.265 2.4032721 
1956 1956 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-
erb-b) oncogene homolog, avian) 
-1.265 2.4032721 
25797 25797 QPCT glutaminyl-peptide cyclotransferase (glutaminyl cyclase) -1.268 2.40827476 
1824 1824 DSC2 desmocollin 2 -1.273 2.41663569 
8626 8626 TP73L tumor protein p73-like -1.281 2.43007358 
771 771 CA12 carbonic anhydrase XII -1.288 2.44189303 
26154 26154 ABCA12 ATP-binding cassette, sub-family A (ABC1), member 12 -1.296 2.45547137 
7851 7851 MALL mal, T-cell differentiation protein-like -1.303 2.46741434 
6820 6820 SULT2B1 sulfotransferase family, cytosolic, 2B, member 1 -1.324 2.50359292 
2261 2261 FGFR3 fibroblast growth factor receptor 3 (achondroplasia, 
thanatophoric dwarfism) 
-1.329 2.51228476 
5646 5646 PRSS3 protease, serine, 3 (mesotrypsin) -1.331 2.51576994 
7051 7051 TGM1 transglutaminase 1 (K polypeptide epidermal type I, protein-
glutamine-gamma-glutamyltransferase) 
-1.338 2.5280062 
80740 80740 LY6G6C lymphocyte antigen 6 complex, locus G6C -1.344 2.53854177 
688 688 KLF5 Kruppel-like factor 5 (intestinal) -1.35 2.54912125 
7447 7447 VSNL1 visinin-like 1 -1.356 2.55974483 
6286 6286 S100P S100 calcium binding protein P -1.374 2.59188193 
57758 57758 SCUBE2 signal peptide, CUB domain, EGF-like 2 -1.4 2.63901582 
5275 5275 SERPINB13 serpin peptidase inhibitor, clade B (ovalbumin), member 13 -1.404 2.64634288 
4493 4493 MT1E metallothionein 1E -1.412 2.66105808 
1634 1634 DCN decorin -1.414 2.66474965 
3613 3613 IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 -1.418 2.67214816 
3898 3898 LAD1 ladinin 1 -1.419 2.67400099 
6337 6337 SCNN1A sodium channel, nonvoltage-gated 1 alpha -1.427 2.68886999 
1308 1308 COL17A1 collagen, type XVII, alpha 1 -1.427 2.68886999 
760 760 CA2 carbonic anhydrase II -1.431 2.69633546 
5055 5055 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 -1.454 2.73966596 
5653 5653 KLK6 kallikrein-related peptidase 6 -1.466 2.7625489 
7739 7739 ZNF185 zinc finger protein 185 (LIM domain) -1.469 2.76829943 
10653 10653 SPINT2 serine peptidase inhibitor, Kunitz type, 2 -1.473 2.77598544 
2205 2205 FCER1A Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide -1.474 2.77791027 
79852 79852 ABHD9 abhydrolase domain containing 9 -1.481 2.79142153 
999 999 CDH1 cadherin 1, type 1, E-cadherin (epithelial) -1.513 2.85402901 
3429 3429 IFI27 interferon, alpha-inducible protein 27 -1.566 2.9608266 
8710 8710 SERPINB7 serpin peptidase inhibitor, clade B (ovalbumin), member 7 -1.57 2.96904714 
9022 9022 CLIC3 chloride intracellular channel 3 -1.575 2.97935493 
8424 8424 BBOX1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-
butyrobetaine hydroxylase) 1 
-1.591 3.01258093 
25984 25984 KRT23 keratin 23 (histone deacetylase inducible) -1.627 3.08870053 
10874 10874 NMU neuromedin U -1.646 3.12964713 
6382 6382 SDC1 syndecan 1 -1.652 3.14269007 
79983 79983 POF1B premature ovarian failure, 1B -1.683 3.21094955 
2697 2697 GJA1 gap junction protein, alpha 1, 43kDa -1.691 3.2288043 
23086 23086 EXPH5 exophilin 5 -1.691 3.2288043 
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3397 3397 ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix 
protein 
-1.703 3.25577274 
57152 57152 SLURP1 secreted LY6/PLAUR domain containing 1 -1.71 3.27160823 
3728 3728 JUP junction plakoglobin -1.759 3.38463439 
7306 7306 TYRP1 tyrosinase-related protein 1 -1.766 3.40109664 
822 822 CAPG capping protein (actin filament), gelsolin-like -1.769 3.40817638 
1525 1525 CXADR coxsackie virus and adenovirus receptor -1.786 3.44857418 
9890 9890 LPPR4 plasticity related gene 1 -1.789 3.45575275 
11012 11012 KLK11 kallikrein-related peptidase 11 -1.797 3.47496874 
4312 4312 MMP1 matrix metallopeptidase 1 (interstitial collagenase) -1.831 3.55783597 
667 667 DST dystonin -1.832 3.56030293 
9982 9982 FGFBP1 fibroblast growth factor binding protein 1 -1.837 3.57266341 
934 934 CD24 CD24 molecule -1.859 3.62756132 
7277 7277 TUBA4A tubulin, alpha 4a -1.862 3.63511247 
8796 8796 SCEL sciellin -1.893 3.71406741 
1E+05 113146 C14orf78 chromosome 14 open reading frame 78 -1.931 3.81319418 
79755 79755 ZNF750 zinc finger protein 750 -1.951 3.86642439 
1041 1041 CDSN corneodesmosin -1.964 3.90142185 
57016 57016 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) -2.013 4.03620654 
57111 57111 RAB25 RAB25, member RAS oncogene family -2.021 4.05865019 
11202 11202 KLK8 kallikrein-related peptidase 8 -2.056 4.15831774 
3858 3858 KRT10 keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et 
plantaris) 
-2.096 4.27522396 
1382 1382 CRABP2 cellular retinoic acid binding protein 2 -2.101 4.29006647 
3815 3815 KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog -2.11 4.31691295 
1672 1672 DEFB1 defensin, beta 1 -2.173 4.50960165 
25818 25818 KLK5 kallikrein-related peptidase 5 -2.201 4.59797939 
3034 3034 HAL histidine ammonia-lyase -2.21 4.62675274 
26239 26239 LCE2B late cornified envelope 2B -2.272 4.82992237 
3866 3866 KRT15 keratin 15 -2.301 4.92799229 
6590 6590 SLPI secretory leukocyte peptidase inhibitor -2.372 5.17658262 
360 360 AQP3 aquaporin 3 (Gill blood group) -2.386 5.22706102 
64065 64065 PERP PERP, TP53 apoptosis effector -2.412 5.32211616 
23650 23650 TRIM29 tripartite motif-containing 29 -2.425 5.37029001 
5493 5493 PPL periplakin -2.488 5.609997 
383 383 ARG1 arginase, liver -2.522 5.74377804 
57402 57402 S100A14 S100 calcium binding protein A14 -2.527 5.763719 
5650 5650 KLK7 kallikrein-related peptidase 7 -2.552 5.86446703 
4070 4070 TACSTD2 tumor-associated calcium signal transducer 2 -2.589 6.01681501 
5266 5266 PI3 peptidase inhibitor 3, skin-derived (SKALP) -2.618 6.13898438 
84525 84525 HOP homeodomain-only protein -2.682 6.41744933 
1825 1825 DSC3 desmocollin 3 -2.682 6.41744933 
1474 1474 CST6 cystatin E/M -2.69 6.45313407 
810 810 CALML3 calmodulin-like 3 -2.698 6.48901724 
27076 27076 LYPD3 LY6/PLAUR domain containing 3 -2.708 6.53415193 
3849 3849 KRT2 keratin 2 (epidermal ichthyosis bullosa of Siemens) -2.727 6.62077453 
1830 1830 DSG3 desmoglein 3 (pemphigus vulgaris antigen) -2.826 7.09105359 
9635 9635 CLCA2 chloride channel, calcium activated, family member 2 -2.902 7.47461878 
4014 4014 LOR loricrin -2.953 7.74357622 
6317 6317 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 -2.993 7.96127777 
3713 3713 IVL involucrin -3.116 8.66980773 
2810 2810 SFN stratifin -3.132 8.76649413 
6318 6318 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 -3.147 8.85811668 
1828 1828 DSG1 desmoglein 1 -3.177 9.04424454 
9547 9547 CXCL14 chemokine (C-X-C motif) ligand 14 -3.24 9.44794129 
51806 51806 CALML5 calmodulin-like 5 -3.451 10.9358996 
1832 1832 DSP desmoplakin -3.469 11.0731977 
1823 1823 DSC1 desmocollin 1 -3.491 11.2433496 
3868 3868 KRT16 keratin 16 (focal non-epidermolytic palmoplantar keratoderma) -3.564 11.8268995 
11005 11005 SPINK5 serine peptidase inhibitor, Kazal type 5 -3.587 12.0169594 
6280 6280 S100A9 S100 calcium binding protein A9 -3.629 12.3719414 
1475 1475 CSTA cystatin A (stefin A) -3.647 12.5272687 
6698 6698 SPRR1A small proline-rich protein 1A -3.774 13.6800348 
3872 3872 KRT17 keratin 17 -3.966 15.6273365 
6273 6273 S100A2 S100 calcium binding protein A2 -4.102 17.1721646 
5268 5268 SERPINB5 serpin peptidase inhibitor, clade B (ovalbumin), member 5 -4.134 17.557311 




3854 3854 KRT6B keratin 6B -4.663 25.3339477 
3848 3848 KRT1 keratin 1 (epidermolytic hyperkeratosis) -4.865 29.1414347 
6699 6699 SPRR1B small proline-rich protein 1B (cornifin) -4.865 29.1414347 
6279 6279 S100A8 S100 calcium binding protein A8 -4.928 30.4421848 
3853 3853 KRT6A keratin 6A -4.965 31.2330163 












Gene up regulated in MM compared to MN 
6696 6696 SPP1 Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, 
early T-lymphocyte activation 1) 
4.612 24.4540243 
23532 23532 PRAME Preferentially expressed antigen in melanoma 3.907 15.0011375 
-1 -1 N.N.   3.574 11.909162 
91316 91316 LOC91316 Similar to bK246H3.1 (immunoglobulin lambda-like polypeptide 
1, pre-B-cell specific) 
3.328 10.0421759 
91353 91353 CTA-246H3.1 Similar to omega protein 3.2 9.18958684 
2335 2335 FN1 Fibronectin 1 3.173 9.0192033 
3492 3492 IGH@   2.976 7.86801659 
7453 7453 WARS Tryptophanyl-tRNA synthetase 2.921 7.57370905 
221692 221692 PHACTR1 Phosphatase and actin regulator 1 2.807 6.99827812 
10537 10537 UBD Ubiquitin D 2.722 6.59786839 
9518 9518 GDF15 Growth differentiation factor 15 2.645 6.25495715 
2 2 A2M Alpha-2-macroglobulin 2.639 6.22899753 
713 713 C1QB Complement component 1, q subcomponent, B chain 2.486 5.60222528 
4111 4111 MAGEA12 Melanoma antigen family A, 12 2.46 5.50216727 
4283 4283 CXCL9 Chemokine (C-X-C motif) ligand 9 2.329 5.02456952 
12 12 SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 3 
2.31 4.9588308 
5996 5996 RGS1 Regulator of G-protein signaling 1 2.253 4.7667303 
3512 3512 IGJ Immunoglobulin J polypeptide, linker protein for 
immunoglobulin alpha and mu polypeptides 
2.243 4.73380409 
712 712 C1QA Complement component 1, q subcomponent, A chain 2.102 4.29304115 
51303 51303 FKBP11 FK506 binding protein 11, 19 kDa 2.079 4.2251425 
6035 6035 RNASE1 Ribonuclease, RNase A family, 1 (pancreatic) 2.062 4.17564771 
4435 4435 CITED1 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 1 
1.967 3.90954307 
3627 3627 CXCL10 Chemokine (C-X-C motif) ligand 10 1.934 3.82113175 
4162 4162 MCAM Melanoma cell adhesion molecule 1.907 3.75028439 
597 597 BCL2A1 BCL2-related protein A1 1.899 3.72954595 
344 344 APOC2 Apolipoprotein C-II 1.873 3.66293475 
7076 7076 TIMP1 TIMP metallopeptidase inhibitor 1 1.839 3.57761961 
10563 10563 CXCL13 Chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant) 1.827 3.54798522 
7852 7852 CXCR4 Chemokine (C-X-C motif) receptor 4 1.822 3.53571012 
55872 55872 PBK PDZ binding kinase 1.803 3.48945082 
4311 4311 MME Membrane metallo-endopeptidase 1.763 3.39403161 
3426 3426 CFI Complement factor I 1.757 3.37994554 
10763 10763 NES Nestin 1.746 3.35427274 
1282 1282 COL4A1 Collagen, type IV, alpha 1 1.724 3.30351066 
5327 5327 PLAT Plasminogen activator, tissue 1.712 3.27614679 
4318 4318 MMP9 Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase) 
1.706 3.26254997 
929 929 CD14 CD14 molecule 1.698 3.24450862 
11065 11065 UBE2C Ubiquitin-conjugating enzyme E2C 1.654 3.14704978 
3485 3485 IGFBP2 Insulin-like growth factor binding protein 2, 36kDa 1.647 3.13181719 
6241 6241 RRM2 Ribonucleotide reductase M2 polypeptide 1.641 3.11881937 
1284 1284 COL4A2 Collagen, type IV, alpha 2 1.633 3.10157283 
51514 51514 DTL Denticleless homolog (Drosophila) 1.633 3.10157283 
9232 9232 PTTG1 Pituitary tumor-transforming 1 1.632 3.09942372 
10437 10437 IFI30 Interferon, gamma-inducible protein 30 1.622 3.07801444 
4100 4100 MAGEA1 Melanoma antigen family A, 1 (directs expression of antigen 
MZ2-E) 
1.599 3.02933263 
2207 2207 FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma 
polypeptide 
1.589 3.0084075 
813 813 CALU Calumenin 1.588 3.00632296 
7805 7805 LAPTM5 Lysosomal associated multispanning membrane protein 5 1.568 2.96493402 
10788 10788 IQGAP2 IQ motif containing GTPase activating protein 2 1.564 2.95672486 
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6574 6574 SLC20A1 Solute carrier family 20 (phosphate transporter), member 1 1.563 2.95467613 
3838 3838 KPNA2 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 1.546 2.92006402 
27242 27242 TNFRSF21 Tumor necrosis factor receptor superfamily, member 21 1.531 2.8898608 
1164 1164 CKS2 CDC28 protein kinase regulatory subunit 2 1.52 2.8679105 
10112 10112 KIF20A Kinesin family member 20A 1.519 2.8659233 
7422 7422 VEGFA Vascular endothelial growth factor A 1.518 2.86393748 
7298 7298 TYMS Thymidylate synthetase 1.514 2.85600796 
11015 11015 KDELR3   1.504 2.83628007 
9787 9787 DLG7 Discs, large homolog 7 (Drosophila) 1.491 2.8108374 
684 684 BST2 Bone marrow stromal cell antigen 2 1.479 2.78755448 
22974 22974 TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) 1.479 2.78755448 
6515 6515 SLC2A3 Solute carrier family 2 (facilitated glucose transporter), member 
3 
1.476 2.78176394 
11145 11145 HRASLS3 HRAS-like suppressor 3 1.468 2.76638126 
891 891 CCNB1 Cyclin B1 1.467 2.76446441 
9133 9133 CCNB2 Cyclin B2 1.464 2.75872184 
4745 4745 NELL1 NEL-like 1 (chicken) 1.447 2.72640521 
4233 4233 MET Met proto-oncogene (hepatocyte growth factor receptor) 1.44 2.71320865 
23643 23643 LY96 Lymphocyte antigen 96 1.437 2.70757256 
9332 9332 CD163 CD163 molecule 1.433 2.70007597 
4256 4256 MGP Matrix Gla protein 1.432 2.69820507 
6271 6271 S100A1 S100 calcium binding protein A1 1.428 2.69073442 
9123 9123 SLC16A3 Solute carrier family 16, member 3 (monocarboxylic acid 
transporter 4) 
1.42 2.67585511 
4837 4837 NNMT Nicotinamide N-methyltransferase 1.414 2.66474965 
7262 7262 PHLDA2 Pleckstrin homology-like domain, family A, member 2 1.412 2.66105808 
9768 9768 KIAA0101 KIAA0101 1.403 2.64450921 
5450 5450 POU2AF1 POU class 2 associating factor 1 1.396 2.63170905 
1687 1687 DFNA5 Deafness, autosomal dominant 5 1.384 2.6099099 
963 963 CD53 CD53 molecule 1.379 2.60088029 
6772 6772 STAT1 Signal transducer and activator of transcription 1, 91kDa 1.368 2.58112498 
397 397 ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 1.366 2.57754926 
7037 7037 TFRC Transferrin receptor (p90, CD71) 1.354 2.55619873 
57103 57103 C12orf5 Chromosome 12 open reading frame 5 1.353 2.55442752 
2026 2026 ENO2 Enolase 2 (gamma, neuronal) 1.35 2.54912125 
3576 3576 IL8 Interleukin 8 1.35 2.54912125 
4321 4321 MMP12 Matrix metallopeptidase 12 (macrophage elastase) 1.348 2.54558987 
5351 5351 PLOD1 Procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 1.346 2.54206338 
63915 63915 MUTED   1.337 2.52625452 
81575 81575 APOLD1 Apolipoprotein L domain containing 1 1.329 2.51228476 
2138 2138 EYA1 Eyes absent homolog 1 (Drosophila) 1.324 2.50359292 
94239 94239 H2AFV H2A histone family, member V 1.32 2.4966611 
2633 2633 GBP1 Guanylate binding protein 1, interferon-inducible, 67kDa 1.317 2.49147483 
5265 5265 SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
1.317 2.49147483 
5329 5329 PLAUR Plasminogen activator, urokinase receptor 1.316 2.48974847 
1063 1063 CENPF Centromere protein F, 350/400ka (mitosin) 1.315 2.48802331 
7980 7980 TFPI2 Tissue factor pathway inhibitor 2 1.314 2.48629934 
9500 9500 MAGED1 Melanoma antigen family D, 1 1.312 2.48285498 
871 871 SERPINH1 Serpin peptidase inhibitor, clade H (heat shock protein 47), 
member 1, (collagen binding protein 1) 
1.298 2.45887773 
7052 7052 TGM2 Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) 
1.296 2.45547137 
3937 3937 LCP2 Lymphocyte cytosolic protein 2 (SH2 domain containing 
leukocyte protein of 76kDa) 
1.294 2.45206972 
2181 2181 ACSL3 Acyl-CoA synthetase long-chain family member 3 1.292 2.44867278 
6790 6790 AURKA Aurora kinase A 1.287 2.44020102 
5920 5920 RARRES3 Retinoic acid receptor responder (tazarotene induced) 3 1.286 2.43851019 
51338 51338 MS4A4A Membrane-spanning 4-domains, subfamily A, member 4 1.281 2.43007358 
7545 7545 ZIC1 Zic family member 1 (odd-paired homolog, Drosophila) 1.28 2.42838977 
10019 10019 SH2B3 SH2B adaptor protein 3 1.278 2.42502564 
11326 11326 VSIG4 V-set and immunoglobulin domain containing 4 1.278 2.42502564 
55379 55379 LRRC59 Leucine rich repeat containing 59 1.278 2.42502564 
9833 9833 MELK Maternal embryonic leucine zipper kinase 1.277 2.42334532 
23327 23327 NEDD4L Neural precursor cell expressed, developmentally down-
regulated 4-like 
1.27 2.41161566 
28959 28959 TMEM176B Transmembrane protein 176B 1.263 2.39994276 




3006 3006 HIST1H1C Histone cluster 1, H1c 1.254 2.38501774 
23406 23406 COTL1 Coactosin-like 1 (Dictyostelium) 1.253 2.38336515 
6781 6781 STC1 Stanniocalcin 1 1.25 2.37841423 
7153 7153 TOP2A Topoisomerase (DNA) II alpha 170kDa 1.25 2.37841423 
3669 3669 ISG20 Interferon stimulated exonuclease gene 20kDa 1.245 2.37018554 
142 142 PARP1 Poly (ADP-ribose) polymerase family, member 1 1.243 2.36690204 
7378 7378 UPP1 Uridine phosphorylase 1 1.235 2.35381347 
991 991 CDC20 Cell division cycle 20 homolog (S. cerevisiae) 1.232 2.34892394 
6745 6745 SSR1 Signal sequence receptor, alpha (translocon-associated protein 
alpha) 
1.231 2.34729636 
6352 6352 CCL5 Chemokine (C-C motif) ligand 5 1.23 2.3456699 
23516 23516 SLC39A14 Solute carrier family 39 (zinc transporter), member 14 1.224 2.33593479 
29887 29887 SNX10 Sorting nexin 10 1.224 2.33593479 
3959 3959 LGALS3BP Lectin, galactoside-binding, soluble, 3 binding protein 1.222 2.33269874 
10095 10095 ARPC1B Actin related protein 2/3 complex, subunit 1B, 41kDa 1.219 2.32785307 
7305 7305 TYROBP TYRO protein tyrosine kinase binding protein 1.211 2.31498043 
116372 116372 LYPD1 LY6/PLAUR domain containing 1 1.211 2.31498043 
8091 8091 HMGA2 High mobility group AT-hook 2 1.21 2.31337637 
10486 10486 CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast) 1.209 2.31177341 
1601 1601 DAB2 Disabled homolog 2, mitogen-responsive phosphoprotein 
(Drosophila) 
1.206 2.30697121 
5577 5577 PRKAR2B Protein kinase, cAMP-dependent, regulatory, type II, beta 1.206 2.30697121 
9055 9055 PRC1 Protein regulator of cytokinesis 1 1.203 2.30217898 
23213 23213 SULF1 Sulfatase 1 1.198 2.29421405 
10211 10211 FLOT1 Flotillin 1 1.196 2.2910358 
87 87 ACTN1 Actinin, alpha 1 1.193 2.28627667 
1846 1846 DUSP4 Dual specificity phosphatase 4 1.191 2.28310941 
3371 3371 TNC Tenascin C (hexabrachion) 1.189 2.27994655 
6876 6876 TAGLN Transgelin 1.179 2.2641978 
27299 27299 ADAMDEC1 ADAM-like, decysin 1 1.178 2.26262893 
8406 8406 SRPX Sushi-repeat-containing protein, X-linked 1.174 2.25636427 
1508 1508 CTSB Cathepsin B 1.173 2.25480082 
6402 6402 SELL Selectin L (lymphocyte adhesion molecule 1) 1.173 2.25480082 
6947 6947 TCN1 Transcobalamin I (vitamin B12 binding protein, R binder family) 1.167 2.24544284 
3357 3357 HTR2B 5-hydroxytryptamine (serotonin) receptor 2B 1.166 2.24388696 
5476 5476 CTSA Cathepsin A 1.166 2.24388696 
5352 5352 PLOD2 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 1.165 2.24233216 
962 962 CD48 CD48 molecule 1.15 2.21913894 
3491 3491 CYR61 Cysteine-rich, angiogenic inducer, 61 1.149 2.21760129 
11014 11014 KDELR2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 2 
1.149 2.21760129 
717 717 C2 Complement component 2 1.136 2.19770844 
5698 5698 PSMB9 Proteasome (prosome, macropain) subunit, beta type, 9 (large 
multifunctional peptidase 2) 
1.131 2.19010494 
4017 4017 LOXL2 Lysyl oxidase-like 2 1.127 2.18404109 
9928 9928 KIF14 Kinesin family member 14 1.123 2.17799403 
10656 10656 KHDRBS3 KH domain containing, RNA binding, signal transduction 
associated 3 
1.123 2.17799403 
1978 1978 EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1 1.122 2.17648488 
2020 2020 EN2 Engrailed homeobox 2 1.122 2.17648488 
11004 11004 KIF2C Kinesin family member 2C 1.119 2.17196371 
51203 51203 NUSAP1 Nucleolar and spindle associated protein 1 1.114 2.16444929 
2258 2258 FGF13 Fibroblast growth factor 13 1.111 2.15995312 
3108 3108 HLA-DMA Major histocompatibility complex, class II, DM alpha 1.109 2.15696086 
3689 3689 ITGB2 Integrin, beta 2 (complement component 3 receptor 3 and 4 
subunit) 
1.106 2.15248025 
6351 6351 CCL4 Chemokine (C-C motif) ligand 4 1.105 2.15098878 
7018 7018 TF Transferrin 1.105 2.15098878 
4104 4104 MAGEA5 Melanoma antigen family A, 5 1.103 2.14800894 
719 719 C3AR1 Complement component 3a receptor 1 1.102 2.14652057 
6347 6347 CCL2 Chemokine (C-C motif) ligand 2 1.102 2.14652057 
4085 4085 MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 1.1 2.14354693 
6999 6999 TDO2 Tryptophan 2,3-dioxygenase 1.099 2.14206165 
64092 64092 SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 1.098 2.1405774 
3383 3383 ICAM1 Intercellular adhesion molecule 1 (CD54), human rhinovirus 
receptor 
1.096 2.13761198 
701 701 BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta 
(yeast) 
1.095 2.13613082 
6891 6891 TAP2 Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 1.094 2.13465068 
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58986 58986 TMEM8 Transmembrane protein 8 (five membrane-spanning domains) 1.094 2.13465068 
8836 8836 GGH Gamma-glutamyl hydrolase (conjugase, 
folylpolygammaglutamyl hydrolase) 
1.093 2.13317156 
10954 10954 PDIA5 Protein disulfide isomerase family A, member 5 1.093 2.13317156 
85236 85236 HIST1H2BK Histone cluster 1, H2bk 1.092 2.13169347 
3059 3059 HCLS1 Hematopoietic cell-specific Lyn substrate 1 1.09 2.12874036 
5315 5315 PKM2 Pyruvate kinase, muscle 1.09 2.12874036 
3017 3017 HIST1H2BD Histone cluster 1, H2bd 1.085 2.12137548 
5272 5272 SERPINB9 Serpin peptidase inhibitor, clade B (ovalbumin), member 9 1.085 2.12137548 
7184 7184 HSP90B1 Heat shock protein 90kDa beta (Grp94), member 1 1.085 2.12137548 
9404 9404 LPXN Leupaxin 1.083 2.11843667 
7351 7351 UCP2 Uncoupling protein 2 (mitochondrial, proton carrier) 1.082 2.11696879 
8905 8905 AP1S2 Adaptor-related protein complex 1, sigma 2 subunit 1.082 2.11696879 
165 165 AEBP1 AE binding protein 1 1.08 2.11403608 
4811 4811 NID1 Nidogen 1 1.078 2.11110744 
6890 6890 TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1.073 2.10380356 
10440 10440 TIMM17A Translocase of inner mitochondrial membrane 17 homolog A 
(yeast) 
1.073 2.10380356 
5721 5721 PSME2 Proteasome (prosome, macropain) activator subunit 2 (PA28 
beta) 
1.071 2.10088909 
1462 1462 VCAN Versican 1.067 2.09507225 
3099 3099 HK2 Hexokinase 2 1.066 2.09362056 
23194 23194 FBXL7 F-box and leucine-rich repeat protein 7 1.066 2.09362056 
5690 5690 PSMB2 Proteasome (prosome, macropain) subunit, beta type, 2 1.064 2.0907202 
23484 23484 LEPROTL1 Leptin receptor overlapping transcript-like 1 1.064 2.0907202 
149111 149111 CNIH3 Cornichon homolog 3 (Drosophila) 1.064 2.0907202 
7077 7077 TIMP2 TIMP metallopeptidase inhibitor 2 1.062 2.08782385 
533 533 ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 1.057 2.08060053 
50515 50515 CHST11 Carbohydrate (chondroitin 4) sulfotransferase 11 1.057 2.08060053 
54828 54828 BCAS3 Breast carcinoma amplified sequence 3 1.057 2.08060053 
9263 9263 STK17A Serine/threonine kinase 17a 1.053 2.07483987 
3620 3620 INDO Indoleamine-pyrrole 2,3 dioxygenase 1.05 2.07052985 
54927 54927 CHCHD3 Coiled-coil-helix-coiled-coil-helix domain containing 3 1.049 2.06909516 
60481 60481 ELOVL5 ELOVL family member 5, elongation of long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3-like, yeast) 
1.049 2.06909516 
6782 6782 STCH Stress 70 protein chaperone, microsome-associated, 60kDa 1.048 2.06766147 
79801 79801 SHCBP1 SHC SH2-domain binding protein 1 1.048 2.06766147 
10460 10460 TACC3 Transforming, acidic coiled-coil containing protein 3 1.047 2.06622878 
23530 23530 NNT Nicotinamide nucleotide transhydrogenase 1.047 2.06622878 
983 983 CDC2 Cell division cycle 2, G1 to S and G2 to M 1.037 2.05195629 
50999 50999 TMED5 Transmembrane emp24 protein transport domain containing 5 1.036 2.05053448 
55647 55647 RAB20 RAB20, member RAS oncogene family 1.036 2.05053448 
2305 2305 FOXM1 Forkhead box M1 1.034 2.0476938 
9212 9212 AURKB Aurora kinase B 1.034 2.0476938 
29028 29028 ATAD2 ATPase family, AAA domain containing 2 1.033 2.04627494 
8934 8934 RAB7L1 RAB7, member RAS oncogene family-like 1 1.032 2.04485706 
256227 256227 MGC87042 Similar to Six transmembrane epithelial antigen of prostate 1.029 2.04060932 
64151 64151 NCAPG Non-SMC condensin I complex, subunit G 1.026 2.0363704 
5641 5641 LGMN Legumain 1.025 2.03495938 
3074 3074 HEXB Hexosaminidase B (beta polypeptide) 1.021 2.02932509 
332 332 BIRC5 Baculoviral IAP repeat-containing 5 (survivin) 1.019 2.0265138 
1503 1503 CTPS CTP synthase 1.018 2.02510961 
9447 9447 AIM2 Absent in melanoma 2 1.017 2.0237064 
914 914 CD2 CD2 molecule 1.014 2.0195026 
11013 11013 TMSL8 Thymosin-like 8 1.013 2.01810327 
50486 50486 G0S2 G0/G1switch 2 1.012 2.01670491 
5230 5230 PGK1 Phosphoglycerate kinase 1 1.01 2.0139111 
6185 6185 RPN2 Ribophorin II 1.009 2.01251565 
528 528 ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 1.008 2.01112116 
3309 3309 HSPA5 Heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 1.006 2.00833509 
4192 4192 MDK Midkine (neurite growth-promoting factor 2) 1.005 2.0069435 
728 728 C5AR1 Complement component 5a receptor 1 1.003 2.00416321 
1020 1020 CDK5 Cyclin-dependent kinase 5 1.002 2.00277451 
5696 5696 PSMB8 Proteasome (prosome, macropain) subunit, beta type, 8 (large 
multifunctional peptidase 7) 
1.002 2.00277451 
10384 10384 BTN3A3 Butyrophilin, subfamily 3, member A3 1.002 2.00277451 
7873 7873 ARMET Arginine-rich, mutated in early stage tumors 1.001 2.00138677 
23753 23753 SDF2L1 Stromal cell-derived factor 2-like 1 1.001 2.00138677 
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Gene down regulated in MM compared to MN 
6136 6136 RPL12 Ribosomal protein L12 -1 2 
7001 7001 PRDX2 Peroxiredoxin 2 -1 2 
59338 59338 PLEKHA1 Pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 1 
-1.002 2.00277451 
170680 170680 PSORS1C2 Psoriasis susceptibility 1 candidate 2 -1.003 2.00416321 
116039 116039 OSR2 Odd-skipped related 2 (Drosophila) -1.004 2.00555287 
6261 6261 RYR1 Ryanodine receptor 1 (skeletal) -1.006 2.00833509 
55214 55214 LEPREL1 Leprecan-like 1 -1.006 2.00833509 
79056 79056 PRRG4 Proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) -1.008 2.01112116 
1294 1294 COL7A1 Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, 
dominant and recessive) 
-1.009 2.01251565 
56288 56288 PARD3 Par-3 partitioning defective 3 homolog (C. elegans) -1.012 2.01670491 
60495 60495 HPSE2 Heparanase 2 -1.013 2.01810327 
9651 9651 PLCH2 Phospholipase C, eta 2 -1.014 2.0195026 
9796 9796 PHYHIP Phytanoyl-CoA 2-hydroxylase interacting protein -1.015 2.02090289 
51232 51232 CRIM1 Cysteine rich transmembrane BMP regulator 1 (chordin-like) -1.02 2.02791896 
3557 3557 IL1RN Interleukin 1 receptor antagonist -1.021 2.02932509 
10924 10924 SMPDL3A Sphingomyelin phosphodiesterase, acid-like 3A -1.021 2.02932509 
80303 80303 EFHD1 EF-hand domain family, member D1 -1.021 2.02932509 
23461 23461 ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5 -1.023 2.03214029 
23259 23259 DDHD2 DDHD domain containing 2 -1.025 2.03495938 
1638 1638 DCT Dopachrome tautomerase (dopachrome delta-isomerase, 
tyrosine-related protein 2) 
-1.027 2.03778239 
7162 7162 TPBG Trophoblast glycoprotein -1.027 2.03778239 
10602 10602 CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 -1.027 2.03778239 
55040 55040 EPN3 Epsin 3 -1.028 2.03919537 
3119 3119 HLA-DQB1 Major histocompatibility complex, class II, DQ beta 1 -1.029 2.04060932 
2152 2152 F3 Coagulation factor III (thromboplastin, tissue factor) -1.035 2.04911365 
10810 10810 WASF3 WAS protein family, member 3 -1.038 2.05337909 
5603 5603 MAPK13 Mitogen-activated protein kinase 13 -1.04 2.05622765 
4692 4692 NDN Necdin homolog (mouse) -1.043 2.06050791 
9414 9414 TJP2 Tight junction protein 2 (zona occludens 2) -1.05 2.07052985 
1028 1028 CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2) -1.053 2.07483987 
5126 5126 PCSK2 Proprotein convertase subtilisin/kexin type 2 -1.054 2.07627854 
1842 1842 ECM2 Extracellular matrix protein 2, female organ and adipocyte 
specific 
-1.058 2.0820432 
3655 3655 ITGA6 Integrin, alpha 6 -1.06 2.08493152 
4897 4897 NRCAM Neuronal cell adhesion molecule -1.062 2.08782385 
23189 23189 ANKRD15 Ankyrin repeat domain 15 -1.063 2.08927153 
928 928 CD9 CD9 molecule -1.065 2.09216988 
4675 4675 NAP1L3 Nucleosome assembly protein 1-like 3 -1.065 2.09216988 
5652 5652 PRSS8 Protease, serine, 8 -1.066 2.09362056 
51309 51309 ARMCX1 Armadillo repeat containing, X-linked 1 -1.067 2.09507225 
91851 91851 CHRDL1 Chordin-like 1 -1.071 2.10088909 
57146 57146 TMEM159 Transmembrane protein 159 -1.072 2.10234582 
1124 1124 CHN2 Chimerin (chimaerin) 2 -1.075 2.10672207 
1906 1906 EDN1 Endothelin 1 -1.077 2.10964463 
4086 4086 SMAD1 SMAD family member 1 -1.077 2.10964463 
1808 1808 DPYSL2 Dihydropyrimidinase-like 2 -1.084 2.11990557 
4128 4128 MAOA Monoamine oxidase A -1.084 2.11990557 
85458 85458 DIXDC1 DIX domain containing 1 -1.084 2.11990557 
154 154 ADRB2 Adrenergic, beta-2-, receptor, surface -1.087 2.12431837 
1515 1515 CTSL2 Cathepsin L2 -1.089 2.12726535 
7503 7503 XIST X (inactive)-specific transcript -1.09 2.12874036 
288 288 ANK3 Ankyrin 3, node of Ranvier (ankyrin G) -1.091 2.13021641 
3918 3918 LAMC2 Laminin, gamma 2 -1.091 2.13021641 
3769 3769 KCNJ13 Potassium inwardly-rectifying channel, subfamily J, member 13 -1.093 2.13317156 
80206 80206 FHOD3 Formin homology 2 domain containing 3 -1.1 2.14354693 
57758 57758 SCUBE2 Signal peptide, CUB domain, EGF-like 2 -1.104 2.14949835 
11211 11211 FZD10 Frizzled homolog 10 (Drosophila) -1.105 2.15098878 
25976 25976 TIPARP TCDD-inducible poly(ADP-ribose) polymerase -1.108 2.15546629 
3205 3205 HOXA9 Homeobox A9 -1.111 2.15995312 
6509 6509 SLC1A4 Solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 
-1.111 2.15995312 
55227 55227 LRRC1 Leucine rich repeat containing 1 -1.111 2.15995312 
6280 6280 S100A9 S100 calcium binding protein A9 -1.112 2.1614508 
6665 6665 SOX15 SRY (sex determining region Y)-box 15 -1.112 2.1614508 
 40
738 738 C11orf2 Chromosome 11 open reading frame2 -1.115 2.16595009 
10351 10351 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 -1.117 2.16895482 
25878 25878 MXRA5 Matrix-remodelling associated 5 -1.118 2.17045874 
2150 2150 F2RL1 Coagulation factor II (thrombin) receptor-like 1 -1.121 2.17497678 
1580 1580 CYP4B1 Cytochrome P450, family 4, subfamily B, polypeptide 1 -1.122 2.17648488 
79686 79686 C14orf139 Chromosome 14 open reading frame 139 -1.122 2.17648488 
1646 1646 AKR1C2 Aldo-keto reductase family 1, member C2 (dihydrodiol 
dehydrogenase 2; bile acid binding protein; 3-alpha 
hydroxysteroid dehydrogenase, type III) 
-1.123 2.17799403 
6662 6662 SOX9 SRY (sex determining region Y)-box 9 (campomelic dysplasia, 
autosomal sex-reversal) 
-1.126 2.18252775 
10278 10278 EFS Embryonal Fyn-associated substrate -1.126 2.18252775 
5349 5349 FXYD3 FXYD domain containing ion transport regulator 3 -1.127 2.18404109 
23382 23382 KIAA0828 Adenosylhomocysteinase 3 -1.127 2.18404109 
2013 2013 EMP2 Epithelial membrane protein 2 -1.129 2.18707091 
55107 55107 TMEM16A Transmembrane protein 16A -1.129 2.18707091 
2069 2069 EREG Epiregulin -1.13 2.1885874 
283638 283638 KIAA0284 KIAA0284 -1.132 2.19162353 
1153 1153 CIRBP Cold inducible RNA binding protein -1.133 2.19314318 
5792 5792 PTPRF Protein tyrosine phosphatase, receptor type, F -1.133 2.19314318 
55294 55294 FBXW7 F-box and WD repeat domain containing 7 -1.136 2.19770844 
26298 26298 EHF Ets homologous factor -1.138 2.20075722 
23002 23002 DAAM1 Dishevelled associated activator of morphogenesis 1 -1.141 2.20533833 
1359 1359 CPA3 Carboxypeptidase A3 (mast cell) -1.144 2.20992897 
23242 23242 COBL Cordon-bleu homolog (mouse) -1.146 2.21299471 
242 242 ALOX12B Arachidonate 12-lipoxygenase, 12R type -1.151 2.22067767 
2941 2941 GSTA4 Glutathione S-transferase A4 -1.152 2.22221746 
51090 51090 PLLP Plasma membrane proteolipid (plasmolipin) -1.155 2.22684324 
11075 11075 STMN2 Stathmin-like 2 -1.156 2.2283873 
23593 23593 HEBP2 Heme binding protein 2 -1.156 2.2283873 
26330 26330 GAPDHS Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic -1.158 2.23147864 
694 694 BTG1 B-cell translocation gene 1, anti-proliferative -1.16 2.23457428 
9413 9413 C9orf61 Chromosome 9 open reading frame 61 -1.16 2.23457428 
2770 2770 GNAI1 Guanine nucleotide binding protein (G protein), alpha inhibiting 
activity polypeptide 1 
-1.161 2.2361237 
26018 26018 LRIG1 Leucine-rich repeats and immunoglobulin-like domains 1 -1.161 2.2361237 
4915 4915 NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 -1.163 2.23922578 
7056 7056 THBD Thrombomodulin -1.168 2.24699981 
6513 6513 SLC2A1 Solute carrier family 2 (facilitated glucose transporter), member 
1 
-1.173 2.25480082 
3590 3590 IL11RA Interleukin 11 receptor, alpha -1.174 2.25636427 
29091 29091 STXBP6 Syntaxin binding protein 6 (amisyn) -1.175 2.25792881 
2153 2153 F5 Coagulation factor V (proaccelerin, labile factor) -1.176 2.25949443 
2709 2709 GJB5 Gap junction protein, beta 5, 31.1kDa -1.178 2.26262893 
3816 3816 KLK1 Kallikrein 1 -1.178 2.26262893 
3775 3775 KCNK1 Potassium channel, subfamily K, member 1 -1.18 2.26576777 
7022 7022 TFAP2C Transcription factor AP-2 gamma (activating enhancer binding 
protein 2 gamma) 
-1.184 2.27205853 
25854 25854 DKFZP564J102 Family with sequence similarity 149, member A -1.185 2.27363395 
23015 23015 GOLGA8A Golgi autoantigen, golgin subfamily a, 8A -1.187 2.27678806 
10579 10579 TACC2 Transforming, acidic coiled-coil containing protein 2 -1.188 2.27836675 
3248 3248 HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) -1.189 2.27994655 
6137 6137 RPL13 Ribosomal protein L13 -1.189 2.27994655 
6385 6385 SDC4 Syndecan 4 -1.195 2.28944832 
1112 1112 CHES1 Forkhead box N3 -1.196 2.2910358 
390 390 RND3 Rho family GTPase 3 -1.2 2.29739671 
2202 2202 EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 -1.201 2.2989897 
26154 26154 ABCA12 ATP-binding cassette, sub-family A (ABC1), member 12 -1.202 2.30058379 
79850 79850 FAM57A Family with sequence similarity 57, member A -1.203 2.30217898 
9891 9891 NUAK1 NUAK family, SNF1-like kinase, 1 -1.206 2.30697121 
2196 2196 FAT2 FAT tumor suppressor homolog 2 (Drosophila) -1.209 2.31177341 
56998 56998 CTNNBIP1 Catenin, beta interacting protein 1 -1.209 2.31177341 
2114 2114 ETS2 V-ets erythroblastosis virus E26 oncogene homolog 2 (avian) -1.212 2.31658561 
117247 117247 SLC16A10 Solute carrier family 16, member 10 (aromatic amino acid 
transporter) 
-1.212 2.31658561 
25875 25875 LETMD1 LETM1 domain containing 1 -1.214 2.31979931 
4610 4610 MYCL1 V-myc myelocytomatosis viral oncogene homolog 1, lung 
carcinoma derived (avian) 
-1.215 2.32140783 
53335 53335 BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) -1.216 2.32301746 
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5593 5593 PRKG2 Protein kinase, cGMP-dependent, type II -1.217 2.32462822 
1050 1050 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha -1.22 2.32946717 
7088 7088 TLE1 Transducin-like enhancer of split 1 (E(sp1) homolog, 
Drosophila) 
-1.22 2.32946717 
3400 3400 ID4 Inhibitor of DNA binding 4, dominant negative helix-loop-helix 
protein 
-1.224 2.33593479 
4477 4477 MSMB Microseminoprotein, beta- -1.231 2.34729636 
6692 6692 SPINT1 Serine peptidase inhibitor, Kunitz type 1 -1.231 2.34729636 
396 396 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha -1.234 2.3521825 
3480 3480 IGF1R Insulin-like growth factor 1 receptor -1.234 2.3521825 
4147 4147 MATN2 Matrilin 2 -1.235 2.35381347 
51228 51228 GLTP Glycolipid transfer protein -1.236 2.35544558 
2125 2125 EVPL Envoplakin -1.237 2.35707882 
23150 23150 FRMD4B FERM domain containing 4B -1.237 2.35707882 
9194 9194 SLC16A7 Solute carrier family 16, member 7 (monocarboxylic acid 
transporter 2) 
-1.238 2.35871318 
10391 10391 CORO2B Coronin, actin binding protein, 2B -1.243 2.36690204 
1902 1902 EDG2 Endothelial differentiation, lysophosphatidic acid G-protein-
coupled receptor, 2 
-1.25 2.37841423 
11341 11341 SCRG1 Scrapie responsive protein 1 -1.252 2.3817137 
26053 26053 AUTS2 Autism susceptibility candidate 2 -1.256 2.38832637 
5453 5453 POU3F1 POU class 3 homeobox 1 -1.257 2.38998241 
1645 1645 AKR1C1 aldo-keto reductase family 1, member C1 (dihydrodiol 
dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase) 
-1.258 2.39163959 
1944 1944 EFNA3 Ephrin-A3 -1.26 2.39495741 
10512 10512 SEMA3C Sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3C 
-1.26 2.39495741 
3080 3080 CFHR2 Complement factor H-related 2 -1.262 2.39827983 
10529 10529 NEBL Nebulette -1.262 2.39827983 
79977 79977 GRHL2 Grainyhead-like 2 (Drosophila) -1.262 2.39827983 
53832 53832 IL20RA Interleukin 20 receptor, alpha -1.268 2.40827476 
9124 9124 PDLIM1 PDZ and LIM domain 1 (elfin) -1.269 2.40994463 
29997 29997 GLTSCR2 Glioma tumor suppressor candidate region gene 2 -1.269 2.40994463 
7447 7447 VSNL1 Visinin-like 1 -1.27 2.41161566 
55118 55118 CRTAC1 Cartilage acidic protein 1 -1.274 2.41831135 
7704 7704 ZBTB16 Zinc finger and BTB domain containing 16 -1.279 2.42670712 
7101 7101 NR2E1 Nuclear receptor subfamily 2, group E, member 1 -1.28 2.42838977 
5348 5348 FXYD1 FXYD domain containing ion transport regulator 1 
(phospholemman) 
-1.283 2.43344472 
161291 161291 TMEM30B Transmembrane protein 30B -1.283 2.43344472 
9231 9231 DLG5 Discs, large homolog 5 (Drosophila) -1.294 2.45206972 
54873 54873 PALMD Palmdelphin -1.297 2.45717396 
5742 5742 PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase) 
-1.3 2.46228883 
9076 9076 CLDN1 Claudin 1 -1.302 2.46570465 
224 224 ALDH3A2 Aldehyde dehydrogenase 3 family, member A2 -1.319 2.49493114 
26751 26751 SH3YL1 SH3 domain containing, Ysc84-like 1 (S. cerevisiae) -1.326 2.50706604 
54361 54361 WNT4 Wingless-type MMTV integration site family, member 4 -1.327 2.50880441 
54566 54566 EPB41L4B Erythrocyte membrane protein band 4.1 like 4B -1.337 2.52625452 
6095 6095 RORA RAR-related orphan receptor A -1.341 2.53326851 
259217 259217 HSPA12A Heat shock 70kDa protein 12A -1.345 2.54030197 
10628 10628 TXNIP Thioredoxin interacting protein -1.347 2.54382601 
54829 54829 ASPN Asporin -1.349 2.54735495 
7850 7850 IL1R2 Interleukin 1 receptor, type II -1.351 2.55088878 
217 217 ALDH2 Aldehyde dehydrogenase 2 family (mitochondrial) -1.354 2.55619873 
10218 10218 ANGPTL7 Angiopoietin-like 7 -1.356 2.55974483 
10265 10265 IRX5 Iroquois homeobox 5 -1.358 2.56329585 
222 222 ALDH3B2 Aldehyde dehydrogenase 3 family, member B2 -1.363 2.57219497 
23037 23037 PDZD2 PDZ domain containing 2 -1.365 2.57576326 
51302 51302 CYP39A1 Cytochrome P450, family 39, subfamily A, polypeptide 1 -1.365 2.57576326 
6820 6820 SULT2B1 Sulfotransferase family, cytosolic, 2B, member 1 -1.375 2.59367911 
4493 4493 MT1E Metallothionein 1E -1.383 2.60810147 
8710 8710 SERPINB7 Serpin peptidase inhibitor, clade B (ovalbumin), member 7 -1.386 2.61353051 
999 999 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) -1.394 2.62806325 
10848 10848 PPP1R13L Protein phosphatase 1, regulatory (inhibitor) subunit 13 like -1.394 2.62806325 
85453 85453 TSPYL5 TSPY-like 5 -1.401 2.64084568 
10418 10418 SPON1 Spondin 1, extracellular matrix protein -1.403 2.64450921 
1287 1287 COL4A5 Collagen, type IV, alpha 5 (Alport syndrome) -1.405 2.64817782 
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1012 1012 CDH13 Cadherin 13, H-cadherin (heart) -1.407 2.65185152 
1675 1675 CFD Complement factor D (adipsin) -1.41 2.65737163 
80004 80004 RBM35B RNA binding motif protein 35B -1.419 2.67400099 
51200 51200 CPA4 Carboxypeptidase A4 -1.42 2.67585511 
2861 2861 GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) -1.421 2.67771051 
10089 10089 KCNK7 Potassium channel, subfamily K, member 7 -1.421 2.67771051 
3606 3606 IL18 Interleukin 18 (interferon-gamma-inducing factor) -1.422 2.6795672 
55638 55638 FLJ20366 Golgi-localized protein -1.422 2.6795672 
651872 651872 LOC651872   -1.422 2.6795672 
7286 7286 TUFT1 Tuftelin 1 -1.425 2.68514501 
79026 79026 AHNAK AHNAK nucleoprotein -1.432 2.69820507 
646 646 BNC1 Basonuclin 1 -1.433 2.70007597 
57447 57447 NDRG2 NDRG family member 2 -1.433 2.70007597 
11187 11187 PKP3 Plakophilin 3 -1.439 2.71132865 
3909 3909 LAMA3 Laminin, alpha 3 -1.44 2.71320865 
83604 83604 TMEM47 Transmembrane protein 47 -1.445 2.72262823 
5325 5325 PLAGL1 Pleiomorphic adenoma gene-like 1 -1.448 2.72829567 
6317 6317 SERPINB3 Serpin peptidase inhibitor, clade B (ovalbumin), member 3 -1.453 2.73776763 
1272 1272 CNTN1 Contactin 1 -1.454 2.73966596 
9022 9022 CLIC3 Chloride intracellular channel 3 -1.461 2.7529912 
55612 55612 C20orf42 Chromosome 20 open reading frame 42 -1.463 2.75681031 
4948 4948 OCA2 Oculocutaneous albinism II (pink-eye dilution homolog, mouse) -1.465 2.76063471 
57152 57152 SLURP1 Secreted LY6/PLAUR domain containing 1 -1.47 2.77021894 
3868 3868 KRT16 Keratin 16 (focal non-epidermolytic palmoplantar keratoderma) -1.473 2.77598544 
2628 2628 GATM Glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) 
-1.474 2.77791027 
218 218 ALDH3A1 Aldehyde dehydrogenase 3 family, memberA1 -1.476 2.78176394 
2263 2263 FGFR2 Fibroblast growth factor receptor 2 (bacteria-expressed kinase, 
keratinocyte growth factor receptor, craniofacial dysostosis 1, 
Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss 
syndrome) 
-1.483 2.79529394 
22798 22798 LAMB4 Laminin, beta 4 -1.49 2.80888975 
81578 81578 COL21A1 Collagen, type XXI, alpha 1 -1.496 2.82059592 
4023 4023 LPL Lipoprotein lipase -1.499 2.82646729 
9355 9355 LHX2 LIM homeobox 2 -1.5 2.82842712 
1634 1634 DCN Decorin -1.502 2.83235088 
1382 1382 CRABP2 Cellular retinoic acid binding protein 2 -1.506 2.84021472 
28231 28231 SLCO4A1 Solute carrier organic anion transporter family, member 4A1 -1.517 2.86195304 
10276 10276 NET1 Neuroepithelial cell transforming gene 1 -1.52 2.8679105 
3397 3397 ID1 Inhibitor of DNA binding 1, dominant negative helix-loop-helix 
protein 
-1.521 2.86989907 
760 760 CA2 Carbonic anhydrase II -1.528 2.88385774 
6785 6785 ELOVL4 Elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 4 
-1.534 2.89587634 
7123 7123 CLEC3B C-type lectin domain family 3, member B -1.534 2.89587634 
5055 5055 SERPINB2 Serpin peptidase inhibitor, clade B (ovalbumin), member 2 -1.537 2.90190442 
1956 1956 EGFR Epidermal growth factor receptor (erythroblastic leukemia viral 
(v-erb-b) oncogene homolog, avian) 
-1.556 2.94037467 
25797 25797 QPCT Glutaminyl-peptide cyclotransferase (glutaminyl cyclase) -1.557 2.94241349 
7164 7164 TPD52L1 Tumor protein D52-like 1 -1.559 2.94649537 
64919 64919 BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) -1.562 2.95262881 
2940 2940 GSTA3 Glutathione S-transferase A3 -1.563 2.95467613 
1040 1040 CDS1 CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 1 
-1.569 2.96698987 
2707 2707 GJB3 Gap junction protein, beta 3, 31kDa -1.573 2.97522752 
2051 2051 EPHB6 EPH receptor B6 -1.589 3.0084075 
23641 23641 LDOC1 Leucine zipper, down-regulated in cancer 1 -1.592 3.01466982 
79852 79852 ABHD9 Abhydrolase domain containing 9 -1.597 3.02513599 
53905 53905 DUOX1 Dual oxidase 1 -1.603 3.03774338 
92211 92211 PCDH21 Protocadherin 21 -1.604 3.03984971 
3898 3898 LAD1 Ladinin 1 -1.605 3.04195751 
8857 8857 FCGBP Fc fragment of IgG binding protein -1.605 3.04195751 
80740 80740 LY6G6C Lymphocyte antigen 6 complex, locus G6C -1.615 3.06311599 
4501 4501 MT1X Metallothionein 1X -1.616 3.06523992 
79652 79652 C16orf30 Chromosome 16 open reading frame 30 -1.633 3.10157283 
202 202 AIM1 Absent in melanoma 1 -1.635 3.1058755 
8626 8626 TP73L Tumor protein p63 -1.639 3.11449876 
51765 51765 RP6-213H19.1 Serine/threonine protein kinase MST4 -1.644 3.12531152 
358 358 AQP1 Aquaporin 1 (Colton blood group) -1.648 3.13398875 
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6337 6337 SCNN1A Sodium channel, nonvoltage-gated 1 alpha -1.655 3.14923191 
51195 51195 RAPGEFL1 Rap guanine nucleotide exchange factor (GEF)-like 1 -1.66 3.16016525 
2173 2173 FABP7 Fatty acid binding protein 7, brain -1.661 3.16235647 
3131 3131 HLF Hepatic leukemia factor -1.665 3.17113655 
10752 10752 CHL1 Cell adhesion molecule with homology to L1CAM (close 
homolog of L1) 
-1.67 3.18214594 
5507 5507 PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3C -1.682 3.20872467 
10974 10974 C10orf116 Chromosome 10 open reading frame 116 -1.683 3.21094955 
1396 1396 CRIP1 Cysteine-rich protein 1 (intestinal) -1.688 3.22209716 
1718 1718 DHCR24 24-dehydrocholesterol reductase -1.689 3.22433133 
6698 6698 SPRR1A Small proline-rich protein 1A -1.712 3.27614679 
2259 2259 FGF14 Fibroblast growth factor 14 -1.719 3.29208138 
64131 64131 XYLT1 Xylosyltransferase I -1.725 3.30580127 
909 909 CD1A CD1a molecule -1.726 3.30809347 
7739 7739 ZNF185 Zinc finger protein 185 (LIM domain) -1.777 3.42712782 
1041 1041 CDSN Corneodesmosin -1.781 3.43664302 
3983 3983 ABLIM1 Actin binding LIM protein 1 -1.812 3.51128719 
9314 9314 KLF4 Kruppel-like factor 4 (gut) -1.849 3.60250392 
3613 3613 IMPA2 Inositol(myo)-1(or 4)-monophosphatase 2 -1.859 3.62756132 
51673 51673 CGI-38 Tubulin polymerization-promoting protein family member 3 -1.86 3.63007662 
3120 3120 HLA-DQB2   -1.864 3.6401553 
7277 7277 TUBA4A Tubulin, alpha 4a -1.864 3.6401553 
10653 10653 SPINT2 Serine peptidase inhibitor, Kunitz type, 2 -1.871 3.65786036 
771 771 CA12 Carbonic anhydrase XII -1.886 3.69609029 
4308 4308 TRPM1 Transient receptor potential cation channel, subfamily M, 
member 1 
-1.896 3.72179863 
25984 25984 KRT23 Keratin 23 (histone deacetylase inducible) -1.914 3.7685251 
25833 25833 POU2F3 POU class 2 homeobox 3 -1.931 3.81319418 
5650 5650 KLK7 Kallikrein-related peptidase 7 -1.938 3.83174087 
3815 3815 KIT V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog 
-1.944 3.84770982 
84909 84909 C9orf3 Chromosome 9 open reading frame 3 -1.952 3.86910532 
2487 2487 FRZB Frizzled-related protein -1.967 3.90954307 
11202 11202 KLK8 Kallikrein-related peptidase 8 -1.987 3.96411825 
6382 6382 SDC1 Syndecan 1 -1.99 3.97236998 
6590 6590 SLPI Secretory leukocyte peptidase inhibitor -2.004 4.01110574 
9982 9982 FGFBP1 Fibroblast growth factor binding protein 1 -2.01 4.0278222 
8424 8424 BBOX1 Butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-
butyrobetaine hydroxylase) 1 
-2.077 4.21928927 
79983 79983 POF1B Premature ovarian failure, 1B -2.082 4.23393758 
3713 3713 IVL Involucrin -2.107 4.3079455 
1428 1428 CRYM Crystallin, mu -2.148 4.43212939 
3034 3034 HAL Histidine ammonia-lyase -2.153 4.44751663 
4118 4118 MAL Mal, T-cell differentiation protein -2.208 4.62034314 
2205 2205 FCER1A Fc fragment of IgE, high affinity I, receptor for; alpha 
polypeptide 
-2.229 4.68808913 
563 563 AZGP1 Alpha-2-glycoprotein 1, zinc-binding -2.251 4.76012679 
63928 63928 LOC63928 Calcineurin B homologous protein 2 -2.253 4.7667303 
1672 1672 DEFB1 Defensin, beta 1 -2.265 4.8065442 
10874 10874 NMU Neuromedin U -2.286 4.87702038 
383 383 ARG1 Arginase, liver -2.306 4.94510104 
2878 2878 GPX3 Glutathione peroxidase 3 (plasma) -2.323 5.00371632 
3728 3728 JUP Junction plakoglobin -2.323 5.00371632 
25818 25818 KLK5 Kallikrein-related peptidase 5 -2.327 5.01760882 
2625 2625 GATA3 GATA binding protein 3 -2.336 5.04900813 
25891 25891 DKFZP586H2123 Regeneration associated muscle protease -2.351 5.10177757 
2261 2261 FGFR3 Fibroblast growth factor receptor 3 (achondroplasia, 
thanatophoric dwarfism) 
-2.386 5.22706102 
11012 11012 KLK11 Kallikrein-related peptidase 11 -2.393 5.2524845 
57111 57111 RAB25 RAB25, member RAS oncogene family -2.398 5.27071981 
2697 2697 GJA1 Gap junction protein, alpha 1, 43kDa -2.422 5.35913441 
810 810 CALML3 Calmodulin-like 3 -2.507 5.68436817 
3854 3854 KRT6B   -2.553 5.86853338 
10850 10850 CCL27 Chemokine (C-C motif) ligand 27 -2.637 6.22036829 
1308 1308 COL17A1 Collagen, type XVII, alpha 1 -2.719 6.58416276 
445 445 ASS1 Argininosuccinate synthetase 1 -2.724 6.60702132 
3872 3872 KRT17 Keratin 17 -2.745 6.70389708 
79755 79755 ZNF750 Zinc finger protein 750 -2.748 6.71785194 
1525 1525 CXADR Coxsackie virus and adenovirus receptor -2.766 6.80219328 
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688 688 KLF5 Kruppel-like factor 5 (intestinal) -2.814 7.03231649 
7306 7306 TYRP1 Tyrosinase-related protein 1 -2.815 7.03719261 
5764 5764 PTN Pleiotrophin (heparin binding growth factor 8, neurite growth-
promoting factor 1) 
-2.846 7.19004101 
1830 1830 DSG3 Desmoglein 3 (pemphigus vulgaris antigen) -2.867 7.29546532 
3853 3853 KRT6A Keratin 6A -2.878 7.35130307 
27076 27076 LYPD3 LY6/PLAUR domain containing 3 -2.925 7.59473697 
9890 9890 LPPR4 Plasticity related gene 1 -2.974 7.85711676 
360 360 AQP3 Aquaporin 3 (Gill blood group) -3.022 8.12292881 
57402 57402 S100A14 S100 calcium binding protein A14 -3.029 8.16243727 
9635 9635 CLCA2 Chloride channel, calcium activated, family member 2 -3.035 8.19645458 
8796 8796 SCEL Sciellin -3.048 8.27064589 
3075 3075 CFH Complement factor H -3.057 8.32240213 
3858 3858 KRT10 Keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et 
plantaris) 
-3.086 8.49138567 
26239 26239 LCE2B Late cornified envelope 2B -3.094 8.5386027 
23650 23650 TRIM29 Tripartite motif-containing 29 -3.133 8.77257271 
4070 4070 TACSTD2 Tumor-associated calcium signal transducer 2 -3.172 9.01295383 
6279 6279 S100A8 S100 calcium binding protein A8 -3.204 9.21510114 
7021 7021 TFAP2B Transcription factor AP-2 beta (activating enhancer binding 
protein 2 beta) 
-3.225 9.35021799 
64065 64065 PERP PERP, TP53 apoptosis effector -3.274 9.67324541 
5493 5493 PPL Periplakin -3.28 9.71355908 
23086 23086 EXPH5 Exophilin 5 -3.299 9.84233076 
6699 6699 SPRR1B Small proline-rich protein 1B (cornifin) -3.314 9.94519735 
113146 113146 C14orf78 AHNAK nucleoprotein 2 -3.332 10.0700574 
667 667 DST Dystonin -3.339 10.1190363 
51806 51806 CALML5 Calmodulin-like 5 -3.449 10.9207497 
2810 2810 SFN Stratifin -3.479 11.1502179 
6273 6273 S100A2 S100 calcium binding protein A2 -3.555 11.7533491 
84525 84525 HOP HOP homeobox -3.679 12.808237 
11005 11005 SPINK5 Serine peptidase inhibitor, Kazal type 5 -3.68 12.817118 
1474 1474 CST6 Cystatin E/M -3.774 13.6800348 
1475 1475 CSTA Cystatin A (stefin A) -3.843 14.3502106 
8581 8581 LY6D Lymphocyte antigen 6 complex, locus D -3.905 14.980356 
1825 1825 DSC3 Desmocollin 3 -4.051 16.5757242 
3849 3849 KRT2 Keratin 2 (epidermal ichthyosis bullosa of Siemens) -4.171 18.0134174 
1828 1828 DSG1 Desmoglein 1 -4.196 18.3282864 
4014 4014 LOR Loricrin -4.252 19.0537096 
1832 1832 DSP Desmoplakin -4.607 24.3694198 
1823 1823 DSC1 Desmocollin 1 -4.736 26.6488247 
9547 9547 CXCL14 Chemokine (C-X-C motif) ligand 14 -4.86 29.040613 
3866 3866 KRT15 Keratin 15 -4.963 31.1897482 
5268 5268 SERPINB5 Serpin peptidase inhibitor, clade B (ovalbumin), member 5 -5.042 32.9452827 
3852 3852 KRT5 Keratin 5 (epidermolysis bullosa simplex, Dowling-
Meara/Kobner/Weber-Cockayne types) 
-5.812 56.180595 
3848 3848 KRT1 Keratin 1 (epidermolytic hyperkeratosis) -6.635 99.388016 




Supplemental Table 1: Significantly regulated genes in PM compared to MN, MM compared to PM, MM 





Category  p-value Molecules 
 Cancer 3,82E-27-
1,08E-03 
 SELL, KRT6A, ASS1, KLK6, CCNB2, EIF4A2, SERPINA3, CXCL10, GPR37, CXCL13, 
CDKN3, FABP7, TYMS, TDO2, CKS2, GSTM3 (includes EG:2947), MT1X, IGH@, RRM2, 
IER3, RAB31, ARHGDIB, NRCAM, CTSB, TFRC, TCN1, PDGFD, ECM1, UBE2C, KIF20A, 
PRAME (includes EG:23532), FN1, GBP1 (includes EG:2633), PHLDA2, PPP1R3C, KPNA2, 
PTN, GDF15, CCL5, CD74, COL4A2, ABCA5, CCL2, STK17A, MAL, HLA-DRA, IGF1R, DAB2, 
SERPINA1, ADAMDEC1, TRIM29, MMP1 (includes EG:4312), PLAT, HEY1, PLA2G16, 
S100A1, PKM2, PSMB9, CCNB1, TNC, GZMK, KRT6B, KRT17, TYROBP, DST, ISG15, 
ITGB2, SERPINB4, S100A9, KRT5, CIRBP, SORBS2, GATA3, SGK3, GZMB, DLGAP5, 
RGS1, MMP3, TRIM9, PTTG1, RNASE1, MELK, LYZ, CD163, PBK, BIRC5, FGFR3, NNMT, 
GPX3, CCL27, CXCL14, IFI30, SCRG1, KRT1, CDKN1C, GZMA, KRT16, IL8, SPP1, CXCL9, 
COL4A1, GGH, SERPINB3, CAPG, AURKA, TUSC3, BST2, EFS, SPARCL1, ABCA8, 
AKR1B10, CD14, IRF8, CCL19, DSC1, TRA@, LGR4, CDK2, IFI27, FRZB, LETMD1, CD2, 
KIAA0101, TFAP2B, ACOT7, GLRX, TNFRSF12A, HLF (includes EG:3131), SOX9, KCNMA1, 
MCAM, F5, S100A8, CFH, STAT1, SILV, KRT14, COTL1, CXCR4, C9ORF3, PRC1, UPP1, 






 RGS1, SELL, KRT6A, MMP3, HLA-DRB1, KLK6, BIRC5, CCL27, CXCL13, IFI30, KRT1, DSP, 
TYMS, IL8, KRT16, SPP1, COL4A1, CXCL9, SERPINB3, DSG1, UBD, COL21A1, TCN1, 
CD14, DSC1, ECM1, LCP2, CDK2, FN1, CD2, GDF15, CCL5, CD74, COL4A2, HLA-DRA, 
KRT2, S100A8, SERPINA1, LOR, STAT1, MMP1 (includes EG:4312), IL11RA, PLAT, KRT14, 
KRT6B, CXCR4, KRT17, CD36, COL17A1, TYRP1, ITGB2, S100A9, KRT5, FCER1G, MMP9 




 KLK6, HLA-DRB1, CXCL10, LGMN, CDKN3, FABP7, ZBTB16, TNFRSF21, TYMS, CKS2, 
IL12RB2, IER3, LDOC1, NRCAM, CTSB, TFRC, BCL2A1, PDGFD, ECM1, LCP2, UBE2C, 
KIF20A, PRAME (includes EG:23532), FN1, GBP1 (includes EG:2633), PHLDA2, GDF15, 
PTN, COL4A2, CCL5, CD74, TAP1, GLTSCR2, CCL2, IGF1R, DAB2, KRT2, SERPINA1, 
IL11RA, HEY1, PLAT, S100A1, PKM2, PLAGL1, CCNB1, TNC, KRT17, TYROBP, ISG15, 
ITGB2, SWAP70, S100A9, CIRBP, FCER1G, GATA3, ID4, GZMB, SGK3, DLGAP5, MMP3, 
PTTG1, CD163, PBK, BIRC5, FGFR3, GPX3, CCL27, IFI30, CDKN1C, DSP, KRT16, IL8, 
CXCL9, COL4A1, SPP1, FXYD1, CITED1, AURKA, BST2, TPX2, EFS, CD14, IRF8, CCL19, 
CST6, CDK2, TRA@, LGR4, FRZB, CD2, KIAA0101, TFAP2B, TNFRSF12A, SOX9, MCAM, 
S100A8, STAT1, ACTN1, DTL, CXCR4, UPP1, CD36, CD48, HCLS1, CADM1, MST4, TYRP1, 





 DLGAP5, MMP3, TRIM9, PTTG1, CCNB2, KLK6, SERPINA3, MELK, EIF4A2, LYZ, PBK, 
BIRC5, NNMT, FGFR3, CXCL10, CDKN3, TYMS, IL8, SPP1, COL4A1, TDO2, MT1X, GGH, 
RRM2, CAPG, AURKA, BST2, RAB31, EFS, CTSB, TCN1, CD14, TFRC, LGR4, UBE2C, 
KIF20A, FN1, KIAA0101, KPNA2, GDF15, ABCA5, CD74, COL4A2, ACOT7, GLRX, CCL2, 
MCAM, HLA-DRA, IGF1R, STAT1, PLAT, PKM2, KRT14, TNC, TYROBP, CXCR4, CD36, 
HCLS1, WARS, CIRBP, MMP9, ISG20 
 Cellular Movement 1,17E-12-
1,2E-03 
 RGS1, SELL, KRT6A, MMP3, PTTG1, KLK6, CCNB2, SERPINA3, PBK, CXCL10, LGMN, 
CCL27, CXCL13, CXCL14, FABP7, ZBTB16, TNFRSF21, KRT16, IL8, CXCL9, SPP1, 
COL4A1, SERPINB3, AURKA, ARHGDIB, EFS, NRCAM, CTSB, CD14, CCL19, PDGFD, 
CST6, CCL18, LGR4, LCP2, C2, FN1, GBP1 (includes EG:2633), ARPC1B, CD2, GDF15, 
PTN, CD74, CCL5, COL4A2, TNFRSF12A, CCL2, MCAM, IGF1R, DAB2, PTPRZ1, S100A8, 
SERPINA1, CFH, STAT1, CHL1, MMP1 (includes EG:4312), PLAT, CXCL11, HEY1, CD53, 
S100A1, TNC, CXCR4, COL17A1, CD48, CD36, CADM1, ITGB2, NR2E1 (includes EG:7101), 
WARS, SWAP70, S100A9, KLF5, FCER1G, GATA3, A2M, MMP9, GZMB 
 Inflammatory Response 1,24E-12-
1,2E-03 
 RGS1, SELL, MMP3, ASS1, PTTG1, HLA-DRB1, C1QA, HLA-DMB, SERPINA3, C1QB, LYZ, 
CD163, CXCL10, CCL27, CXCL13, CXCL14, IFI30, GZMA, TNFRSF21, IL8, SPP1, CXCL9, 
IL12RB2, CAPG, IER3, ARHGDIB, CTSB, CD14, IRF8, CCL19, CCL18, DSC1, TRA@, LCP2, 
C2, FN1, CD2, CD74, CCL5, TAP1, TNFRSF12A, CCL2, F5, HLA-DRA, IGF1R, IFI6, S100A8, 
SERPINA1, CFH, STAT1, CXCL11, IL11RA, PLAT, SILV, PSMB9, HLA-DMA, TNC, TYROBP, 
CXCR4, CD48, CD36, COL17A1, ISG15, TYRP1, ITGB2, S100A9, SATB1, PI3, FCER1G, 
GATA3, A2M, MMP9, GZMB 




 RGS1, SELL, LHX2, HLA-DRB1, KLK6, HLA-DMB, C1QA, LYZ, CD163, CXCL10, FGFR3, 
CXCL13, CCL27, ALDH3A2, CXCL14, LPL, FABP7, CDKN1C, KRT1, GZMA, KRT16, IL8, 
CXCL9, SPP1, SERPINB3, IL12RB2, BST2, ARHGDIB, ANGPTL7, NRCAM, TFRC, CD14, 
IRF8, CCL19, BCL2A1, CST6, CCL18, LGR4, TRA@, LCP2, CDK2, UBE2C, FN1, CD2, 
GDF15, CCL5, CD74, TNFRSF12A, SOX9, CCL2, KCNMA1, MCAM, HLA-DRA, F5, IGF1R, 
KRT2, DAB2, PTPRZ1, S100A8, CFH, STAT1, CHL1, GATM, MMP1 (includes EG:4312), 
PLAT, DSC3, CXCL11, PSMB9, HLA-DMA, TNC, FEZ1, TYROBP, CXCR4, FGF14, COL17A1, 
CD48, CD36, AZGP1, CADM1, SYBU, ITGB2, SWAP70, S100A9, LGALS3BP, SATB1, PI3, 
FCER1G, GATA3, A2M, MMP9, GZMB 
 Genetic Disorder 2,58E-12-
7,09E-04 
 SELL, KRT6A, AUTS2 (includes EG:26053), ASS1, LRRC1, TLE1, CCNB2, EIF4A2, 
SERPINA3, CRYM, TYMS, RRM2, IL12RB2, DSG1, ARHGDIB, C14ORF132, CTSB, TFRC, 
ECM1, UBE2C, CYP39A1, GBP1 (includes EG:2633), GDF15, CCL5, CD74, CCL2, KRT2, 
DAB2, SERPINA1, TRIM29, CHL1, MMP1 (includes EG:4312), S100A1, PKM2, MLLT11, 
KRT17, DST, COL17A1, PAMR1, CSTB, ISG15, PDZD2, SWAP70, KRT5, WIPI1, DERL1, 
GATA3, ID4, GZMB, DLGAP5, MMP3, LHX2, PTTG1, RNASE1, LYZ, CD163, GPX3, CXCL14, 
LPL, CDKN1C, NEDD4L, IL8, FXYD1, CAPG, AURKA, TUSC3, TMEM204, SPARCL1, ABCA8, 
AKR1B10, IRF8, C2, LGR4, LETMD1, FRZB, KIAA0101, TFAP2B, GLRX, MCAM, CFH, 
STAT1, KRT14, SLC20A1, HLA-DMA, FEZ1, PRC1, CD36, PYGL, HSPA12A, CADM1, 
TYRP1, KLF5, A2M, ISG20, KLK6, HLA-DRB1, HLA-DMB, EXPH5, CXCL10, LGMN, GPR37, 
CDKN3, FABP7, ZBTB16, DFNA5, CKS2, TDO2, CHN1 (includes EG:1123), MT1X, IER3, 
RAB31, UBD, NRCAM, MS4A4A, TCN1, TRPM1, PDGFD, LCP2, FN1, TSPAN7, KPNA2, PTN, 
COL4A2, ABCA5, CORO2B, HLA-DRA, MAL, IGF1R, SNX10, IFI6, ADAMDEC1, LAMB4, 
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RPL13, DSC3, PLAT, IL11RA, CD53, PSMB9, PLAGL1, CCNB1, TNC, CNTN1, KRT6B, 
OAS2, TYROBP, FGF14, CRTAC1, ITGB2, S100A9, CIRBP, FCER1G, SORBS2, TRIM9, 
LPPR4, MELK, PBK, BIRC5, FGFR3, CCL27, ALDH3A2, IFI30, SCEL, KRT1, DSP, GZMA, 
KRT16, COL4A1, SPP1, CXCL9, XYLT1, PHACTR1, GGH, SERPINB3, TMEM47, BST2, 
COL21A1, CD14, DSC1, CCL18, CDK2, TRA@, CD2, CDHR1, APOC2, ACOT7, TNFRSF12A, 
SOX9, KCNMA1, F5, PTPRZ1, S100A8, LOR, GATM, ACTN1, FAM149A, COTL1, CXCR4, 
C9ORF3, CD48, AHCYL2, PFKP, CD3D, KCNJ13, SYBU, NR2E1 (includes EG:7101), IGJ, 
MMP9 





 RGS1, SELL, MMP3, CCNB2, HLA-DRB1, HLA-DMB, C1QA, SERPINA3, LYZ, CD163, 
BIRC5, CXCL10, CCL27, CXCL13, CXCL14, ZBTB16, GZMA, TNFRSF21, IL8, COL4A1, 
SPP1, CXCL9, IL12RB2, IER3, EFS, CTSB, CD14, CCL19, IRF8, DSC1, CCL18, BCL2A1, C2, 
CDK2, LCP2, TRA@, FN1, CD2, CD74, CCL5, TAP1, CCL2, HLA-DRA, F5, IGF1R, DAB2, 
S100A8, SERPINA1, CFH, STAT1, MMP1 (includes EG:4312), CXCL11, PLAT, IL11RA, 
PSMB9, HLA-DMA, TNC, CCNB1, CXCR4, TYROBP, COL17A1, CD36, CD48, HCLS1, CD3D, 
ISG15, CADM1, TYRP1, ITGB2, SWAP70, S100A9, PI3, SATB1, FCER1G, GATA3, A2M, 
MMP9, ISG20, GZMB 
 Immune Cell Trafficking 1,14E-11-
1,2E-03 
 RGS1, SELL, MMP3, HLA-DRB1, SERPINA3, C1QA, HLA-DMB, LYZ, CD163, CXCL10, 
CXCL13, CCL27, CXCL14, ZBTB16, GZMA, TNFRSF21, IL8, COL4A1, SPP1, CXCL9, 
SERPINB3, IER3, EFS, CTSB, CD14, CCL19, CCL18, DSC1, LCP2, C2, FN1, CD2, CCL5, 
CD74, CCL2, HLA-DRA, F5, SERPINA1, S100A8, CFH, STAT1, CXCL11, PLAT, HLA-DMA, 
PSMB9, TNC, TYROBP, CXCR4, CD48, COL17A1, CD36, ITGB2, SWAP70, S100A9, SATB1, 
FCER1G, GATA3, MMP9, GZMB 
 Tissue Morphology 5,1E-11-
1,2E-03 
 SELL, MMP3, PTTG1, C1QA, BIRC5, FGFR3, CXCL10, CXCL13, CDKN1C, ZBTB16, TYMS, 
TNFRSF21, IL8, SPP1, COL4A1, IL12RB2, CTSB, IRF8, CCL19, BCL2A1, TRA@, LCP2, 
CDK2, FN1, GDF15, COL4A2, CCL5, TAP1, SOX9, CCL2, IGF1R, SERPINA1, S100A8, CFH, 
STAT1, MMP1 (includes EG:4312), PLAT, S100A1, TNC, CCNB1, CXCR4, TYROBP, PRC1, 
CD3D, ISG15, CADM1, ITGB2, NR2E1 (includes EG:7101), SWAP70, S100A9, IGJ, PI3, 
SATB1, FCER1G, GATA3, MMP9 
 Cellular Development 3,77E-10-
1,2E-03 
 SELL, KRT6A, LPXN, SSBP2, SERPINA3, CXCL10, FABP7, ZBTB16, TYMS, DFNA5, CHN1 
(includes EG:1123), IL12RB2, IER3, CTSB, TRPM1, TFRC, BCL2A1, LCP2, PRAME (includes 
EG:23532), FN1, TSPAN7, PTN, GDF15, CD74, CCL5, SPRR1A, CCL2, MAL, IGF1R, DAB2, 
CHL1, MMP1 (includes EG:4312), HEY1, PLAT, IL11RA, S100A1, PSMB9, PLAGL1, IVL, 
CCNB1, TNC, TYROBP, ITGB2, S100A9, FCER1G, GATA3, CHRDL1, ID4, GZMB, DLGAP5, 
MMP3, LHX2, RNASE1, CD163, BIRC5, FGFR3, SCEL, CDKN1C, DSP, GZMA, IL8, SPP1, 
COL4A1, CAPG, CITED1, CD14, IRF8, CCL19, DSC1, TRA@, CDK2, CD2, FRZB, TFAP2B, 
TNFRSF12A, SOX9, KCNMA1, F5, PTPRZ1, S100A8, STAT1, LOR, CXCL11, HLA-DMA, 
CXCR4, FEZ1, SPRR1B, CD36, CD3D, HCLS1, CADM1, MST4, TYRP1, NR2E1 (includes 
EG:7101), SATB1, KLF5, A2M, MMP9 




 SELL, KRT6A, ASS1, KLK6, CXCL10, LGMN, CXCL13, FABP7, ZBTB16, TYMS, MT1X, 
GSTM3 (includes EG:2947), RRM2, IER3, ARHGDIB, CTSB, TCN1, TFRC, PDGFD, ECM1, 
UBE2C, PRAME (includes EG:23532), KIF20A, FN1, PHLDA2, KPNA2, GDF15, CD74, 
ABCA5, CCL5, CCL2, IGF1R, DAB2, SERPINA1, ADAMDEC1, MMP1 (includes EG:4312), 
S100A1, PSMB9, CCNB1, TNC, CNTN1, KRT6B, KRT17, DST, ISG15, SERPINB4, S100A9, 
CIRBP, KRT5, SORBS2, GATA3, SGK3, RGS1, MMP3, TRIM9, PTTG1, LYZ, CD163, PBK, 
BIRC5, FGFR3, GPX3, CXCL14, IFI30, SCRG1, KRT1, CDKN1C, GZMA, IL8, CXCL9, SPP1, 
COL4A1, SERPINB3, AURKA, TUSC3, ABCA8, CD14, CCL19, CCL18, LGR4, CDK2, 
LETMD1, IFI27, KIAA0101, SOX9, KCNMA1, MCAM, S100A8, CFH, STAT1, CXCR4, 
C9ORF3, PRC1, UPP1, CADM1, IGJ, MMP9, ISG20 





 KRT14, KRT16, IVL, FN1, SPRR1B, KRT17, COL17A1, CITED1, SPRR1A, TYRP1, KRT5, 
ALDH3A2, TRPM1, KRT2, SCEL, LOR, CST6, KRT1, KRT15, DSP 
 Organ Development 1,39E-09-
1,39E-09 
 KRT14, KRT16, SPRR1B, KRT17, COL17A1, SPRR1A, KRT5, ALDH3A2, KRT2, SCEL, 
CST6, KRT1, KRT15, DSP 
 Immunological Disease 4,2E-09-
1,2E-03 
 SELL, MMP3, TRIM9, AUTS2 (includes EG:26053), LRRC1, HLA-DRB1, C1QA, SERPINA3, 
HLA-DMB, LYZ, BIRC5, FGFR3, CXCL10, CXCL13, CXCL14, IFI30, NEDD4L, TYMS, 
TNFRSF21, GZMA, IL8, SPP1, COL4A1, CXCL9, XYLT1, RRM2, IL12RB2, TUSC3, TPX2, 
DSG1, RAB31, ARHGDIB, NRCAM, CTSB, CD14, TFRC, IRF8, CCL19, CCL18, DSC1, CDK2, 
LCP2, C2, FN1, CD2, FRZB, CCL5, COL4A2, CD74, ACOT7, TAP1, HLA-DPA1, TNFRSF12A, 
CCL2, KCNMA1, HLA-DRA, IGF1R, S100A8, CFH, STAT1, CHL1, MMP1 (includes EG:4312), 
RPL13, LAMB4, PLAT, S100A1, CD53, PSMB9, HLA-DMA, CCNB1, TYROBP, CXCR4, 
C9ORF3, FGF14, COL17A1, CD36, HCLS1, CD3D, CADM1, PDZD2, ITGB2, WARS, 
SWAP70, S100A9, FCER1G, SORBS2, GATA3, A2M, MMP9, GZMB 




 SELL, FN1, CD2, CCNB2, CD74, CCL5, BIRC5, CXCL10, CXCL13, CCL27, CCL2, F5, 
IGF1R, STAT1, CXCL11, GZMA, TNFRSF21, HLA-DMA, PSMB9, IL8, SPP1, CCNB1, 
COL4A1, CXCL9, CXCR4, CD48, SERPINB3, IL12RB2, IER3, CD3D, EFS, ITGB2, SATB1, 
FCER1G, IRF8, CCL19, GATA3, CCL18, BCL2A1, LCP2, TRA@, CDK2, GZMB 
 Cell Death 8,25E-09-
1,2E-03 
 HSPB2, HLA-DRB1, SERPINA3, C1QA, CXCL10, GPR37, ZBTB16, TYMS, TNFRSF21, 
MT1X, RRM2, IL12RB2, IER3, DSG1, UBD, NRCAM, CTSB, TFRC, BCL2A1, UBE2C, PRAME 
(includes EG:23532), FN1, PHLDA2, GDF15, PTN, CCL5, COL4A2, CD74, SPRR1A, TAP1, 
CCL2, STK17A, MAL, IGF1R, DAB2, IFI6, SERPINA1, CHL1, MMP1 (includes EG:4312), 
IL11RA, HEY1, PLAT, PLA2G16, PKM2, CD53, S100A1, PLAGL1, GZMK, TNC, CCNB1, 
TYROBP, SERPINB4, ITGB2, SWAP70, S100A9, FCER1G, SORBS2, ID4, GZMB, SGK3, 
MMP3, PTTG1, RNASE1, LYZ, PBK, BIRC5, FGFR3, CCL27, CDKN1C, DSP, GZMA, IL8, 
CXCL9, SPP1, SERPINB3, AURKA, CD14, IRF8, CCL19, CDK2, TRA@, FRZB, CD2, 
TFAP2B, CDHR1, GLRX, TNFRSF12A, HLF (includes EG:3131), SOX9, KCNMA1, MCAM, 
PTPRZ1, S100A8, CFH, STAT1, CXCL11, HLA-DMA, CXCR4, CD36, CD48, HCLS1, CADM1, 
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MST4, NR2E1 (includes EG:7101), LGALS3BP, KLF5, SATB1, A2M, MMP9 
 Tissue Development 1,32E-08-
1,2E-03 
 RGS1, SELL, MMP3, PTTG1, KLK6, C1QA, BIRC5, FGFR3, CXCL10, CDKN1C, TNFRSF21, 
IL8, KRT16, COL4A1, CXCL9, SPP1, IER3, AURKA, CITED1, TPX2, ARHGDIB, NRCAM, 
CCL19, DSC1, CST6, LCP2, FN1, CD2, PTN, COL4A2, CCL5, TNFRSF12A, SOX9, CCL2, 
MCAM, IGF1R, DAB2, PTPRZ1, S100A8, STAT1, CHL1, MMP1 (includes EG:4312), IL11RA, 
PLAT, DSC3, CXCL11, TNC, FEZ1, CXCR4, CD36, CD48, AZGP1, HCLS1, CADM1, ITGB2, 
SWAP70, S100A9, LGALS3BP, KLF5, FCER1G, MMP9, GZMB 
 Inflammatory Disease 2,62E-07-
1,2E-03 
 SELL, AUTS2 (includes EG:26053), LRRC1, TLE1, HLA-DRB1, C1QA, SERPINA3, HLA-DMB, 
CXCL10, CXCL13, TYMS, TNFRSF21, TDO2, RRM2, IL12RB2, ARHGDIB, RAB31, CTSB, 
TFRC, BCL2A1, LCP2, FN1, CCL5, COL4A2, CD74, TAP1, HLA-DPA1, CCL2, HLA-DRA, 
IGF1R, KRT2, IFI6, SERPINA1, MMP1 (includes EG:4312), RPL13, LAMB4, IL11RA, PLAT, 
CD53, PSMB9, CCNB1, TNC, OAS2, TYROBP, DST, FGF14, ITGB2, PDZD2, SWAP70, 
S100A9, FCER1G, SORBS2, GATA3, GZMB, MMP3, LHX2, TRIM9, LYZ, CD163, BIRC5, 
FGFR3, CXCL14, IFI30, NEDD4L, GZMA, IL8, SPP1, CXCL9, COL4A1, XYLT1, TMEM47, 
CD14, CCL19, DSC1, CCL18, C2, TRA@, LGR4, CDK2, CD2, FRZB, CDHR1, ACOT7, 
TNFRSF12A, KCNMA1, F5, PTPRZ1, S100A8, CFH, STAT1, HLA-DMA, CXCR4, COTL1, 
C9ORF3, CD48, CD36, AZGP1, CD3D, HCLS1, CADM1, A2M, MMP9 
 Infection Mechanism 3,8E-07-
5,09E-04 
 IL8, CXCL9, FN1, CXCR4, CD74, CCL5, BST2, CXCL10, ITGB2, S100A9, CCL2, PI3, SNX10, 
S100A8, SERPINA1, IRF8, CXCL11 
 Infectious Disease 3,8E-07-
8,81E-04 
 TRIM9, PTTG1, C1QA, LYZ, CD163, CXCL10, LPL, IFI30, NEDD4L, TYMS, IL8, SPP1, 
CXCL9, MT1X, RRM2, IL12RB2, IER3, RAB31, UBD, MS4A4A, CTSB, TFRC, TCN1, CD14, 
IRF8, C2, LCP2, UBE2C, FN1, LAPTM5, GDF15, CD74, CCL5, GLTSCR2, CCL2, F5, IGF1R, 
PTPRZ1, SERPINA1, TRIM29, STAT1, ACTN1, CXCL11, PLAT, SLC20A1, S100A1, CXCR4, 
CD36, PYGL, ITGB2, S100A9, PI3, FCER1G, GATA3, A2M, MMP9 
 Respiratory Disease 5,8E-07-
7,09E-04 
 PTTG1, KLK6, CCNB2, HLA-DRB1, RNASE1, LYZ, BIRC5, FGFR3, CXCL10, IFI30, 
CDKN1C, TYMS, IL8, SPP1, CKS2, SERPINB3, RRM2, AURKA, IER3, RAB31, AKR1B10, 
TCN1, CD14, CCL19, IRF8, UBE2C, FN1, CCL5, SOX9, CCL2, KCNMA1, HLA-DRA, F5, 
IGF1R, SERPINA1, STAT1, ACTN1, CXCL11, PLAT, IVL, TNC, CCNB1, KRT6B, CXCR4, 
PYGL, PFKP, AZGP1, ITGB2, S100A9, KRT5, IGJ, GATA3, MMP9, GZMB 
 Neurological Disease 6,54E-07-
6,6E-04 
 SELL, KRT6A, AUTS2 (includes EG:26053), HLA-DRB1, TLE1, EIF4A2, C1QA, HLA-DMB, 
SERPINA3, CXCL10, GPR37, CRYM, FABP7, ZBTB16, TYMS, TNFRSF21, DFNA5, CHN1 
(includes EG:1123), MT1X, RRM2, IL12RB2, IER3, ARHGDIB, RAB31, C14ORF132, NRCAM, 
MS4A4A, CTSB, TCN1, TRPM1, PDGFD, ECM1, UBE2C, TSPAN7, GBP1 (includes 
EG:2633), PTN, COL4A2, CD74, CCL5, CORO2B, CCL2, HLA-DRA, MAL, SNX10, IGF1R, 
SERPINA1, CHL1, MMP1 (includes EG:4312), RPL13, LAMB4, PLAT, DSC3, S100A1, PKM2, 
PSMB9, MLLT11, CCNB1, TNC, CNTN1, TYROBP, KRT17, DST, FGF14, CSTB, PAMR1, 
ITGB2, PDZD2, SWAP70, S100A9, CIRBP, WIPI1, FCER1G, SORBS2, GATA3, ID4, GZMB, 
DLGAP5, PTTG1, LPPR4, FGFR3, CCL27, LPL, SCEL, CDKN1C, DSP, KRT16, IL8, SPP1, 
COL4A1, PHACTR1, FXYD1, TMEM47, CAPG, TUSC3, TMEM204, SPARCL1, CD14, IRF8, 
DSC1, TRA@, CDK2, LETMD1, APOC2, ACOT7, GLRX, TNFRSF12A, SOX9, KCNMA1, F5, 
STAT1, GATM, FAM149A, KRT14, HLA-DMA, FEZ1, CXCR4, CD36, PYGL, PFKP, HSPA12A, 
KLF5, A2M, MMP9 
 Cell Signaling 9,66E-07-
1,55E-04 
 RGS1, SELL, FN1, CD2, PTN, APOC2, CCL5, LYZ, CXCL10, CCL27, CXCL13, CCL2, 
MCAM, IGF1R, S100A8, MMP1 (includes EG:4312), CXCL11, S100A1, IL8, CNTN1, SPP1, 
CXCL9, TYROBP, CXCR4, CD36, CD48, FXYD1, CD3D, ITGB2, S100A9, FCER1G, CCL19, 
A2M, TRA@, LCP2 
 Molecular Transport 9,66E-07-
1,08E-04 
 RGS1, SELL, FN1, CD2, CCL5, LYZ, CXCL10, CCL27, CXCL13, CCL2, MCAM, S100A8, 
MMP1 (includes EG:4312), CXCL11, S100A1, IL8, SPP1, CXCL9, TYROBP, CXCR4, FXYD1, 
CD3D, ITGB2, S100A9, FCER1G, CCL19, A2M, TRA@, LCP2 




 RGS1, SELL, FN1, CD2, CCL5, LYZ, CXCL10, CCL27, CXCL13, CCL2, MCAM, S100A8, 
MMP1 (includes EG:4312), CXCL11, S100A1, IL8, SPP1, CXCL9, TYROBP, CXCR4, FXYD1, 
CD3D, ITGB2, S100A9, FCER1G, CCL19, A2M, TRA@, LCP2 
 Tumor Morphology 1,04E-06-
1,19E-03 
 CD53, FN1, MMP3, CXCR4, MCAM, GDF15, CD14, ZBTB16, MMP1 (includes EG:4312), 
MMP9, GZMB 





 SELL, FN1, GBP1 (includes EG:2633), MMP3, PTN, C1QA, CCL5, COL4A2, TNFRSF12A, 
FGFR3, CXCL10, CCL2, F5, CXCL14, MMP1 (includes EG:4312), HEY1, CXCL11, PLAT, 
S100A1, IL8, SPP1, COL4A1, CXCL9, CXCR4, CD36, CITED1, ITGB2, WARS, NR2E1 
(includes EG:7101), KLF5, CTSB, ECM1, MMP9 
 Cell Morphology 1,91E-06-
1,19E-03 
 SELL, FN1, KRT6A, TSPAN7, LPXN, SERPINA3, CCL5, CD74, CXCL10, CCL2, KRT2, DAB2, 
IL8, SPP1, TNC, CXCL9, KRT17, CHN1 (includes EG:1123), IL12RB2, CAPG, ITGB2, 
SWAP70, CCL19, GATA3, A2M, MMP9, GZMB 
 Antigen Presentation 1,95E-06-
1,2E-03 
 RGS1, SELL, FN1, HLA-DRB1, HLA-DMB, CCL5, CD74, CXCL10, CCL2, CXCL13, CXCL14, 
HLA-DRA, IFI30, S100A8, SERPINA1, CFH, STAT1, CXCL11, PSMB9, IL8, HLA-DMA, 
CXCL9, SPP1, CXCR4, TYROBP, CD36, IL12RB2, ITGB2, S100A9, PI3, FCER1G, CD14, 
IRF8, CCL19, CCL18, MMP9 




 FN1, CD2, CCNB2, CCL5, CD74, BIRC5, CCL2, CXCL13, F5, IGF1R, STAT1, IL11RA, 
GZMA, HLA-DMA, PSMB9, IL8, SPP1, CCNB1, CXCR4, TYROBP, IL12RB2, IER3, CD3D, 
ITGB2, SATB1, FCER1G, CCL19, IRF8, GATA3, BCL2A1, LCP2, TRA@, CDK2, GZMB 





 IL8, SELL, CXCL9, SPP1, MMP3, C1QA, CCL5, BIRC5, CXCL10, ITGB2, CCL2, CXCL13, 
S100A9, CXCL14, PI3, FCER1G, S100A8, SERPINA1, IRF8, CFH, ZBTB16, MMP9 
 Hematopoiesis 5,05E-06-
1,2E-03 
 SELL, FN1, CD2, CCL5, CD74, BIRC5, CXCL10, CCL2, F5, IGF1R, SERPINA1, S100A8, 
STAT1, ZBTB16, IL11RA, CXCL11, GZMA, HLA-DMA, PSMB9, IL8, SPP1, CCNB1, CXCL9, 
CXCR4, IL12RB2, IER3, CD3D, ITGB2, S100A9, SATB1, FCER1G, CD14, IRF8, CCL19, 
GATA3, BCL2A1, TRA@, LCP2, CDK2, MMP9, GZMB 
 48




 RGS1, EFS, CXCL9, CXCL13, CCL19, CCL18, MMP9 
 Cellular Compromise 6,36E-06-
6,36E-04 
 IL8, FN1, KRT6A, SPP1, TYROBP, TYRP1, ITGB2, CCL2, PI3, FCER1G, CD14, IRF8, CFH 




 MMP3, AUTS2 (includes EG:26053), TRIM9, LRRC1, HLA-DRB1, HLA-DMB, SERPINA3, 
C1QA, LYZ, BIRC5, FGFR3, CXCL10, CXCL13, CXCL14, TNFRSF21, GZMA, IL8, COL4A1, 
SPP1, CXCL9, XYLT1, ARHGDIB, RAB31, COL21A1, CTSB, TFRC, CCL19, DSC1, CCL18, 
CDK2, TRA@, C2, FN1, FRZB, CCL5, COL4A2, CD74, ACOT7, TAP1, HLA-DPA1, CCL2, 
KCNMA1, HLA-DRA, S100A8, STAT1, MMP1 (includes EG:4312), RPL13, LAMB4, PLAT, 
IL11RA, CD53, HLA-DMA, PSMB9, CCNB1, CXCR4, C9ORF3, FGF14, COL17A1, CD36, 
AZGP1, HCLS1, CD3D, CADM1, PDZD2, ITGB2, SWAP70, S100A9, FCER1G, SORBS2, 
A2M, MMP9, GZMB 




 AUTS2 (includes EG:26053), ASS1, LRRC1, HLA-DRB1, C1QA, SERPINA3, HLA-DMB, 
EIF4A2, CXCL10, CXCL13, CRYM, FABP7, ZBTB16, TNFRSF21, TYMS, CKS2, CHN1 
(includes EG:1123), MT1X, RRM2, IER3, RAB31, ARHGDIB, C14ORF132, CTSB, TFRC, 
UBE2C, FN1, GBP1 (includes EG:2633), CD74, COL4A2, CCL5, TAP1, CORO2B, HLA-DPA1, 
CCL2, HLA-DRA, IGF1R, SNX10, SERPINA1, LAMB4, RPL13, MMP1 (includes EG:4312), 
IL11RA, PLAT, CD53, PKM2, PSMB9, CCNB1, TYROBP, DST, FGF14, ITGB2, PDZD2, 
SWAP70, S100A9, CIRBP, FCER1G, SORBS2, ID4, GZMB, MMP3, TRIM9, MELK, LYZ, PBK, 
BIRC5, FGFR3, CXCL14, LPL, SCEL, CDKN1C, DSP, GZMA, IL8, CXCL9, SPP1, COL4A1, 
XYLT1, TMEM204, SPARCL1, CD14, CCL19, IRF8, CCL18, DSC1, C2, TRA@, CDK2, FRZB, 
TFAP2B, ACOT7, TNFRSF12A, SOX9, KCNMA1, F5, S100A8, STAT1, HLA-DMA, CXCR4, 





 IL8, SELL, FN1, SPP1, CNTN1, TSPAN7, CD2, TYROBP, PTN, CD36, CD48, APOC2, CCL5, 
TUSC3, FGFR3, ITGB2, SATB1, FCER1G, IGF1R, SERPINA1, STAT1, CDK2, MMP1 
(includes EG:4312), UBE2C 
 Hematological Disease 1,52E-05-
6,23E-04 
 SELL, FN1, CD2, KPNA2, PTTG1, C1QA, CCL5, CD74, BIRC5, CXCL10, FGFR3, CCL2, 
CXCL13, KCNMA1, F5, CXCL14, LPL, PTPRZ1, CFH, PLAT, IL11RA, IL8, CXCL9, COL4A1, 
SPP1, CXCR4, CD36, RRM2, HCLS1, CD3D, ITGB2, ABCA8, S100A9, SATB1, FCER1G, 
CD14, IRF8, GATA3, CDK2, C2, MMP9 




 SELL, KRT6A, LHX2, IFI27, HSPB2, CXCL10, CCL2, LPL, HLA-DRA, SERPINA1, IFI6, 
STAT1, DSP, CXCL11, IL11RA, IL8, PSMB9, SPP1, CXCL9, OAS2, CXCR4, UPP1, COL17A1, 
CD36, ITGB2, S100A9, KLF5, CTSB, DSC1, MMP9, CDK2 
 Cell Cycle 5,02E-05-
1,2E-03 
 KIF20A, TYMS, DLGAP5, PLAGL1, CCNB1, FN1, TNC, CKS2, PTTG1, GDF15, SSBP2, 
IER3, AURKA, BIRC5, NR2E1 (includes EG:7101), SOX9, STAT1, CDKN1C, NEDD4L, 





 CXCL10, IL8, ITGB2, CXCL9, CD2, CCL2, CD48, CCL5, CXCL11 




 CXCL10, CXCL9, CXCL11 














 IL8, COL4A1, FN1, MMP3, CXCR4, CD36, COL4A2, CITED1, TNFRSF12A, CXCL10, ITGB2, 
WARS, NR2E1 (includes EG:7101), CCL2, KLF5, CXCL14, CTSB, ECM1, MMP1 (includes 
EG:4312), MMP9, HEY1, PLAT 




 SWAP70, CCL2, CCL5 




 RGS1, COL4A1, SPP1, FN1, SERPINA3, CD74, A2M, C2 
 Metabolic Disease 3,11E-04-
3,11E-04 
 RGS1, COL4A1, SPP1, FN1, SERPINA3, CD74, A2M, C2 
 Organismal Survival 3,79E-04-
3,79E-04 
 S100A1, CXCL9, CNTN1, CD2, CD48, LYZ, CD74, TAP1, BIRC5, CXCL10, CCL2, HLA-DRA, 





 COL4A1, COL4A2 





 FN1, CHL1 





 NR2E1 (includes EG:7101), CDKN1C 
 Cardiovascular Disease 4,22E-04-
1,06E-03 
 MMP3, HSPB2, LPL, CD36, MMP1 (includes EG:4312), MMP9, DSP 
 Organismal Functions 4,94E-04-
4,94E-04 
 GZMA, PTPRZ1, PLAT, GZMB 





 FGFR3, SOX9, MMP9 





 FGFR3, S100A1, SOX9, FN1, SERPINA3, A2M, MMP9, MMP1 (includes EG:4312) 









 PKM2, FGFR3, TYMS, PRC1, RRM2, AURKA, MMP9, PLAT, UBE2C, BIRC5 
 Antimicrobial Response 1,2E-03-
1,2E-03 
 GZMA, GZMB 
 Organ Morphology 1,2E-03-
1,2E-03 
 S100A1, MMP1 (includes EG:4312) 
 
Supplemental Table 2: The Functional Analysis according to Ingenuity’sTM Knowledge Base identified the 
biological functions that were most significant to regulated genes in PM compared to MN comprising cancer, 






Category  p-value Molecules 





 CSTA, KRT6A, KLK6, CTSL2, VEGFA, KLK5, SCEL, JUP, KRT1, DSP, KRT16, SELE, GJA1, 
CDSN, KRT10, KLF4, KLK7, CDH1, TGM1, SPINK5, LAMA3, DSC1, CST6, KRT15, ALOX12B, 
FN1, SPRR1A, ID1, DSG3, CDH3, KRT2, KIT, LOR, EGFR, KRT14, TIMP3, CALML5, IVL, 
TP63, KRT17, SPRR1B, COL17A1, LAMC2, KLK8, TYRP1, DHCR24, KRT5, BNC1, CRABP2, 
SFN 
 Organ Development 7,99E-26-
1,23E-02 
 ALOX12B, FN1, SPRR1A, CTSL2, VEGFA, FGFR3, ALDH1A1, KLK5, KIT, KRT2, SCEL, 
DSC2, LOR, KRT1, DSP, EGFR, KRT14, KRT16, GJA1, CALML5, TP63, SPRR1B, KRT17, 
COL17A1, CDSN, KRT10, LAMC2, MET, HOPX, KLK7, CDH1, SPINK5, TF, DHCR24, KRT5, 






 KRT6A, FCER1A, KLK6, SERPINB2, CTSL2, VEGFA, SLURP1, CCL27, ZNF750, JUP, KRT1, 
DSP, KRT16, GJA1, SELE, SPP1, SERPINB3, CDSN, KRT10, DSG1, CDH1, SPINK5, TGM1, 
IL1RN, FERMT1, LAMA3, DSC1, ABCA12, ALOX12B, FN1, GJB3, HLA-DQA1, SLPI, DSG3, 
CD1A, KIT, KRT2, S100A8, LOR, MMP1 (includes EG:4312), EGFR, KRT14, SDC1, TP63, 
KRT6B, KRT17, PERP, COL17A1, TUBA4A, S100A12, LAMC2, TYRP1, S100A9, KRT5 
 Cancer 5,73E-16-
1,21E-02 
 KRT6A, ASS1, KLK6, SERPINA3, RPS4Y1, SERPINB2, CTSL2, VEGFA, KLK5, MGP, PTGIS, 
SELE, IGH@, DCN, GSTM3 (includes EG:2947), KRT23, KRT10, S100A2, MET, KLK7, CDH1, 
SPINT2, ANK3, CA2, FN1, SLPI, AQP3, KLK11, DSG3, ID1, MT1E, CDH3, TRIM29, KLK10, 
MMP1 (includes EG:4312), EGFR, TACSTD2, PLOD2, KRT6B, KRT17, DST, DEFB1, 
S100A14, C10ORF116, LAMC2, SERPINB4, NOV, S100A9, DHCR24, KRT5, BNC1, SFN, 
CXADR, EYA1, QPCT (includes EG:25797), TRIM9, MBP, SCUBE2, FCER1A, LAD1, FGFR3, 
GPX3, ALDH1A1, CCL27, CXCL14, CFI, JUP, SERPINB5, KRT1, AIM1 (includes EG:202), 
KRT16, GJA1, SPP1, LCN2, SERPINB3, CAPG, ZNF185, TUSC3, AKR1C2, KLF4, IGFBP2, 
STC1, IL1RN, AKR1B10, LAMA3, DSC1, S100P, IFI27, CD1A, C7, KIT, S100A8, CD24, 
KRT14, KLK13, TIMP3, TP63, SDC1, TUBA4A, PERP, PPL, CPA4, KLK8, HOPX, CRABP2, 
KLF5 




 NELL1, KRT6A, TRIM9, MBP, ASS1, SCUBE2, LAD1, KLK6, VEGFA, FGFR3, CTSL2, GPX3, 
ALDH1A1, CXCL14, KLK5, CFI, MGP, SERPINB5, JUP, KRT1, AIM1 (includes EG:202), 
SELE, SPP1, GSTM3 (includes EG:2947), DCN, LCN2, KRT23, SERPINB3, AKR1C2, TUSC3, 
KLF4, S100A2, IGFBP2, MET, STC1, CDH1, KLK7, LAMA3, SPINT2, CCL18, S100P, ANK3, 
FN1, IFI27, SLPI, KLK11, ID1, MT1E, CDH3, C7, KIT, S100A8, CD24, MMP1 (includes 
EG:4312), KLK10, EGFR, TACSTD2, POF1B, TIMP3, TP63, KRT6B, KRT17, DST, TUBA4A, 
DEFB1, S100A14, KLK8, SERPINB4, HOPX, S100A9, DHCR24, KRT5, BNC1, CRABP2, SFN, 
EYA1, CXADR 
 Cellular Development 2,54E-13-
1,43E-02 
 NELL1, CSTA, KRT6A, MBP, SERPINA3, SERPINB2, FGFR3, CTSL2, VEGFA, SLURP1, 
ALDH1A1, MGP, SERPINB7, SCEL, JUP, DSP, GJA1, SPP1, PKP3, DCN, LCN2, CAPG, 
KRT10, KLF4, IGFBP2, MET, STC1, CDH1, SPINK5, TGM1, IL1RN, LAMA3, CST6, DSC1, 
CA2, FN1, HLA-DQA1, SPRR1A, SYNM, ID1, KIT, S100A8, LOR, CD24, MMP1 (includes 
EG:4312), EGFR, TIMP3, IVL, SDC1, TP63, SPRR1B, TYRP1, HOPX, NOV, S100A9, 
CRABP2, KLF5, SFN, CXADR, EYA1 
 Genetic Disorder 1,38E-11-
1,43E-02 
 NELL1, KRT6A, ASS1, CA12, KLK6, SERPINA3, EXPH5, VEGFA, SCNN1A, SLURP1, HAL, 
KLK5, MGP, SERPINB7, PTGIS, MALL, SELE, DCN, CPA3, KRT10, S100A2, DSG1, MET, 
KLK7, CDH1, TGM1, SPINT2, VSNL1, ANK3, CA2, FN1, HLA-DQA1, SLPI, ABLIM1, DSG3, 
KLK11, ID1, AQP3, HLA-DQB2, MT1E, CDH3, KRT2, CLIC3, TRIM29, MMP1 (includes 
EG:4312), KLK10, EGFR, TACSTD2, NMU, DSC3, POF1B, PLOD2, KRT6B, KRT17, DST, 
COL17A1, ELOVL4, DEFB1, LAMC2, S100A9, TF, DHCR24, KRT5, BNC1, ANXA3, EYA1, 
QPCT (includes EG:25797), TRIM9, SLC6A14, MBP, SCUBE2, FCER1A, LPPR4, MT1M, 
FGFR3, GPX3, ALDH1A1, ZNF750, CCL27, CXCL14, CFI, IMPA2, SCEL, SERPINB5, JUP, 
KRT1, DSC2, DSP, AIM1 (includes EG:202), KRT16, BBOX1, GJA1, SPP1, LCN2, SERPINB3, 
CDSN, CAPG, ZNF185, AKR1C2, TUSC3, IGFBP2, SPINK5, FERMT1, IL1RN, AKR1B10, 
LAMA3, DSC1, CCL18, ABCA12, ARG1, S100P, ALOX12B, GJB3, TUFT1, CDS1, CD1A, C7, 
KIT, S100A8, LOR, CD24, KRT14, TIMP3, TP63, SDC1, PERP, TUBA4A, S100A12, KLK8, 
TYRP1, HOPX, KLF5, RHCG 
 Cellular Movement 1,79E-08-
1,43E-02 
 KRT6A, FCER1A, KLK6, SERPINA3, SERPINB2, CTSL2, VEGFA, CCL27, CXCL14, MGP, 
SERPINB5, JUP, KRT16, SELE, GJA1, SPP1, PKP3, DCN, LCN2, SERPINB3, KRT10, 
S100A2, KLF4, IGFBP2, STC1, MET, CDH1, IL1RN, LAMA3, SPINT2, CCL18, CST6, VSNL1, 
S100P, FN1, SLPI, SYNM, ID1, CDH3, KIT, S100A8, CD24, CALML3, MMP1 (includes 
EG:4312), NMU, EGFR, TIMP3, TP63, SDC1, PRSS3 (includes EG:5646), COL17A1, DEFB1, 
LRRC15, LAMC2, LYPD3, NOV, S100A9, KLF5 




 NELL1, MBP, FCER1A, KLK6, SERPINB2, CTSL2, FGFR3, VEGFA, SLURP1, ALDH1A1, 
CCL27, MGP, SERPINB7, SERPINB5, JUP, CLCA2 (includes EG:9635), KRT16, GJA1, SPP1, 
PKP3, DCN, LCN2, KRT10, FGFBP1, KLF4, IGFBP2, MET, STC1, CDH1, IL1RN, LAMA3, 
SPINT2, CST6, ARG1, S100P, FN1, SLPI, SYNM, ID1, DSG3, MT1E, KIT, KRT2, S100A8, 
CD24, EGFR, TACSTD2, KLK13, TIMP3, TP63, DEFB1, KLK8, TYRP1, NOV, S100A9, TF, 
DHCR24, BNC1, CRABP2, KLF5, SFN, CXADR 
 Respiratory Disease 4,28E-08-
1,16E-02 
 CA2, FN1, CA12, KLK6, SLPI, RPS4Y1, SCNN1A, FGFR3, VEGFA, ID1, DSG3, KLK11, 
KLK5, MGP, IMPA2, KIT, SERPINB5, CD24, KLK10, EGFR, PTGIS, TIMP3, IVL, SELE, SPP1, 
TP63, KRT6B, LCN2, SERPINB3, TUBA4A, S100A12, AZGP1, KLK8, MET, CDH1, KLK7, TF, 
S100A9, IL1RN, KRT5, ANXA3, AKR1B10, LAMA3, ARG1, S100P 




 MBP, FCER1A, KLK6, SERPINB2, CTSL2, VEGFA, SLURP1, CCL27, SERPINB5, JUP, 
KRT1, DSC2, DSP, CLCA2 (includes EG:9635), KRT16, SELE, GJA1, SPP1, DCN, LCN2, 
SERPINB3, CDSN, KLF4, IGFBP2, STC1, MET, CDH1, SPINK5, IL1RN, LAMA3, VSNL1, 
CST6, ANK3, FN1, HLA-DQA1, SLPI, ID1, DSG3, CD1A, CDH3, KRT2, KIT, S100A8, CD24, 
MMP1 (includes EG:4312), NMU, EGFR, DSC3, TIMP3, SDC1, TP63, COL17A1, PERP, 
S100A12, AZGP1, LAMC2, LYPD3, S100A9, PI3, CXADR 
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 Tissue Development 1,1E-07-
1,43E-02 
 NELL1, KRT6A, KLK6, SERPINB2, FGFR3, VEGFA, SLURP1, ALDH1A1, SERPINB5, JUP, 
DSC2, CLCA2 (includes EG:9635), KRT16, SELE, GJA1, SPP1, DCN, LCN2, CDSN, STC1, 
MET, CDH1, SPINK5, IL1RN, LAMA3, DSC1, VSNL1, CST6, CA2, FN1, SLPI, ID1, DSG3, 
CDH3, C7, KIT, S100A8, CD24, EGFR, DSC3, TIMP3, TP63, SDC1, KRT6B, KRT17, PERP, 
AZGP1, LAMC2, DHCR24, S100A9, KLF5, EYA1, CXADR 




 CA2, SELE, FN1, SPP1, LCN2, CA12, SERPINA3, KLF4, IGFBP2, VEGFA, ID1, CDS1, TF, 
IL1RN, EYA1, EGFR 
 Metabolic Disease 1,39E-07-
7,7E-04 
 CA2, SELE, FN1, SPP1, LCN2, CA12, SERPINA3, KLF4, IGFBP2, VEGFA, ID1, CDS1, TF, 
IL1RN 





 NELL1, GJA1, FN1, SPP1, PKP3, DCN, VEGFA, STC1, FGFR3, MET, CDH1, IL1RN, CDH3, 
MGP, JUP, EGFR 




 CA2, FN1, MBP, CA12, SERPINA3, VEGFA, FGFR3, AQP3, MT1E, CFI, KIT, JUP, AIM1 
(includes EG:202), EGFR, TIMP3, SPP1, LCN2, TUBA4A, PPL, DEFB1, IGFBP2, MET, STC1, 





 FN1, FCER1A, SERPINA3, SLPI, VEGFA, CTSL2, DSG3, CCL27, CXCL14, C7, S100A8, 
NMU, EGFR, SELE, GJA1, SDC1, SPP1, COL17A1, DEFB1, CAPG, S100A12, TYRP1, 
S100A9, TF, IL1RN, PI3, DSC1, CCL18 
 Neurological Disease 8,18E-06-
1,43E-02 
 NELL1, KRT6A, MBP, SCUBE2, LPPR4, CA12, MT1M, SERPINA3, FGFR3, CTSL2, VEGFA, 
ALDH1A1, CCL27, MGP, IMPA2, SCEL, DSP, AIM1 (includes EG:202), PTGIS, KRT16, SELE, 
GJA1, BBOX1, SPP1, DCN, LCN2, CAPG, CDSN, TUSC3, AKR1C2, ZNF185, KRT10, 
IGFBP2, TGM1, IL1RN, FERMT1, LAMA3, VSNL1, DSC1, S100P, ARG1, ABCA12, ANK3, 
CA2, GJB3, HLA-DQA1, TUFT1, ABLIM1, HLA-DQB2, CDS1, MT1E, CD1A, C7, CLIC3, KIT, 
CD24, MMP1 (includes EG:4312), DSC3, EGFR, POF1B, KRT14, TIMP3, PLOD2, SDC1, 
TP63, KRT17, DST, PRSS3 (includes EG:5646), PERP, TUBA4A, DEFB1, S100A12, DHCR24, 





 ANK3, CA2, FN1, TRIM9, KLK6, SERPINA3, FGFR3, CTSL2, VEGFA, AQP3, MT1E, KLK5, 
KIT, SERPINB5, CD24, KLK10, AIM1 (includes EG:202), EGFR, KRT14, KLK13, PLOD2, 
TIMP3, GJA1, SDC1, SPP1, TP63, LCN2, TUBA4A, CAPG, KRT10, AKR1C2, KLF4, CPA4, 
C10ORF116, MET, CDH1, IL1RN, CRABP2, LAMA3, SFN, QPCT (includes EG:25797) 




 CA2, NELL1, KRT6A, IFI27, CA12, SLPI, FGFR3, VEGFA, CTSL2, SCNN1A, DSG3, MT1E, 
KIT, DSP, MMP1 (includes EG:4312), EGFR, NMU, PTGIS, PLOD2, SELE, GJA1, SPP1, 
PRSS3 (includes EG:5646), COL17A1, TUBA4A, SERPINB3, KRT10, STC1, HOPX, S100A9, 
IL1RN, KLF5, DSC1, ARG1 
 Cell Morphology 1,56E-05-
1,43E-02 
 NELL1, KRT6A, FN1, KLK6, SERPINA3, SYNM, VEGFA, ID1, MGP, KRT2, SERPINB5, 
CD24, CALML3, EGFR, KRT16, TIMP3, SELE, GJA1, SPP1, SDC1, TP63, KRT17, DCN, 
LCN2, CAPG, KLF4, IGFBP2, STC1, MET, CDH1, SPINK5, IL1RN, BNC1, KLF5, LAMA3, 
ARG1 
 Immunological Disease 2,42E-05-
1,43E-02 
 SPP1, FN1, MBP, FCER1A, COL17A1, HLA-DQA1, DSG1, VEGFA, FGFR3, DSG3, SPINK5, 
S100A9, IL1RN, KIT, CD24, CXADR 





 NELL1, GJA1, SDC1, FN1, SPP1, DCN, SERPINA3, KLF4, MET, CTSL2, STC1, FGFR3, 
VEGFA, NOV, IL1RN, KLF5, MGP, KIT, SERPINB5, CXADR, MMP1 (includes EG:4312), 
ARG1, EGFR 





 FN1, MBP, FCER1A, SERPINA3, SLPI, CTSL2, VEGFA, CCL27, CDH3, CXCL14, C7, KIT, 
S100A8, NMU, EGFR, TIMP3, GJA1, SELE, SPP1, LCN2, PRSS3 (includes EG:5646), 
COL17A1, DEFB1, CAPG, KRT10, STC1, TF, S100A9, IL1RN, PI3, CCL18, DSC1 




 FN1, FCER1A, SERPINA3, SLPI, VEGFA, CTSL2, CCL27, CDH3, CXCL14, C7, KIT, S100A8, 
CD24, NMU, EGFR, TIMP3, SELE, SPP1, SDC1, PRSS3 (includes EG:5646), SERPINB3, 
COL17A1, DEFB1, KRT10, STC1, S100A9, IL1RN, DSC1, CCL18 
 Organismal Functions 3,81E-05-
4,11E-03 
 MET, VEGFA, HOPX, GJA1, SPP1, FN1, IL1RN, SLPI, SERPINB2 
 Inflammatory Disease 4,7E-05-
7,5E-03 
 VEGFA, CA2, SPP1, S100A9, IL1RN, CA12, S100A8, S100A12, SERPINB2 
 Nutritional Disease 4,7E-05-
4,7E-05 
 SCNN1A, DSG3, SPINK5 





 PTGIS, TIMP3, SELE, GJA1, SPP1, FN1, DCN, KLF4, VEGFA, MET, CTSL2, STC1, SLURP1, 
ID1, S100A9, KLF5, KIT, SERPINB5, KRT1, CXADR, MMP1 (includes EG:4312), EGFR 
 Ophthalmic Disease 8,11E-05-
8,95E-03 
 CA2, SELE, DCN, ELOVL4, CA12, TUBA4A, VEGFA, FGFR3, TYRP1, TF, IL1RN, KIT, 
TACSTD2 
 Tumor Morphology 9,35E-05-
1,43E-02 
 SELE, FN1, DCN, PERP, LRRC15, IGFBP2, SERPINB2, CTSL2, VEGFA, CDH1, NOV, 
IL1RN, JUP, SERPINB5, MMP1 (includes EG:4312), EGFR 
 Cell Death 1,73E-04-
1,43E-02 
 CSTA, NELL1, MBP, FCER1A, SERPINA3, SERPINB2, VEGFA, CTSL2, FGFR3, ALDH1A1, 
CCL27, CFI, MGP, JUP, SERPINB5, DSP, CLCA2 (includes EG:9635), PTGIS, GJA1, SPP1, 
DCN, LCN2, SERPINB3, KRT10, KLF4, IGFBP2, DSG1, STC1, MET, CDH1, TGM1, IL1RN, 
S100P, ARG1, RAB25, FN1, SPRR1A, ID1, DSG3, MT1E, C7, KIT, S100A8, CD24, MMP1 
(includes EG:4312), EGFR, TIMP3, SDC1, TP63, PERP, DEFB1, KLK8, SULT2B1, SERPINB4, 





 PTGIS, CA2, SELE, GJA1, KRT6A, LCN2, CA12, S100A12, SLPI, CTSL2, VEGFA, SCNN1A, 
S100A9, IMPA2, SERPINB5, JUP, DSC2, VSNL1, DSP, AIM1 (includes EG:202), S100P 
 Cellular Compromise 2,53E-04-
3,09E-03 
 TYRP1, SELE, GJA1, SPP1, KRT6A, MT1E, IL1RN, PI3, EGFR 




 VEGFA, SPP1, S100A9, IL1RN, S100A8, S100A12, SERPINB2 
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 Cell Cycle 3,75E-04-
1,43E-02 





 KRT14, VEGFA, CDH1, SPP1, FN1, SLPI 
 Infectious Disease 8,37E-04-
1,43E-02 
 FN1, S100A9, PI3, LCN2, IMPA2, S100A12, SLPI, RPS4Y1, CXADR, CD24, S100P 




 GJA1, KRT6A, FN1, SPP1, KRT17, LAMC2, VEGFA, MET, CDH1, CCL27, MGP, LAMA3, 
JUP, DSP, EGFR 









 TIMP3, GJA1, KRT6A, FN1, TP63, KRT6B, LCN2, KLK6, MET, VEGFA, FGFR3, SLURP1, 
ALDH1A1, MGP, SERPINB5, EYA1, EGFR 
 Organ Morphology 8,51E-04-
8,5E-03 
 KRT16, GJA1, FN1, TP63, KRT10, CTSL2, TYRP1, VEGFA, CDH1, TGM1, ALDH1A1, 





 FGFR3, VEGFA, GPX3, TP63, ALDH1A1, TGM1, FCER1A, KIT, CD24, EGFR 
 Protein Folding 8,51E-04-
8,51E-04 
 VEGFA, TGM1 





 VEGFA, SELE, GJA1, CDH1, TP63, ALDH1A1, TF, KLF5, KIT, DSC2, CLCA2 (includes 
EG:9635) 
 Tissue Morphology 8,51E-04-
8,43E-03 
 GJA1, SELE, SPP1, FCER1A, KLF4, MET, CTSL2, VEGFA, STC1, TF, S100A9, PI3, S100A8, 





 MET, VEGFA, STC1, TIMP3, SLURP1, FN1, KLF5, SERPINB5, MMP1 (includes EG:4312) 




 MT1E, IL1RN 





 MET, TIMP3, CDH1, FN1, TP63, ALDH1A1, LCN2, KLK6 
 Hematological Disease 2,24E-03-
1,43E-02 
 VEGFA, PLOD2, SELE, SPP1, FN1, S100A9, IL1RN, KIT, CXADR 




 GJA1, SPP1, ASS1, LCN2, TUBA4A, S100A12, RPS4Y1, FGFR3, S100A9, CRABP2, IMPA2, 
KIT, S100A8, VSNL1, AIM1 (includes EG:202), S100P 
 Cell Signaling 2,77E-03-
7,51E-03 
 ASS1, FCER1A, VAMP8, ARG1 
 Drug Metabolism 2,77E-03-
2,77E-03 
 PTGIS, VEGFA 
 Lipid Metabolism 2,77E-03-
1,08E-02 
 VEGFA, PTGIS, ALOX12B, SPP1, S100A9, FCER1A, S100A8, AKR1C2, NMU 
 Molecular Transport 2,77E-03-
1,18E-02 
 SPP1, TF, MT1E, S100A9, SLC6A14, FCER1A, S100A8, VAMP8, ARG1, NMU 




 PTGIS, ALOX12B, SPP1, SLC6A14, FCER1A, AKR1C2, FGFR3, VEGFA, CDH1, ALDH1A1, 
S100A9, AKR1B10, KIT, S100A8, CD24, EGFR, NMU, ARG1 





 PTGIS, SELE, GJA1, S100A9, TF, KLF5, PI3, FCER1A, S100A8, KLF4 





 MET, VEGFA 
 Hematopoiesis 4,44E-03-
1,18E-02 
 VEGFA, SELE, IL1RN, MBP, LCN2, KIT, EGFR 
 Infection Mechanism 5,7E-03-
5,7E-03 
 PI3, CXADR 




 CTSL2, SELE, SPP1, FN1, CCL27, IL1RN, MBP, DEFB1, CCL18 




 FGFR3, ASS1, SLC6A14, FCER1A, KIT, CD24, EGFR, ARG1 
 Protein Degradation 7,51E-03-
7,51E-03 
 TIMP3, KLK6 










 FGFR3, VEGFA, EYA1, EGFR 
 Protein Synthesis 9,4E-03-
9,4E-03 
 GPX3, TP63, ALDH1A1 





 SPP1, NMU 
 Antigen Presentation 1,18E-02-
1,18E-02 
 FN1, CAPG 
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Supplemental Table 3: The Functional Analysis according to Ingenuity’sTM Knowledge Base identified the 
biological functions that were most significant to regulated genes in MM compared to PM comprising cancer, 





MN PM MM 
 A.M. T.V. mean A.M. T.V. mean A.M. T.V. mean 
- negative 
 




45 51 48 2 3 2,5 3 4 3,5 
+ positive 
 








0 0 0 11 14 12,5 
 




MN PM MM 
 A.M. T.V. mean A.M. T.V. mean A.M. T.V. mean 
- negative 
 




14 22 18 1 0 0,5 11 14 12,5 
+ positive 
 








6 4 5 17 14 15,5 19 14 16,5 
 
Supplemental Table 4: Two independent investigators (A.M., T.V.) evaluated immunostaining of tissue 





Supplemental Figure 1: Principal component analysis displays spatial separation of melanocytic nevi (MN), 
primary melanomas (PM), and melanoma metastases (MM). Results of PCA are shown in the three-dimensional 





Supplemental Figure 2A/B/C/D: Ingenuity Network analysis of all significantly regulated genes in PM 
compared to MN (Figure A), MM compared to PM (Figure B). Analysis of genes with a minimum log ratio of 
1.5 in PM compared to MN (Figure C), MM compared to PM (Figure D). Green symbols show down-regulation, 









Deutsche Zusammenfassung der Promotionsarbeit  
mit dem publizierten Titel:  
“Identification of new genes associated with melanoma”  
 
 




Mit der vorliegenden Arbeit sollen neue Erkenntnisse über die Genexpressionsmuster und 
Signalkaskaden des malignen Melanoms gewonnen werden. Während Melanom-Patienten mit 
einer Tumordicke von unter 1 mm (Stadium I) eine gute Prognose haben, sinkt die Fünf-
jahresüberlebensrate bei Vorliegen von Fernmetastasen (Stadium IV) unter 10 % [1]. Auf eine 
Standardchemotherapie sprechen nur zwischen 5,3 und 23% der Patienten an [2, 3]. Wegen 
dieser geringen Ansprechrate werden neue Therapieansätze verfolgt, die auf der Blockade 
molekularer Prozesse in der Signaltransduktion der Zelle beruhen. Die Selbstregulation der 
Melanomzelle wird von einer Vielzahl an Genen gesteuert. Deshalb ist es für neue 
diagnostische und therapeutische Ansätze wichtig, bevorzugt das Gesamtexpressionsmuster 
zu betrachten anstatt nur ein Einzelgen zu verfolgen [4]. Seit der Entwicklung der 
Mikroarray-Technologie ist es möglich die Expression einer Vielzahl von Genen in einer 
Gewebeprobe zu untersuchen. Mit einer geeigneten Software können Netzwerke von 
Signalkaskaden in den einzelnen Proben analysiert und verglichen werden.  
 
In dieser Arbeit wurden humane Gewebeproben von 18 melanozytären Nävuszellnävi (MN), 
20 Melanomen (PM) und 20 Melanommetastasen (MM) aus der Abteilung für Dermatologie 
der Universität Regensburg verwendet. Ein Teil des entfernten Patientengewebes wurde nach 
der Gewinnung kryokonserviert. Nach Abschluss der Diagnosestellung wurde mittels 
Mikrodissektion Gewebe zur weiteren Untersuchung isoliert. Anschließend erfolgte die 
Isolierung der RNA und Überschreibung in zweisträngige cDNA und Biotin markierte cRNA. 
Nach deren Fragmentierung erfolgte die Hybridisierung auf Mikroarrays (Affymetrix Human 
Genome U133A 2.0 GeneChip; Affymetrix, Santa Clara, USA). Zur Analyse und 
statistischen Untersuchung der gewonnen CEL Files wurde Chipinspector Version 1.3 
(Genomatix Software GmbH, München, Germany) verwendet [5]. Mit IngenuityTM Pathways 
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Analysis (www.ingenuity.com, IngenuityTM Systems, Mountain View, USA) [6] wurden 
funktionelle Verbindungen der signifikant regulierten Gene, Netzwerke und eingebundene 
Signalkaskaden aufgedeckt. Eine Hauptkomponentenanalyse erlaubte die dreidimensionale 
Darstellung der Einzelproben in Abhängigkeit von ihrem Expressionsmuster (Partek Genomic 
Suite 6.4 ,Partek Inc., St. Louis, USA).  
Zur Validierung der Mikroarray Daten wurden zusätzlich quantitative Echtzeit-PCR (QPCR) 
Untersuchungen durchgeführt. Hierfür wurde RNA von fünf repräsentativen MN, von fünf 
PM und von fünf MM isoliert und in cDNA (SuperScript II, Invitrogen, Carlsbad, USA) 
übersetzt. Die Untersuchung erfolgte in dreifacher Ausführung mit Hilfe der kommerziell 
erhältlichen  TaqManTM-Assays (Applied Biosystem, Foster City, USA) und individueller 
Primer (Apara Bioscience, Denzlingen, Germany). 
Um die Genprodukte von GDF15 und MMP1 nachzuweisen, führten wir Tissue-Mikroarrays 
(TMA) durch [7]. Diese enthielten Gewebezylinder von 127 MN, 73 PM, und 89 MM auf 
einem Paraffinblock. Anhand von Standardprotokollen erfolgte eine Inkubierung mit 
polyklonalen anti-GDF15 Antikörpern (Abcam, Cambridge, UK) und monoklonalen anti-
MMP1 Antikörpern (Millipore Corporation, Billerica, USA); danach Färbung mit Hilfe von 
biotinylierten Sekundärantikörpern (Zytochem Plus HRP Broad Spectrum Kit, Zytomed 
Systems, Berlin, Germany). Die Auswertung erfolgte durch zwei unabhängige Untersucher 
(A.M., T.V.) anhand eines fünfstufigen Bewertungssystems (0 bis 4+). Um die Überlebenszeit 
mit niedrigen und hohen Expressiongraden der Gene Serpin B3 und Serpin B4 zu vergleichen, 
verwendeten wir SPSS V.18.0 (SPSS Inc., Chicago, USA). Ein p-Wert <0.05 wurde als 
signifikant gewertet [8]. 
 
Bei der Auswertung der CEL Files wurden die Gruppe der PM mit der Gruppe der MN und 
die Gruppe der MM mit der Gruppe der PM verglichen. Die Werte mussten sich hierbei um 
den Faktor zwei unterscheiden, um als signifikant zu gelten. Chipinspector identifizierte für 
die Gruppe der PM im Vergleich mit der Gruppe der MN 167 Gene, die vermehrt, und 117 
Gene, die vermindert exprimiert wurden. Beim Vergleich der Gruppe der MM mit der Gruppe 
der PM ergaben sich 26 vermehrt und 163 vermindert exprimierte Gene. 
Beim Vergleich der Ergebnisse mit bereits publizierten Daten zeigten sich große Überein-
stimmungen. Erhöhte Expressionswerte bei Melanomen im Vergleich mit melanozytären 
Nävi sind bekannt für PRAME, SSP1 [9, 10], CXCL9, PHACTR1, CITED-1, BCL2A1 [9, 
11] S100A9, MMP1, FN1 [12], NNMT, SERPIN A3 [9], MCAM [13], ISG15 [14], CDK-2, 
und CDK-4 [15], GDF15 [9, 11, 16] und Hey1 [11, 12]. Erniedrigte Werte sind für CIRBP, 
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FEZ1, PPP1R3C, LDOC1, TRPM1 [12], Desmoglein [13], KRT-15 [9], FABP7 [16], 
p57KIP2 und CDKN1 [17] beschrieben.  
Für die Gruppe der Melanommetastasen im Vergleich mit Melanomen ergab die 
Literaturrecherche ebenfalls erhöhte Expressionswerte für VEGFA [18, 19], FN1 [20, 21], 
IGFBP2 [22], SPP1, MAGEA12, c-MET [11, 21, 23], STC1, und PLOD2 [21] sowie 
verminderte Werte für Serpin B5 [24], SPRR1A, KRT 16/17/6B, CD 24, LOR, DSC1 [23], 
KRT 1/14/6A/5, CXCL14 und SPINT2 [21].  
Wir nahmen an, dass die drei histologisch unterschiedlichen Gruppen anhand ihres 
Transkriptoms klassifiziert werden können und untersuchten dies mit Hilfe der 
Hauptkomponentenanalyse. Hierbei wurden die 58 Patientenproben anhand ihres 
Expressionsmusters räumlich dargestellt. Tatsächlich ergab sich in der dreidimensionalen 
Darstellung eine klare räumliche Trennung der drei Entitäten.  
Um die Funktion der transkribierten Gene und deren Verbindungen untereinander zu 
analysieren nutzten wir die Datenbank der IngenuityTM Software. Bei PM im Vergleich mit 
MN waren insbesondere die Gene exprimiert, die für Tumoren, dermatologische 
Erkrankungen, Zellwachstum, Zellwanderung und Entzündungsreaktionen eine Rolle spielen. 
Darüberhinaus konnten mit Hilfe des Ingenuity Network AlgorithmTM 15 funktionelle 
Gennetzwerke erstellt werden. Darunter waren Gene, die in wichtige Zellfunktionen und in 
Signalkaskaden des malignen Melanoms involviert sind, insbesondere in die Apoptose, die 
Kontrolle der G1/S und G2/M Phasen, den Notch-, den MAP-Kinase-, den WNT/beta 
Catenin- und Integrin-Signalweg [25, 26]. Die beim Vergleich der MM mit den PM 
signifikant regulierten Transkripte sind laut IngenuityTM Datenbank beteiligt an Haar und 
Hautentwicklung, dermatologischen Erkrankungen, Tumoren, Zellwachstum, Zellwanderung 
und Entzündungsreaktionen. Auch hier konnten wichtige Signalwege identifiziert werden, 
unter anderen VEGF-, PI3/AKT-, WNT/beta Catenin- und Integrin-Signalwege. 
Um bisher noch nicht für das Melanom beschriebene Gene zu identifizieren, führten wir eine 
IngenuityTM Analyse durch, bei der nur diejenigen differentiell exprimierten Transkripte 
einbezogen wurden, die eine minimale log- Ratio von 1,5 aufwiesen. Basierend auf intensiven 
Gene-Ontology Recherchen erwarteten wir insbesondere Gene, die in die bedeutenden 
Melanom-Signalwege MAP-Kinase-, Notch- und Wnt-Signalweg involviert sind. Hierbei 
identifizierten wir Contactin1 (CNTN1), ein Adhäsionsmolekül, das in den Notch- Signalweg 
eingebunden ist und bei PM im Vergleich mit MN geringer exprimiert war. Frizzled-related 
Protein (FRZB) und transducin-like enhancer of split 1 (TLE1) sind in den Wnt-Signalweg 
eingebunden und waren bei PM im Vergleich mit MN geringer exprimiert. Die Serpin 
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Peptidase Inhibitoren Serpin B3 und B4 waren bei PM im Vergleich mit MN sehr stark 
exprimiert und sind assoziiert mit dem MAP-Kinase Weg [27]. Zudem konnten wir die 
kürzlich beschriebene verstärkte Expression des growth differentiation factor 15 (GDF15) in 
PM [9, 11, 12] verifizieren.  
Diese Beobachtung validierten wir mit Hilfe der Echtzeit-PCR Methode. Die von MN über 
PM bis hin zu MM abnehmenden Expressionswerte für CNTN1, FRZB und TLE1 wurden 
weitgehend mit hoher statistischer Signifikanz bestätigt. Auch die hohen Serpin B4 
Expressionswerte bei PM verglichen mit MN und MM konnten reproduziert werden. Für 
Serpin B3 fanden wir signifikant erhöhte Werte bei PM verglichen mit MM und einen Trend 
in Richtung erhöhter Werte bei PM verglichen mit MN. 
GDF15, ein potenzieller Marker mit interessanter Biologie, wurde exemplarisch ausgewählt, 
um unsere auf transkribierten Genen basierenden Daten auf Proteinebene zu überprüfen. 
Hierfür wählten wir Tissue-Mikroarrays (TMA) mit mehr als 280 humanen Gewebeproben. 
Als Kontrolle verwendeten wir MMP1, deren Genregulation bereits bekannt ist. Die immun-
histochemischen Färbungen wurden anhand eines fünfstufigen Bewertungssystems (0 bis 4+) 
kategorisiert und zeigten hohe GDF15 Werte bei PM und MM, während das GDF15 Protein 
bei MN kaum nachweisbar war. Diese Beobachtungen stimmten mit den Werten des 
GeneChips überein. Interessanterweise war die progressionsfreie Überlebenszeit der 
Melanom Patienten mit niedrigen GDF15 Protein Werten (0 bis 2+) signifikant höher als die 
der Patienten mit hohen GDF15 Werten (3+ bis 4+; p=0.037). Übereinstimmend mit früheren 
Berichten über Metalloproteinasen [28, 29] beobachteten wir hohe Werte für MMP1 bei PM 
und signifikant niedrigere Werte bei MM und MN. Beim Vergleich der Färbeintensität mit 
der Zeit des progressionsfreien Überlebens zeigte sich für MMP1 kein signifikanter 
Unterschied. 
 
Wie bereits oben erwähnt, findet man in praktisch jeder Melanomzelle Veränderungen im 
MAP-Kinase-Weg, die zu einer Aktivierung dieses Signalwegs führen [30]. Seit der Ent-
deckung aktivierender Mutationen des BRAF Proteins beim Melanom [31-33] stand der 
MAP-Kinase-Weg im Mittelpunkt des Forschungsinteresses. Auch in unseren Daten fanden 
wir differentiell exprimierte Gene mit Bezug zu MAP-Kinase Signalen. So waren STAT1 und 
SPP1 bei PM verglichen mit MN verstärkt exprimiert, während PPP1R3C vermindert 
exprimiert wurde. Mitglieder der STAT-Familie werden als Antwort auf Zytokine und 
Wachstumsfaktoren phosphoryliert und können daraufhin dimerisieren und am Zellkern als 
Transkriptionsfaktoren agieren. Wie auch in früheren Studien gezeigt wurde, wird SPP1 bei 
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PM und MM sehr stark exprimiert [9, 21, 34]. Dagegen ist relativ wenig über PPP1R3C bei 
Tumoren bekannt. PPP1R3C werden Tumor-Suppressorfunktionen zugeschrieben, da bei 
Melanomen verglichen mit Melanozyten eine Promotor-Hypermethylierung und eine 
geringere mRNA Expression beobachtet wurden [35].  Als neue progressionsassoziierte 
Marker mit Bezug zu MAP-Kinase Signalen konnten wir zwei Serpin-Peptidase-Inhibitoren, 
Serpin B3 und Serpin B4, identifizieren. Beide waren bei PM verglichen mit MN stark 
hochreguliert und bei Metastasen herunterreguliert. Kürzlich wurde gezeigt, dass Serpin B3 
ein spezifischer endogener Inhibitor der c-Jun-NH²-Terminal Kinase-1 (JNK1/MAPK8) ist 
und UV-exponierte Keratinozyten vor apoptotischem Zelltod nach Sonnenexposition bewahrt 
[36]. Über die Rolle von Serpin B3 und B4 beim Melanom ist wenig bekannt. Bei 
Plattenepithelkarzinomen der Zervix, der Lunge, des Kopf-Hals-Bereichs wird Serpin B3 
bereits als Tumormarker verwendet [37, 38]. Serpin B4 könnte ein allgemeiner Marker für 
Tumorinvasion und Metastasierung sein. Eine Inaktivierung durch Antisense cDNA führt bei 
humanen Zervixkarzinom-Zellkulturen zu einem Abfall der E-Cadherin-Expression, was 
allgemein einen bekannten Schritt für den Verlust der Zell-Zell-Adhäsion darstellt. [39]. Da 
auch Melanomzellen durch Herunterregulation von E-Cadherin der Kerationozytenkontrolle 
entkommen können [13], nehmen wir an, dass Serpine eine wichtige Rolle in der 
Melanomprogression spielen. Diese Annahme wird durch die Beobachtung bekräftigt, dass 
ein weiteres Mitglied der Familie der Serpine, Serpin B5 (Maspin), bei MM vermindert 
exprimiert wurde. Der Verlust von Serpin B5 gilt als Marker für Invasion und Migration bei 
anderen Tumorentitäten wie Brust-, Prostata- und Pankreaskarzinomen [40]. 
Ein weiteres signifikant reguliertes Gen in unseren Daten mit Verbindungen zum MAP-
Kinase Signalweg ist GDF15, ein Mitglied der TGF-ß Superfamilie [41]. Wir fanden deutlich 
erhöhte Expressionswerte für PM und MM verglichen mit MN; gleichzeitig konnten wir nach 
Auswertung unserer Patientendaten feststellen, dass erhöhte GDF15 Werte mit einer 
verkürzten progressionsfreien Überlebenszeit assoziiert waren. Wie Boyle et al. bereits 
feststellen konnten, kann die Tumorigenität von unterschiedlichen Melanom-Zelllinien in 
einem Maus-Xenograft Model durch Inhibierung von GDF15 reduziert werden [42]. Erhöhte 
GDF15 Werte bei PM und MM wurden auch von Talantov et al. beschrieben, die zudem 
GDF15 als geeigneten Marker zur Differenzierung von Melanomen und Nävi vorschlugen 
[11]. Da GDF15 in weitere Tumor-Signalwege eingebunden ist, wie z. B. p53 [43], MITF 
[44], und PI3K/AKT-Signalwege [42, 45, 46], könnte es eine Schlüsselposition für die 
Entwicklung von Melanommetastasen mit schlechter Prognose und Überlebenszeit besitzen 
[47]. 
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Beim Melanom wurden zudem aberrante Aktivierungen des Wnt-Signalwegs beobachtet [48]. 
Mit FRZB und TLE1 wurden in unseren Daten zwei wichtige Bausteine des Wnt-Signalwegs 
bei PM verglichen mit MN geringer exprimiert. FRZB (sFRP3) gehört zur Familie der 
secreted Frizzled-related Proteine, deren Mitglieder eine Ligand-Rezeptor Interaktion durch 
die Bindung extraxellulärer Wnt-Liganden verhindern [49, 50]. Da FRZB bei Pleura-
mesotheliomen [51] und Prostatakarzinomen [52] geringer exprimiert wird, wurde eine 
Tumor-Suppressorfunktion vermutet.  
TLE1, ein Corepressor, ist Mitglied der Groucho/TLE/Grg Familie und an einigen 
Signalwegen beteiligt [53, 54]. Im Wnt-Signalweg interagiert es mit wichtigen Trans-
skriptionsfaktoren, unter anderen mit TCF/LEF-1 [55]. Es wird angenommen, dass eine 
Inaktivierung von TLE1 an der Entwicklung hämatoonkologischer Erkrankungen beteiligt ist, 
da entscheidende Differenzierungswege und wachstumshemmende Signalwege unterbrochen 
werden [56]. Im Notch-Signalweg fungiert TLE1 als Corepressor von HES1, einem Gen, das 
bei einigen humanen Tumorerkrankungen aktiviert ist und Tumorzellen erlaubt, der 
Differenzierung und der irreversiblen Ruhephase zu entkommen [50, 57]. Auch CNTN1 ist 
am Notch-Signalweg beteiligt. Es ist ein Mitglied der Immunglobulin-Superfamilie und ein 
neuronales Membranprotein, das als Adhäsionsmolekül und funktioneller Ligand von Notch 
wirkt. Es ist unter anderem an der Oligodendrozytenreifung beteiligt [58]. Abhängig vom 
Gewebe können Notch-Signalwege durch die Beeinflussung von Tumorzelldifferenzierung, 
Proliferation und Apoptose sowohl tumorinitiierende als auch tumorsupprimierende  Effekte 
auslösen. [59, 60]. Bei Melanomen scheint eine Aktivierung von Notch-Signalwegen wichtig 
für die gesamte Tumorprogression. So führt eine verstärkte Expression von Nic, der aktiven 
Form von Notch, in Melanozyten zu einer malignen Transformation, während eine Akti-
vierung von Notch1 bei Melanomzellen eher einen metastatischen Phänotyp bewirkt [61, 62].  
Die Studie konnte zeigen, dass sich Primärtumoren und Metastasen des Melanoms durch 
unterschiedliche Genexpressionsmuster unterscheiden, insbesondere auch im Vergleich mit 
gutartigen Melanozyten. Die differentiell regulierten Gene spiegeln die Aktivierung und 
Inaktivierung  wichtiger Tumor-Signalwege wider. Hierbei fanden sich die für Melanome 
bereits beschriebenen MAP-Kinase-, Wnt- und Notch- Signalwege mit bisher noch nicht 
beteiligten Genen. Um daraus diagnostischen und therapeutischen Nutzen ziehen zu können, 
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